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Abstract——The smooth muscle cell directly drives
the contraction of the vascular wall and hence regu-
lates the size of the blood vessel lumen. We review here
the current understanding of the molecular mecha-
nisms by which agonists, therapeutics, and diseases
regulate contractility of the vascular smooth muscle
cell and we place this within the context of whole body
function. We also discuss the implications for person-
alized medicine and highlight specific potential target
molecules that may provide opportunities for the fu-
ture development of new therapeutics to regulate
vascular function.
I. Introduction
A. Scope and Limitations
The smooth muscle cells of blood vessels display
considerable plasticity in their phenotype. In healthy,
young blood vessels, the phenotype is largely contractile
and blood pressure is well autoregulated. However,
during the life span of an individual, vascular cells can
switch to a synthetic, largely noncontractile phenotype
in response to proinflammatory stimuli, diet or other
factors that result in the development of atherosclerosis
or vessel remodeling. We will not focus on these
processes here but refer the reader to several recent
reviews on this topic (Heusch et al., 2014; Brown and
Griendling, 2015; Tabas et al., 2015).
Here we will focus on the contractile phenotype,
which also can display plasticity of function through a
range of more subtle adaptations to aging, biomechan-
ical stress, and vasoactive physiologic and pathophysi-
ologic molecules. The current review will focus on these
responses and especially focus, as a prototype disease of
contractile vascular smooth muscle, on the complex role
of this cell type in hypertension and where many
opportunities exist for the exploration of untapped
potential therapeutic targets.
B. Overview of Regulation of Blood Pressure/
Vascular Tone
1. Guyton View of Regulation Blood Pressure, Kidney
Role, Volume Regulation. In humans, the diagnosis of
hypertension is widespread, but typically asymptom-
atic; 20–50% of the world’s population has hypertension
and in the United States ;30% of the population is
hypertensive (Hajjar et al., 2006). Furthermore, hyper-
tension is a major risk factor for cardiovascular disease,
stroke, and end-stage renal disease, and thus, there is
significant morbidity andmortality associated with this
disease. Because blood pressure (BP) is related to the
cardiac output (CO) and systemic vascular resistance
(SVR) by the equation BP = CO  SVR, increases in
either CO or SVR should produce hypertension. Thus,
although the molecular mechanism(s) that produce
hypertension would be expected to be relatively
straightforward, over 50 years of investigation have
not defined the molecular mechanism(s) that underlies
this medical condition.
The control of blood pressure is an integrated re-
sponse that includes regulation by neural receptors,
hormones, and renal fluid balance (Guyton, 1991).
However, the handling of sodium within the kidney is
well accepted to be the major factor that regulates blood
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pressure (Fig. 1), and hence, in the pathogenesis of
hypertension renal Na+ excretion, which regulates in-
travascular volume, is the primary determinant of
cardiac output (CO) and therefore blood pressure
(Guyton, 1991). The role of control of intravascular
volume by the kidney for the pathogenesis of hyperten-
sion is supported by the results of an elegant series of
studies by Lifton’s group (reviewed in Lifton et al.,
2001). These investigators demonstrated that in hu-
mans, rare genetic causes of hypertension all arise from
a defect in the handling of Na+ in the kidney; mutations
that increase Na+ reabsorption (volume expansion)
result in severe hypertension, whereas mutations that
decrease Na+ resorption (volume contraction) produce
hypotension. We will not discuss the well-accepted role
of renal fluid balance in regulation blood pressure,
because this topic has been the subject of a number of
reviews (Lifton et al., 2001; Oparil et al., 2003; Coffman
and Crowley, 2008; Johnson et al., 2008).
2. Recent Direct Confirmation of Changes in Vascular
Tone/Resistance Related to Changes in Systemic Vascu-
lar Resistance and Blood Pressure and the Importance of
Vascular Smooth Muscle Contraction in both Normal
Physiology and Pathophysiology—Hypertension.
More than 90% of patients are diagnosed with essential
hypertension, or hypertension of unknown etiology
(Oparil et al., 2003). Fortunately, despite the lack of a
clear mechanism, there are a number of classes of
antihypertensive agents that effectively lower blood
pressure. Intuitively, one would expect that changes
in vascular tone would result in changes in systemic
vascular resistance (SVR) and result in either hyper-
and/or hypotension. And, although a number of the
classes of antihypertensive agents target the vascular
smooth muscle [a-blockers, angiotensin converting en-
zyme (ACE) inhibitors, angiotensin receptor blockers
(ARBs), calcium channel blockers (CCBs)], until re-
cently, there was little experimental evidence consis-
tent with the regulation of vascular tone being an
important factor for the molecular mechanism that
produces hypertension (Fig. 1). However, a number of
studies have demonstrated the importance of changes
in vascular reactivity or the regulation of vascular
smooth muscle contraction and/or vascular tone for
the control of blood pressure. For these experiments,
investigators have genetically modified a mouse to
produce abnormalities in the regulation of vascular
tone and/or vascular dysfunction; these mouse models
include the BKCa2+ channel b1 subunit knockout (KO)
(Brenner et al., 2000), estrogen receptor b KO (Zhu
et al., 2002), vascular smooth muscle cell Sur2 K(ATP)
channel KO (Chutkow et al., 2002), endothelial nitric
oxide synthase (eNOS) KO (Huang et al., 1995), RGS2
KO (Tang et al., 2003), PKGI KO (Tang et al., 2003),
PKGIa leucine zippermutant (Michael et al., 2008), and
theMYPT1KO (Qiao et al., 2014). All of thesemice have
both vascular dysfunction and hypertension, and these
data suggest that vascular dysfunction produces hyper-
tension. However, in these transgenic models, vascular
dysfunction within the kidney could alter fluid balance
and a resulting increase in intravascular volume and
the resulting increase in CO could be responsible for
producing hypertension. The most compelling argu-
ment that isolated vascular dysfunction results in
hypertension are the results of Crowley et al. (2005).
These investigators demonstrated that mice with a KO
of the angiotensin type 1 (AT1) receptor were hypoten-
sive. Furthermore, these investigators produced mice
with the KO of the AT1 receptors in the kidney with
normal AT1 expression in the peripheral vasculature,
as well as the KO of AT1 receptors in the peripheral
vascular smooth muscle with normal AT1 expression in
the kidney. The blood pressure in these two strains was
equal and intermediate between the AT1 KO and wild-
type (WT) mice. These results demonstrate that in
isolation, an abnormality in the regulation of vascular
smooth muscle contraction produces a change in blood
pressure, and therefore, an isolated increase in vascular
smooth muscle tone will produce hypertension. Thus
the regulation of vascular smooth muscle contraction is
important in both health and disease.
3. Racial Differences/Personalized Medicine.
Further complicating investigation of the mechanism
underlying the pathogenesis of hypertension are racial
differences in the effectiveness of the various classes of
antihypertensives (Cushman et al., 2000; Johnson,
2008; Gupta, 2010), including the response to b-block-
ers, ACE inhibitors, and ARBs. White compared with
black patients with hypertension are more likely to
respond to b-blockers, ACE inhibitors, and ARBs,
whereas for black patients, treatment with a diuretic
or calcium channel blocker (CCB) is more likely to be
effective (Johnson et al., 2008). Additionally, there also
Fig. 1. SVR versus kidney: Blood pressure is the product of systemic
vascular resistance and cardiac output (BP = SVR  CO). Changes in Na+
reabsorption will increase or decrease intravascular volume and result in an
increase or decrease cardiac output, which will alter blood pressure.
Similarly, alterations in vascular tone can either increase or decrease SVR,
which leads to an increase or decrease in blood pressure (see text for details).
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appears to be regional differences in the response to
antihypertensive agents; there is a 10 state region in the
Southeastern U.S., referred to as the Stroke Belt, in
which the mortality from cerebral vascular accidents is
10% greater than the rest of the country. In this region,
compared with the rest of the U.S., treatment of
hypertension with diuretics, b-blockers, ACE inhibi-
tors, and clonidine is less effective, whereas there is no
difference in the effectiveness of CCBs and prazosin
(Cushman et al., 2000). After controlling for race, the
differences in the therapeutic success of diuretics and
clonidine is still present. Furthermore, for black pa-
tients with hypertension in this region, similar to the
rest of the U.S., CCBs are more likely to control blood
pressure and the effectiveness of b-blockers and prazo-
sin therapy is poor.
These racial differences in response to therapy are also
present for the treatment of heart failure. Analysis of the
results of the V-HeFT (Vasodilator-Heart Failure) trial
demonstrated that treatment of black patientswith heart
failure with the combination of hydralazine and isosor-
bide dinitrate reduced mortality, whereas this regimen
did not changemortality comparedwith placebo for white
patients (Carson et al., 1999). In contrast to these results,
treatment of heart failure with enalapril reduced mor-
tality in white, but not black, patients, and in white
patients, enalapril produced a larger reduction in blood
pressure and regression of cardiac size than hydralazine
and isosorbide dinitrate (Carson et al., 1999).
These racial and regional differences in the response
to antihypertensive regimens could be due to polymor-
phisms. A number of genome wide-association studies
(GWAS) have investigated this question (reviewed in
Cushman et al., 2000; Johnson et al., 2008), and these
studies as well as their implications will be discussed
later in this review. However, changes in the vascular
smooth muscle phenotype could be responsible for
diversity in the effectiveness of the different classes of
antihypertensive agents. Defining the role of the vas-
cular smooth muscle phenotype in the pathogenesis of
hypertension could identify novel therapeutic targets,
which could be exploited in rational drug design.
Furthermore, comparing the vascular smooth muscle
phenotype between races and regions could potentially
define themechanism that governs the heterogeneity in
the response to antihypertensive therapy and form the
basis for an individualized approach for selecting an
effective antihypertensive regimen.
II. Regulation of Ca2+
A. Ca2+ Determines Vascular Smooth Muscle Cell
Contractility and Phenotype
Vascular smooth muscle cells (VSMC), like all other
muscle cells, depend on Ca2+ influx to initiate contrac-
tion. However, the VSMC intracellular Ca2+ concen-
tration does not only determine the contractile state,
but also affects the activity of several Ca2+ dependent
transcription factors and thereby determines VSMC
phenotype. To govern the various Ca2+-dependent
functions and in reaction to different stimuli, VSMCs
use a variety of plasmalemmal and sarcoplasmic
reticulum (SR) Ca2+ channels to produce a large
repertoire of Ca2+ signals, which differ in their spatial
and temporal distribution (reviewed by Amberg and
Navedo, 2013). These signals range from cell-wide
changes in [Ca2+] to highly localized Ca2+ entry or
release events. Ca2+ can enter the cell from the
extracellular space or be released from the largest
intracellular Ca2+ store, the sarcoplasmic reticulum
(SR). Extracellular Ca2+ influx is mainly mediated by
the opening of voltage dependent L-type Ca2+ chan-
nels (LTCC), but there are a number of other channels
that modulate intracellular Ca2+, including transient
receptor potential (TRP) cation channels. Because of
their high single-channel conductance and expression
in VSMCs, LTCCs have the largest influence on global
[Ca2+]i, and their activity largely determines the
VSMC’s contractile state and ultimately vessel di-
ameter (Knot and Nelson, 1998). In response to
agonist activation of SR-bound inositol trisphosphate
(IP3) or ryanodine receptors (RyR), Ca2+ is released
into the cytoplasm from the SR. Local Ca2+ signals
from the plasmalemma or the junctional SR can
augment or oppose increases in global Ca2+ through
the activation of Ca2+-dependent ion channels and
their regulatory signaling molecules that ultimately
affect plasma membrane potential and therefore
LTCC activity.
B. Compartmentalization of Ca2+ Signaling
The concept of Ca2+ compartmentalization was in-
troduced when it was demonstrated that local increases
in Ca2+ could activate the contractile apparatus without
influencing other Ca2+-dependent signaling pathways
(Karaki, 1989). Ca2+ is slow to diffuse across the
cytoplasm (Berridge, 2006) and a large flux of Ca2+ is
required to achieve the high Ca2+ concentration neces-
sary for activation of Ca2+-dependent processes. There-
fore, to compartmentalize and regulate Ca2+ signals,
VSMCs arrange their organelles in a fashion that limits
the space for diffusion and thereby increases the effect of
local changes in [Ca2+] (Kargacin, 1994; Poburko et al.,
2004) (Fig. 2). The effects of Ca2+ entry hence depend
on the way that organelles, Ca2+ pumps, channels, and
Ca2+-dependent signaling molecules are organized in
signaling microdomains around the source of the Ca2+
signal, as well as its duration and amplitude.More on the
organization of such microdomains in VSMCs and how
they affect VSMC contractility and phenotype can be
found in the review on regulation of cellular communica-
tion by signaling microdomains by Billaud et al. (2014).
1. Ca2+ Sparklets. Local increases in cytoplasmic
Ca2+ resulting from influx through single or small
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clusters of LTCCs are called Ca2+ sparklets (reviewed
by Navedo and Amberg, 2013). Because of the steep
voltage sensitivity of LTCCs, the sparklet frequency
and persistence are closely linked to membrane poten-
tial. Thus local changes in membrane potential will
result in alterations of local sparklet activity, whereas
cell-wide depolarization leads to extensive opening of
LTCCs and global influx of Ca2+ (Navedo et al., 2005;
Amberg et al., 2007). Increases in [Ca2+]i and Ca
2+
sensitivity of the contractile apparatus in VSMCs are
considered hallmarks of essential hypertension, and it
has been widely assumed that the increase in in-
tracellular Ca2+ is mediated by increased influx
through LTCCs. Consistent with this are results in
the rat where banding was used to produce a sudden
high intravascular pressure in the right renal artery.
After only 2 days, VSMCs from the right renal artery
showed increased expression of a1C subunits of the
LTCC and increased Ca2+ currents compared with
VSMCs from the left renal artery (Pesic et al., 2004).
However, the ratio of right renal artery/left renal artery
a1C subunit expression decreased over time, which may
indicate a dynamic adjustment to this sudden pressure
overload occurring within the VSMCs.
Surprisingly, overall LTCC expression and cell-wide
Ca2+ influx was recently found to be decreased in a
mouse model of essential hypertension (Tajada et al.,
2013). However, although there was a decrease in the
number of LTCCs present on the plasmamembrane, the
LTCCs showed increased local sparklet activity. These
investigators demonstrated that fewer, but highly
active, LTCCs were able to increase [Ca2+]i locally as
well as cell-wide. The activity of Ca2+ sparklets has been
shown to depend on whether the LTCC is part of a
pentad complex bound to the plasma membrane by the
scaffolding protein AKAP150 (Navedo et al., 2008).
LTCCs that are not coupled in such complexes have a
higher probability of producing stochastic sparklets
with low flux and short duration, whereas AKAP-
associated channels can produce high-activity persis-
tent sparklets.
The dynamics of these persistent sparklets are regu-
lated by kinases and phosphatases that are targeted to
a subpopulation of LTCCs by the plasmalemmal anchor
AKAP150. Under physiologic conditions in these sig-
nalingmicrodomains, the formation of persistent spark-
letsmainly relies on protein kinase C (PKC) activity and
is counteracted by the serine phosphatase calcineurin.
In pathologic conditions such as diabetes, however,
protein kinase A (PKA) becomes amediator of enhanced
sparklet activity (Navedo et al., 2010). In a study by
Navedo et al. (2008) it was shown that the inhibition of
cytoplasmic calcineurin with cyclosporine A in AKAP2/2
mice had no effect on LTCC sparklet activity, whereas
the inhibition of AKAP150-anchored calcineurin in wild-
type mice yielded an increase in persistent sparklets.
This confirmed the hypothesis that there was a negative
relationship between calcineurin and LTCC sparklet
activity but highlighted the importance of calcineurin
being targeted to the plasmalemma by AKAP150. The
relevance of PKC interaction with LTCCs in the devel-
opment of ATII-induced hypertension has been demon-
strated in a number of experiments, in which not only the
KO of PKC but also the ablation of AKAP150 lead to an
Fig. 2. Compartmentalization of Ca signaling.
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inability of ATII infusion to produce hypertension
(Navedo et al., 2008). In this model, the level of cellular
PKCwas unchanged in AKAP1502/2VSMCs. These data
suggest that recruitment of PKC to the LTCC by
AKAP150 is crucial for the development of this form of
hypertension. AKAP150 is also thought to play a role in
the functional coupling of LTCCs to each other, which
amplifies Ca2+ influx and is, similar to persistent sparklet
activity, increased in hypertension (Nieves-Cintron et al.,
2008). Although the mechanism of coupled gating is
still under investigation, a model has been proposed by
which coupled gating is mediated by calmodulin (CaM)-
dependent interactions between the carboxy-terminals of
AKAP150-coupled LTCCs and is increased with PKC
activation and calcineurin inhibition (Navedo et al., 2010;
Cheng et al., 2011).
It should be noted, that in some studies, there was
significant PKC activation in agonist-mediated vaso-
constriction, but not in pressure-mediated vasoconstric-
tion (Jarajapu and Knot, 2005; Ito et al., 2007),
suggesting that PKC has a negligible role in myogenic
tone. However, other groups reported PKC involvement
in themodulation of the arteriolar myogenic response to
increased intravascular pressure (Hill et al., 1990). This
study demonstrated that inhibition of PKC led to
inhibition of themyogenic response,whereas a stimulator
of PKC activity increased myogenic responsiveness.
In a recent study (Mercado et al., 2014), investigators
demonstrated that AKAP150-recruited PKC also regu-
lates the activity of Ca2+-permeable, nonselective
TRPV4 channels. These channels can produce Ca2+
sparklets with 100-fold higher Ca2+ flux compared with
LTCCs, yet they have been linked to VSMC relaxation
(Earley et al., 2009). This association results from the
high Ca2+ flux that enables TRPV4 to stimulate SR-
membrane bound RyRs in relative proximity to the
plasmalemma as a form of Ca2+-induced Ca2+ release
(CICR) found in VSMCs.
In contrast to TRPV4 sparklets, LTCC sparklet flux is
much lower and therefore not sufficient to trigger Ca2+
release from the SR, but overall LTCC sparklet activity
is higher and hence LTCCs have a much greater effect
on global Ca2+. Through the effect on global Ca2+, LTCC
sparklet activity determines the rate at which the SR
can refill its Ca2+ stores. However, neither the SR Ca2+
content nor the number and amplitude of SR Ca2+
release events appear to be directly linked to LTCC
sparklet activity (Collier et al., 2000; Essin et al., 2007).
Other important members of the TRP channel family
include TRPC1, TRPC3, TRPC6, and TRPM4. They
have been found to have a role in regulating myogenic
tone as well as the myogenic response and are known to
be involved in the mechanism of action of vasoconstric-
tors (refer to reviews by Beech, 2005, 2013) and will be
discussed in the section II.B.4. However, for details on
the role of TRP channels in vascular function and how
the dysregulation of vascular as well as endothelial TRP
channels is related to vascular-related pathologies,
please see the recent review by Earley and Brayden
(2015).
2. Ca2+ Sparks. Highly restricted and large Ca2+
release events through SR RyRs are called Ca2+ sparks,
and Ca2+ sparks have an important regulatory role in
VSMCs. Similar to sparklets, their spatial reach is
small, so they have no direct effect on contractility;
however, the proximity of RyRs to the plasma mem-
brane allows them to affect global [Ca2+]i indirectly
(reviewed by Amberg and Navedo, 2013). The nature
of the VSMC’s response to Ca2+ sparks depends on the
Ca2+-activated plasmalemmal ion channels that are
spatially coupled to the RyRs. In many VSMC, tissues
sparks are targeted to large conductanceCa2+-dependent
K+ channels (BK) that oppose vasoconstriction by allow-
ing hyperpolarizing outward K+ currents (Nelson et al.,
1995). On the other hand, Ca2+ gated Cl2 channels
(CaCCs) depolarize the plasmalemma and thereby en-
hance Ca2+ influx through LTCCs (Kitamura and
Yamazaki, 2001; Leblanc et al., 2005).
a. Ca2+-dependent K+ channel-coupled sparks. A
single Ca2+ spark increases the open probability of
about 30 BK channels in its proximity by 100-fold
(Jaggar et al., 2000; Perez et al., 2001). Sparks can
occur spontaneously or be triggered by TRPV4 sparklets
in the form of a CICR mechanism. Structurally, plas-
malemmal BK channels in VSMCs are formed by four
pore forming alpha subunits encoded by the slo gene
and regulatory b1 subunits that are not necessary for
the formation of a functional channel (Toro et al., 1998).
However, the b1 subunits play a significant role in
modulating the Ca2+ sensitivity and hence functional
coupling to RyRs (Brenner et al., 2000). It has been
demonstrated by several groups that ablation of the b1
subunit in mice leads to desensitization to Ca2+ and
functional uncoupling of BK channels from Ca2+ sparks,
causing membrane depolarization, increases in arterial
tone, and eventually hypertension (Brenner et al., 2000;
Pluger et al., 2000). Furthermore for ATII-induced
hypertension, it has been reported that the b1, but not
the pore-forming alpha subunit, is downregulated,
which mediates a decrease in the sensitivity of BK
channels and thereby contributes to vascular dysfunc-
tion (Amberg et al., 2003; Nieves-Cintron et al., 2007).
Consistent with these results, associations between
gain of function mutations of the b1 subunit and a
lower prevalence of diastolic hypertension have been
described (Fernandez-Fernandez et al., 2004; Nelson
and Bonev, 2004; Senti et al., 2005). Additionally, it has
been demonstrated that b1 subunit downregulation in
ATII-induced hypertension is mediated by enhanced
activity of the transcription factor NFATc3 (Amberg
et al., 2004; Nieves-Cintron et al., 2007). However in
hypertensive animals, there have also been studies that
have found higher expression of the a subunit in
VSMCs, suggesting that the BK channel is primarily
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involved in a compensatory response to increased
VSMC tone from enhanced LTCC or decreased Kv
activity (reviewed in Cox and Rusch, 2002). Hence BK
channels appear to be involved in the pathogenesis in
some as well as compensation and protection in other
forms of hypertension.
Using different strategies tomodulate plasmalemmal
K+ channel activity to inhibit b1 downregulation in
developing hypertension or to increase b1 expression in
VSMCswould appear to be a promising approach for the
treatment of hypertension. In addition, a number of BK
channel openers are currently in development (Webb
et al., 2015); however, the use of BK channel openers for
the treatment of hypertension is limited by concerns for
off-site effects in other smooth muscle tissues. As the b1
subunit of the BK channel seems to be expressed
predominantly in VSMCs (Tanaka et al., 1997), target-
ing b1 expression through gene therapy or modulation
of the NFATc3 pathway represents a possible alterna-
tive (reviewed by Joseph et al., 2013).
b. Ca2+ gated Cl2 channel-coupled sparks. In some
VSMCs, Ca2+ sparks are coupled to CaCCs, and their
activation is followed by “spontaneous transient inward
currents” or STICs. The two families of CaCCs that have
only recently been identified are called bestrophins and
TMEM16A. They are also expressed in renal tubular
epithelium aswell as the heart and are hence thought to
have a multidimensional role in blood pressure regula-
tion (reviewed by Matchkov et al., 2015). Because the
activation of these channels results in plasma mem-
brane depolarizing currents, they are thought to have
an amplifying effect on vascular contractile stimuli by
indirectly causing the opening of LTCCs (Leblanc et al.,
2005; Matchkov et al., 2013; Bulley and Jaggar, 2014).
Indeed, downregulation or inhibition of TMEM16A led
to decreased arterial constriction in a variety of studies
(Jensen and Skott, 1996; Bulley et al., 2012; Davis et al.,
2013; Dam et al., 2014), and a smooth muscle KO of
TMEM16A in mice lead to a decrease in the ability of
ATII infusion to produce hypertension. As CaCCs are
also permeable to other anions such as HCO3
2, it is also
possible that some effect may be due to changes in
intracellular pH that would affect pH-sensitive en-
zymes including Rho kinase (Boedtkjer et al., 2011).
Although there are a number of substances that can
inhibit CaCC activity in vitro, the unknown molecular
identity of TMEM16A as well as its expression in
various tissues would suggest that there is poor phar-
macological specificity in vivo and there would be many
off target effects (Greenwood and Leblanc, 2007;
Boedtkjer et al., 2008).
3. Ca2+ Waves. Activation of CaCCs is also often
mediated by Ca2+ waves, a Ca2+ signal in which sub-
sequent openings of IP3Rs and in some tissues RyRs on
the SR cause a wave of Ca2+ release events across the
entire length of the VSMC, usually close to the plasma
membrane (Iino et al., 1994; Hill-Eubanks et al., 2011;
Amberg and Navedo, 2013). Westcott and colleagues
described the contrasting roles of RyRs and IP3Rs for
the effects of Ca2+waves in arterioles and upstream feed
arteries. Although arteriolar Ca2+ waves are solely IP3R
mediated and therefore not inhibited by ryanodine, RyR
inhibitors decreasedCa2+waves in feed arteries. In both
tissues, Ca2+ waves were inhibited with phospholipase
C (PLC) inhibitors and IP3R blockers, which led to a
decrease in [Ca2+i] and vasodilation. Therefore, IP3Rs
contribute to Ca2+ waves in both tissues as part of a
positive feedback loop for myogenic tone. In contrast,
despite the inhibition of Ca2+ sparks and waves in feed
arteries, inhibition of RyRs caused an increase in [Ca2+i]
and led to vasoconstriction. This was abolished in the
presence of BK-channel blocker paxilline, which sup-
ports the hypothesis that RyRs, which are involved in
Ca2+ waves, are also coupled to BK channels and part of
a negative feedback regulation of myogenic tone
(Lamont et al., 2003; Westcott and Jackson, 2011;
Stewart et al., 2012; Westcott et al., 2012).
In arterioles, Ca2+ waves are initiated by IP3-
dependent opening of an IP3R creating a Ca
2+ “blip,” a
single IP3R opening (Bootman and Berridge, 1996), or a
“puff,” short Ca2+ release from a small cluster of IP3Rs
that is biophysically different from a RyR-mediated
spark (Bootman and Berridge, 1996; Thomas et al.,
1998). Subsequently, clusters of IP3Rs open in response
to the Ca2+ released by adjacent IP3Rs (CICR) and are
inactivated as the [Ca2+] rises further. The IP3R’s
Ca2+-dependent activation/inactivation properties are
reflected in the wave-like pattern of IP3R-mediated
Ca2+ release (Foskett et al., 2007). Ca2+ wave initiation
depends on IP3 synthesis by PLC, which occurs after
activation of G-protein-coupled receptors by their re-
spective agonists, including norepinephrine and
endothelin-1 (Lamont et al., 2003;Westcott and Jackson,
2011; Stewart et al., 2012; Westcott et al., 2012).
However, Ca2+ waves are also seen in the absence of
agonists and depend on the spontaneous basal produc-
tion of IP3 by PLC, which varies in different vascular
beds, and thus will affect the frequency of Ca2+ release
throughRyRs via CICR (Gordienko andBolton, 2002). In
arterioles, the wave leads to VSMC contraction by
directly increasing [Ca2+]I, and this effect is amplified
by the Ca2+-dependent opening of CaCCs in the plasma
membrane that leads to membrane depolarization and
increased Ca2+ influx through LTCCs.
4. Store-Operated Calcium Entry. When SR Ca2+
stores are depleted after release through IP3Rs, the SR
Ca2+ sensor STIM (stromal interaction molecule) relo-
cates to the SR-plasmalemmal junction and physically
interacts with and activates the selective Ca2+ channel
Orai [CRAC (calcium release activated calcium chan-
nel); reviewed by Trebak, 2012]. For VSMCs in the
normal physiologic contractile phenotype, the expres-
sion of STIM/Orai is relatively low, but its expression is
upregulated when the VSMC changes its phenotype to
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the proliferative state (Potier et al., 2009). In a rodent
STIM/Orai knockdown model, nuclear factor activated
T-cells (NFAT) translocation to the nucleus was de-
creased and VSMC proliferation in response to vascular
injury was impaired (Aubart et al., 2009; Guo et al.,
2009; Zhang et al., 2011). In spontaneously hyperten-
sive rats, STIM/Orai is upregulated and depletion of SR
stores lead to greater SOCE, which may represent an
independent mechanism leading to increased VSMC
[Ca2+]i in hypertension (Giachini et al., 2009b). Fur-
thermore, these investigators found evidence suggest-
ing that increased STIM/Orai activity may underlie sex
differences in the development of hypertension. They
determined that inactivation of the STIM/Orai mecha-
nism with CRAC inhibitors as well as antibodies to
STIM or Orai during and after store depletion abolished
sex differences in spontaneous contractions of VSMCs
(Giachini et al., 2009a). Thus CRACs represent a novel
target in the treatment of hypertension.
However, there are a number of studies also suggest-
ing a role of TRPC channels in SOCE (reviewed by
Beech, 2012). Both TRPCs and Orai channels can be
activated by STIM after store depletion (Zeng et al.,
2008; Park et al., 2009); however, their individual
contribution to SOCE is variable. Studies have demon-
strated a partial suppression of SOCE by Orai and
TRPC siRNA, respectively (Li et al., 2008). The nature
of TRPC-Orai interaction, or if there is in fact one, is
currently unresolved (refer to Earley and Brayden,
2015), but both channels can also be activated indepen-
dently from store depletion or Ca2+ release and their
downstream effects on activation differ. TRPs exhibit
multiplicity of gating and hence have been suggested to
integrate various cellular signals including store de-
pletion (Albert and Large, 2002). TRPC1 mediates Ca2+
influx after store depletion with thapsigargin (Xu
and Beech, 2001; Sweeney et al., 2002; Lin et al.,
2004) and is thought to be involved in contractile
modulation and regulation of cell proliferation; how-
ever, more data are needed to determine its exact
function. TRPC6 is a channel that mediates cation
movement in a variety of experimental settings. In
some tissues, inhibition of TRPC6 leads to a decrease in
SOCE, but it also appears to be involved in SR-
independent signaling. Studies demonstrated that
TRPC6 is store and receptor operated, as well as stretch
and osmotically activated in VSMCs. It can associate
and form heteromultimers with TRPC3, which leads to
tonic channel activation (Dietrich et al., 2003). TRPC3
and TRPC6 are upregulated in idiopathic pulmonary
hypertension and an siRNA-induced decrease of TRPC6
expression decreases proliferation of cultured pulmo-
nary arteryVSMC isolated frompatientswithpulmonary
hypertension. Furthermore, chronic hypoxia increases
TRPC6 expression, whereas the ET-1 antagonist bosentan,
a common treatment of PAH, lowers TRPC6 expression
in pulmonary VSMCs (Kunichika et al., 2004; Lin
et al., 2004). These are merely examples of the various
roles TRPC channels occupy in VSMC signaling and a
complete discussion of TRPC channels in health and
disease has been recently presented in a number of
reviews (Beech, 2005, 2012; Earley and Brayden,
2015).
C. Excitation-Transcription Coupling
An importantmode in which Ca2+ can regulate VSMC
contractility is by regulating the composition of the
contractile apparatus, ion channels, and cellular sig-
naling molecules by influencing VSMC gene transcrip-
tion (reviewed by Kudryavtseva et al., 2013). In certain
cytoplasmic locations, high [Ca2+] activates specific
kinases or phosphatases that in turn lead to activation
and translocation of transcription factors to the nucleus.
In the nucleus, Ca2+ can bind helix-loop-helix-loop
structural domain or motif (EF hand) containing tran-
scription factors directly (Carrion et al., 1999) or modu-
late transcription factor binding via Ca2+/CaM-S100
complexes (Hermann et al., 1998). Although in many
disease states VSMCs can completely lose their contrac-
tile function due to a phenotype switch toward a prolif-
erative ECM-producing phenotype, more subtle changes
within the contractile phenotype are also thought to play
a role in the increased VSMC contractility observed in
hypertension.
NFAT is a major target of calcineurin, and it trans-
locates to the nucleus upon calcineurin-mediated de-
phosphorylation. Calcineurin activation is enhanced by
the activity of the AKAP150-bound LTCC signaling
pentad (Oliveria et al., 2007; Nieves-Cintron et al.,
2008). Hence, NFAT activity is regulated by the level
of persistent sparklet activity, but is also dependent on
simultaneous inhibition of its nuclear export (Gomez
et al., 2003). Interestingly, although membrane-
depolarizing signals such as IP3R-mediated Ca
2+ waves
are thought to cause an increase in NFATc3 activation
via enhanced LTCC activity, RyR-mediated Ca2+ re-
lease from the SR decreases NFAT activity by an LTCC
independent mechanism (Gomez et al., 2002). SOCE
has also been implicated in NFAT activation, and its
disruption led to reduced hypoxia-induced NFAT nu-
clear translocation in pulmonary VSMCs (Bierer et al.,
2011; Hou et al., 2013). Although a variety of Ca2+
signals lead to NFAT activation, persistently
raised levels of intracellular Ca2+ fail to induce NFAT
(Stevenson et al., 2001; Gonzalez Bosc et al., 2004).
Therefore it is thought that oscillating Ca2+ signals
(Matchkov et al., 2012) and concomitant inhibition of
nuclear export (Gomez et al., 2003) leads to nuclear
NFAT accumulation. It is well documented that in-
hibition of the calcineurin/NFAT pathway reduces
VSMC proliferation, neointima formation, and vascular
remodeling in response to injury (Liu et al., 2005;
Nilsson et al., 2008; Esteban et al., 2011; Hou et al.,
2013). However there are also studies indicating a role
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for NFAT within the contractile phenotype, altering the
expression of plasmalemmal ion channels including BK
(Nieves-Cintron et al., 2007) and Kv channels (Amberg
et al., 2004) and thereby increasing VSMC contractility
and ultimately arterial tone.
In contrast to NFAT, CREB is regulated by the Ca2+
dependent kinases CaMKII and CaMKIV (Cartin et al.,
2000). Ca2+ influx through LTCCs is important for
activated phospho-CREB to accumulate in the nucleus
(Stevenson et al., 2001). Signals that increase LTCC
activity including IP3R-mediated Ca
2+ waves (Barlow
et al., 2006) and SOCE (Pulver et al., 2004; Takahashi
et al., 2007) lead to increased CREB-induced transcrip-
tion, whereas Ca2+ sparks counteract CREB activity by
hyperpolarizing the plasmalemma and reducing LTCC
flux (Cartin et al., 2000; Wellman and Nelson, 2003).
Because CREB activates genes involved in the contrac-
tile, as well as the proliferative phenotype, the ultimate
effect of CREB activation on VSMC phenotype has not
yet been determined. However in contrast to NFAT,
CREB is induced by any signal that causes a sustained
increase in Ca2+ entry through LTCCs.
In addition to controlling transcription indirectly
through CREB, LTCCs have also been found to directly
influence gene expression in VSMCs. In a study by
Bannister et al. (2013) it was determined that when the
C-terminal end of the LTCC (CCt) is cleaved, it either
reassociates with LTCCs and reduces LTCC sparklet
activity or it relocates to the nucleus and inhibits the
transcription of LTCCs. The CCt thus acts as a bimodal
vasodilator by decreasing LTCC transcription and re-
ducing voltage-dependent LTCC opening. However, the
enzyme responsible for CCt cleavage and the mechanism
(s) for regulation have yet to be determined. Potentiating
the effects of CCt through increased cleavage or possibly
stimulation of CCt promoter sequencesmay offer another
novel approach to controlling vascular contractility.
D. Conclusion
There are a variety of Ca2+-mediated mechanisms
that increase VSMC contractility and are possible
targets in antihypertensive therapy, some of which
are well understood and can be specifically inhibited
in vitro. However the development of novel treatments
is often limited by the expression of the targets in
nonvascular smooth muscle tissues and thus the many
off site effects. A possible solution to this issue could be
targeting specific therapies to VSMCs using viral
vectors. There are a number of successful proof of
concept studies using this technique that were recently
reviewed by Joseph et al. (2013). Another issue that
limits progress in the effort to find novel pharmacologic
therapies in Ca2+ signaling is that the composition of
Ca2+ signaling microdomains differs in various vascular
beds, and hence results cannot always be generalized
for VSMCs. This problem again highlights the impor-
tance of genetic KO and knockdown studies as a tool to
explore targets for gene therapy for the treatment of
hypertension.
III. Vascular Smooth Muscle Signal Transduction
A. Signaling Pathways—Overview
Many potential therapeutic strategies are designed to
activate or inhibit specific signaling pathways in the
vascular smooth muscle cell. It is clear that multiple
vascular signaling pathways coexist as spatially sepa-
rate signaling compartments in individual differenti-
ated vascular smoothmuscle (dVSM) cells and coordinated
by a multitude of scaffolding proteins. However, these
pathways are often overlapping, multilayered, and tissue
specific. The tissue-specific nature of these pathways, even
between different vessels or sizes of vessels, has led to
much controversy on the relative importance of one path-
way versus another.Ultimately, however, the possibility of
multiple pathways that could be activated or inhibited in
various disease states or as functional compensation to
physiologic stress gives the system considerable functional
plasticity.
At the simplest level, it is well established that
vascular tone can be increased either by increasing
activation of myosin (Pathways #1 & #2, Fig. 3) or, in a
manner analogous to that in striated muscle, by re-
moval of inhibition of actin (Pathway #3, Fig. 3). Either
mechanism will lead to an increase in actomyosin
activation and crossbridge cycling. Recently, several
laboratories have reported more controversial mecha-
nisms by which agonists or biomechanical forces can
regulate both vascular and airway smooth muscle
contractility by remodeling cytoskeletal attachments
(Walsh and Cole, 2013; Zhang et al., 2015) (Pathway
#4, Fig. 3). These four pathways are discussed in more
detail below.
1. Major Pathways Leading to Changes in the
Activity of Smooth Muscle Myosin. This has been a
very active area of investigation by vascular smooth
muscle biologists and, as discussed below, has already
identified many potential pharmacologic target mole-
cules and in some cases led to possible drug candidates.
Smooth muscle myosin differs from skeletal and
cardiacmyosins in that it lacks intrinsicmyosin ATPase
activity in the pure state. Smooth muscle myosin
requires a posttranslational modification, phosphoryla-
tion of Ser 19 of the 20-kDa regulatory light chain to
display enzymatic activity. This phosphorylation is
caused by a dedicated Ser/Thr kinase, myosin light
chain kinase (MLCK). (Ito and Hartshorne, 1990)
MLCK is a Ca/CaM-dependent kinase and is most
simply activated by increases in cytoplasmic ionized Ca
([Ca2+i]) levels (Pathway #1, Fig. 3) such as occurs with
a large number of G-protein coupled receptor-mediated
agonists, such as alpha agonists or by depolarization of
the cell membrane by channel activity or experimen-
tally by equimolar replacement of NaCl with KCl in
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physiologic saline solution. It has also been reported
that increases in the free CaM level (Hulvershorn et al.,
2001) or Ca-independent changes in the kinase activ-
ity of MLCK can also occur (Kim et al., 2000) by
phosphorylation-mediated events.
Dephosphorylation of myosin by myosin phosphatase
(MP) decreases its activity, and conversely, inhibition of
MP will increase its activity. A large number of
pathways, such as those activated by PGF2a and
lysophosphatidic acid (Pathway #2, Fig. 3), have been
reported to inhibit MP through either Rho-associated
protein kinase (ROCK)-dependentmechanisms or those
involving Zipper-interacting protein kinase. These
pathways are discussed in detail in section IV.
CaMKinase II is another Ca/CaM-dependent kinase
with the interesting property, when activated, of auto-
phosphorylating itself on T287, which leads to a sustained
activity after Ca is removed, giving it a chemical “mem-
ory” of having been activated (Hudmon and Schulman,
2002; Lisman et al., 2002). Conversely, when S26 in the
catalytic domain is autophosphorylated, it can termi-
nate sustained kinase activity, making it “forget” prior
activation (Yilmaz et al., 2013).
There are four main isoforms of CaMKII, the alpha,
beta, gamma, and delta isoforms. The gamma (espe-
cially the G-2 variant) (Kim et al., 2000; Marganski
et al., 2005) and delta (especially the d2 variant)
(Ginnan et al., 2012) isoforms have been shown to play
important roles in smooth muscle, with the gamma
isoforms primarily regulating contractility and the
delta isoforms regulating proliferation. To a large de-
gree the gamma/delta ratio represents the degree of a
phenotype switch between the contractile/proliferative
phenotypes displayed by smooth muscle in different
settings. Vascular injury reduces gamma isoform ex-
pression and upregulates delta expression (Singer,
2012). Conversely, siRNA-mediated knock down of the
delta isoform attenuates VSM proliferation and neo-
intimal formation. The conditional smooth muscle
knockout of CaMKIIdelta significantly delays the pro-
gression of airway smooth muscle hyperresponsiveness
to an ovalbumin challenge and this isoform is upregu-
lated in the wild-type mouse in response to the same
challenge. Thus the delta isoform may play a role in
smooth muscle inflammatory responses (Spinelli et al.,
2015).
With respect to the gamma isoform and its regulation of
smooth muscle contractility, six smooth variants of the
gammaisoformofCaMKIIhavebeendescribedwithvarying
kinetics of Ca/CaM-dependent activation/deactivation
(Gangopadhyay et al., 2003). One variant, the G-2
variant, which has unique sequence in the association
domain of the kinase (Gangopadhyay et al., 2003), has
been shown to have scaffolding properties with respect
to ERK (extracellular regulated kinase). Antisense
specific for the G-2 variant (Marganski et al., 2005) or
generic against the gamma isoform or small molecule
inhibitor studies (Kim et al., 2000; Rokolya and Singer,
2000) have all demonstrated roles for gamma CaMKII
in the regulation of contractility. The CaMKII gamma
G-2 variant is reported to be associated with vimentin
intermediate filaments and dense bodies in unstimu-
lated vascular smooth muscle cells and on activation by
depolarization-mediated increases in cytosolic Ca2+
levels the G-2 variant translocates to the cortical focal
adhesions (Marganski et al., 2005; Gangopadhyay et al.,
2008). This variant also has been shown to be specifi-
cally dephosphorylated by an SCP3 phosphatase. SCP3
is a PP2C typed protein phosphatase, primarily
expressed in vascular tissues and specifically binds to
the unique association domain sequence in CaMKII
gamma G-2. G-2 is bound to this phosphatase in
Fig. 3. Overview of pathways regulating vascular tone. See text for details. For additional detailed pathways, see subsequent figures.
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unstimulated vascular smooth muscle tissue but is
released upon depolarization-mediated Ca2+ influx.
This phosphatase does not appear to regulate kinase
activity but rather is thought to result in the exposure of
a SH3 domain targeting of the kinase, which leads to
targeting to focal adhesions (Gangopadhyay et al.,
2008).
Although CaMKIIgamma is known to be activated by
stimuli that increase the free Ca2+ level in dVSM, and
antisense or inhibitors to CaMKII decrease the ampli-
tude of the contraction to KCl PSS, the exact pathways
that regulate contractility are still being confirmed. It
has been shown that knock down of the gamma isoform
or the G-2 variant specifically, as well as small molecule
inhibitors of the kinase, lead to an inhibition of ERK
activation and an inhibition of MLCK (Kim et al., 2000;
Rokolya and Singer, 2000; Marganski et al., 2005). ERK
has been shown to be capable of activating MLCK in
other systems (Morrison et al., 1996; Nguyen et al.,
1999), but whether this is the link in smooth muscle has
not been definitively shown. Additionally in cultured
vascular cells, CaMKII is rapidly activated after upon
adherence of the cells upon plating onto ECM or poly-
lysine. Adherence led to CaMKII-dependent tyrosine
phosphorylation of paxillin and ERK activation (Lu
et al., 2005). The CaMKII delta 2 variant has also been
shown to regulate vascular smooth muscle cell motility
in culture through a Src-family tyrosine kinase, Fyn
(Ginnan et al., 2013). Because focal adhesions are
known to serve as ERK scaffolds in contractile smooth
muscle, this is an appealing possible link. Thus, at the
present time, although CaMKII is clearly an important
regulator of Ca2+-dependent vascular contractility, the
complete molecular details of the CaMKII pathway
used by contractile vascular smooth muscle to regulate
contractility are not yet resolved. It is clear, however,
that these details represent considerable untapped
potential as future therapeutic targets for the modula-
tion of Ca2+-dependent vascular contractility and hence
blood pressure. Additionally, the wealth of information
on isoform specific effects of CaMKII, especially the
gamma G-2 variant, offers the potential of considerable
tissue and smooth muscle phenotype specificity of such
therapeutics.
2. Pathways Leading to Changes in Actin Availability
for Interaction with Myosin. In contrast to the path-
ways described above, ex vivo studies (Walsh et al.,
1994; Horowitz et al., 1996a; Dessy et al., 1998) have
demonstrated that phorbol esters, or alpha agonists, by
activating PKC can trigger increases in contractile force
that in some tissues are either Ca2+ independent or
cause leftward shifts in the [Ca2+i]-force relationship.
The Ca2+ dependence of phorbol ester contractions
varies in different smooth muscle tissues, dependent
on the isoforms of PKC present in those tissues. The
alpha, beta, and gamma isoforms are calcium depen-
dent, but delta and epsilon are calcium independent.
Thus, phorbol ester and alpha agonist-induced contrac-
tions have been described as being Ca2+ independent in
experiments using the aorta of the ferret, which con-
tains significant amounts of the epsilon isoform of PKC,
but tissues containing more PKC alpha, such as the
portal vein of the ferret, show an increased Ca2+
sensitivity but are still Ca2+ sensitive (Lee et al., 1999)
and lead to the activation of Pathway #3 in Fig. 3.
Pathway 3 can be activated by diacylglycerol (DAG)
release, generated by the activation of GPCRs in
vascular smooth muscle, or by myometrial stretch,
RU486, and labor in the rat and human myometrium
(Li et al., 2003, 2004; Morgan, 2014). Interestingly, in
the presence of extracellular Ca2+ (Cae), phenylephrine
(PE) will activate pathways 1, 3, and 4 but in the
absence of Cae and in the absence of changes in 20kda
light chain phosphorylation, a contraction persists in
aorta of the ferret (Dessy et al., 1998). Phorbol esters
give a maximal tonic contraction in the absence of
changes in 20kda light chain phosphorylation, even in
the presence of Cae in this system (Jiang and Morgan,
1989).
When activated, Pathway #3 leads, indirectly, to the
PKC-dependent activation of MEK, a dual activity
kinase that phosphorylates ERK on a tyrosine and
threonine, resulting in activation of ERK. ERK activa-
tion can have multiple downstream effects, largely
controlled by output-specific scaffolding proteins (see
below). In contractile smoothmuscle, these downstream
effects include phosphorylation of the actin binding
protein caldesmon. Caldesmon has been described as
being functionally analogous to the troponin complex in
striated muscle in that it blocks the access of myosin
to actin and hence impairs crossbridge cycling. The
C-terminal end of caldesmon is responsible for the
direct inhibition of myosin ATPase activity (Sobue
et al., 1982; Bryan et al., 1990; Wang et al., 1991).
Investigators have demonstrated that the interaction of
the actin-binding domain of caldesmon with actin is
responsible for the inhibition the actomyosin ATPase
(AMATPase) (Velaz et al., 1990) by decreasing the rate
of Pi release by 80% (Alahyan et al., 2006).
Caldesmon has an NH2-terminal myosin-binding
domain, in addition to the COOH-terminal actin-
binding domain, and thus, in theory, could crosslink
actin and myosin (Goncharova et al., 2001). However,
Lee et al. (2000b) also observed a tethering effect of the
N-terminal region of caldesmon to myosin that has the
proposed agonist-dependent functional effect of posi-
tioning caldesmon so that its C-terminal end no longer
inhibits myosin activity. The binding of caldesmon to
myosin is regulated by Ca2+-calmodulin, whereas the
interaction with actin is regulated by ERK phosphory-
lation at Ser789 on caldesmon (Hemric et al., 1993;
Patchell et al., 2002).
In general, in most systems it appears that phosphor-
ylation of caldesmon on Ser789 by ERK, PAK, or other
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serine kinases can reverse caldesmon-mediated inhibi-
tion of myosin ATPase activity (Childs et al., 1992;
Foster et al., 2000; Kim et al., 2008a) (Pathway #3, Fig.
3). However, results from mechanical experiments
examining caldesmon function are variable. In smooth
muscle from caldesmon KO mice, compared with WT
controls, both the rate of force activation and the steady-
state force in response to depolarization, phorbol esters,
and carbachol were similar, but the rate of force re-
laxation was reduced (Guo et al., 2013). In contrast to
these results, an siRNA-induced decrease in caldesmon
expression lowered both isometric force and muscle
shortening velocity (Smolock et al., 2009).
In cultured smooth muscle cells, p42/44 MAPK has
been clearly demonstrated to phosphorylate caldesmon
at Ser789 (Hedges et al., 2000), but for agonist activa-
tion of intact smooth muscle, the kinase responsible for
caldesmon phosphorylation remains a matter of contro-
versy or may involve different kinases in different
settings (Wang, 2008). In skinned smoothmuscle strips,
ERK-induced phosphorylation of caldesmon did not
alter the force-Ca2+ relationship (Nixon et al., 1995).
Porcine carotid artery preparations did not display
detectable phosphorylation of caldesmon at the ERK
sites during phorbol ester stimulation, (D’Angelo et al.,
1999), but PAK phosphorylation at Thr627, Ser631,
Ser635, and Ser642 was demonstrated to reduce cal-
desmon’s inhibition of the AMATPase (Hamden et al.,
2010). On the other hand, ERK-mediated phosphoryla-
tion of caldesmon at 789 has been clearly shown in ferret
aorta preparations as well as mouse aorta and rat
myometrium. Furthermore, although an increase in
caldesmon phosphorylation was observed by Katoch
and Moreland (1995) in porcine carotid artery during
both depolarization and histamine stimulation, exper-
iments using inhibitors suggested that a second kinase
in addition to ERK also phosphorylates caldesmon
(Gorenne et al., 2004).
In contrast to the myosin regulatory pathways, this is
a relatively untapped area of investigation for the
discovery of new target molecules with therapeutic
potential. The relative importance of these pathways
are definitely tissue and species specific. Interestingly,
the strongest evidence of the importance of these
pathways appears to have come from myometrial
smooth muscle in the setting of preterm labor (Li
et al., 2003, 2004, 2007, 2009). Thus, the potential is
there for novel and possibly quite specific therapeutic
targets within these pathways.
3. Tyrosine Phosphorylation of Smooth Muscle
Proteins. The vast majority of known protein phos-
phorylation events in the contractile, differentiated
smooth muscle cell are serine/threonine events. Where
phosphotyrosine screening with immunoblots of con-
tractile vascular as well as myometrial (Li et al., 2007,
2009; Min et al., 2012) smooth muscle tissue has been
performed, the reactive bands have been almost
exclusively focal adhesion-associated proteins. These
tyrosine phosphorylations are largely sensitive to Src
inhibitors, pointing to the presence of focal adhesion
remodeling in nonproliferating, nonmigrating smooth
muscle (Poythress et al., 2013; Ohanian et al., 2014;
Zhang et al., 2015). These mechanisms have been
especially studied in vascular and airway smooth
muscles, resulting in pathways extending from Path-
way #4 (Fig. 3). These mechanisms will be discussed in
further detail in section V below.
4. Calcium Sensitization of the Contractile Apparatus.
When our group first (Bradley and Morgan, 1982, 1985)
measured intracellular Ca levels ([Ca2+]i) in dVSMwith
the photoprotein aequorin, we noticed that agonists
often cause tonic contractions with only transient
increases in [Ca2+]i or differing magnitudes of [Ca
2+]i,
reflecting apparent changes in “Ca2+ sensitivity” of the
contractile apparatus (Bradley andMorgan, 1985). This
dissociation between [Ca2+]i and force has been con-
firmed with many agonists and many different Ca2+
indicators in contractile smoothmuscle tissues andwith
permeabilized smooth muscle preparations where left-
ward shifts in the Ca2+-force relationship in response to
agonists and various agents are seen (Ruegg and Pfitzer,
1985; Somlyo et al., 1999). Mechanistically, we now have
molecular explanations for this phenomenology. Changes
in the apparent Ca2+ sensitivity of the contractile appa-
ratus have been partially explained by the ability of
agonists to regulate the activity of myosin phosphatase
(MP) (Somlyo and Somlyo, 2003) (Pathway #2, Fig. 3),
partially by the ability of ERK to regulate the action of
caldesmon (CaD) to inhibit acto-myosin interactions
(Kordowska et al., 2006) (Pathway #3, Fig. 3) and clearly
also by yet to be defined pathways.
B. Subcellular Spatial Organization of
Signaling Pathways
The complexity of signaling pathways in the smooth
muscle cell raises the issue of how kinases connect with
their complex specific upstream activators and down-
stream substrates in an agonist-specific manner within
the three-dimensional space of the interior of a cell.
Scaffold proteins are now recognized to play important
roles in coordinating mammalian signal transduction
(Morrison and Davis, 2003; Kolch, 2005). Protein scaf-
folds are defined as docking platforms that colocalize
components of kinase cascades and facilitate activation
of the kinases (McKay and Morrison, 2007). The
scaffolds themselves generally lack enzymatic activity
but promote specific outcomes of the pathway. Protein
scaffolds can be thought of as “traffic cops” in what
would otherwise be the chaos of multiple competing
intracellular signaling pathways. Because scaffold pro-
teins add specificity to the cellular pathways, they also
present very attractive targets for drug discovery
programs. Two major types of scaffolds relevant for
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the smooth muscle cell are ERK scaffolds and scaffolds
for regulators of myosin phosphatase.
1. Extracellular Regulated Kinase Scaffolds (Calpo-
nin, SmAV, Paxillin, Caveolin, FAK, IQGAP).
ERK is known to often be targeted to the intranuclear
space in proliferative cells and to regulate nuclear
signaling, especially to transcription factors (Dhanase-
karan et al., 2007). In the smooth muscle cell these
pathways can lead to a proliferative phenotype for the
smooth muscle cell. These pathways will not be dis-
cussed here, but rather we will focus on those most
relevant for the fully differentiated contractile cell.
Even so, much of this work has been performed using
cell culture models and no doubt needs further work in
specific contractile smooth muscle tissue systems.
Calponin is a bit of an enigma and its function in
smooth muscle is still debated. It has been reported to
serve both cytoskeletal and signaling functions (Winder
and Walsh, 1990; Birukov et al., 1991; Menice et al.,
1997; Leinweber et al., 1999a,b, 2000; Appel et al.,
2010). Both PKC and CAM kinase II phosphorylate
calponin at Ser175 (Winder andWalsh, 1990), and after
phosphorylation, calponin loses its ability both to bind
actin and inhibit the AMATPase (Winder et al., 1993).
Calponin has been reported directly to regulate con-
tractility (el-Mezgueldi andMarston, 1996; Obara et al.,
1996; Winder et al., 1998; Takahashi et al., 2000; Je
et al., 2001; Szymanski et al., 2003) but others have
reported negative results (Matthew et al., 2000). Calpo-
nin phosphorylation increases during carbachol stimu-
lation of smooth muscle (Winder et al., 1993). Consistent
with a physiologic role for calponin in the regulation of
contractility are results in skinned smooth muscle; the
addition of exogenous calponin reduces both Ca2+ acti-
vated force (Horowitz et al., 1996b;Obara et al., 1996) and
maximal shortening velocity (Jaworowski et al., 1995). In
the smooth muscle isolated from calponin KO mice,
compared with WT controls, muscle-shortening velocity
is significantly higher, but there is no difference in the
force produced by Ca2+, carbachol, or phorbol esters
(Matthew et al., 2000). However, the addition of exoge-
nous calponin reduces force in skinned single smooth
muscle cells, and the Ser175Ala calponin mutant has no
effect on force (Horowitz et al., 1996a). In intact smooth
muscle during agonist-induced activation, calponin redis-
tributes from the contractile filaments to the cell surface,
which is attenuated with the inhibition of PKC (Parker
et al., 1994, 1998;Gallant et al., 2011). Thus, these results
are consistent with a role for calponin in the regulation of
smooth muscle contraction; agonist stimulation leads to
the activation of PKC, which phosphorylates calponin at
Ser-175 to decrease calponin’s interaction with actin to
relieve calponin’s inhibition of the AMATPase.
Three isoforms exist for calponin. h1CaP/CNN1/basic
calponin is one of themost specific and rigorousmarkers
for the differentiated smoothmuscle phenotype. h2CaP/
CNN2/neutral calponin and h3/acidic CaP/CNN3/aCaP
are more widely distributed but appear to also be
expressed in some smooth muscles (Takahashi et al.,
1988; Strasser et al., 1993; Applegate et al., 1994). Work
in our group has led us to propose that calponin is an
adaptor protein for ERK (Leinweber et al., 1999a,b;
Appel et al., 2010). Antisense knock down of calponin
(Je et al., 2001) led to decreased ERK activity and
contractile force after alpha agonist activation but not
after a depolarizing stimulus. Also, protein chemistry
studies and cellular immunoprecipitation studies dem-
onstrated that CaP directly binds both PKC and ERK
and in intact vascular smooth muscle cells (Leinweber
et al., 2000) and is bound to the thin filaments but
translocates to the cortex of the cell in response to alpha
agonists (Parker et al., 1998). A detailedmodel has been
suggested where agonists activate PKC, which phos-
phorylates CaP, releasing it from the thin filaments
(Kim et al., 2008a). Colocalization of ERK and CaP is
seen in unstimulated vascular smooth muscle cells and
agonist-activation leads to the translocation of a PKC/
CaP/ERK complex to the cell cortex, likely meeting up
with SmaV (see below), Raf, and MEK, which leads to
the activation of ERK, at which point it is seen to return
to the contractile filaments and CaD phosphorylation of
the ERK sites is observed (Khalil and Morgan, 1993).
SmAV is the smooth muscle isoform of a major
scaffolding protein supervillin (Pestonjamasp et al.,
1997). SmAV was initially cloned and identified SmAV
as a CaP binding partner in a two-hybrid assay with
CaP as bait (Gangopadhyay et al., 2004), and it was
found that SmAV acts as an ERK scaffold, leading to the
regulation of CaD phosphorylation (Gangopadhyay
et al., 2009). Data have been published indicating that
CaP (Menice et al., 1997), SmAV (Gangopadhyay et al.,
2004) and CaV (Je et al., 2001) function as scaffolds
coordinating Pathway #3.
Paxillin, better known as a focal adhesion protein, is
also known to bind the classic ERK “signaling module”
of Raf, MEK, and ERK (McKay and Morrison, 2007). In
quiescent cultured cells, paxillin is constitutively asso-
ciated with MEK, but Ishibe et al. (2003) showed that
when cells are stimulated with HGF, Src-mediated
phosphorylation of paxillin at Y118 leads to the re-
cruitment of ERK, followed by Raf, which leads to ERK
phosphorylation and activation. Shortly thereafter focal
adhesion kinase (FAK) is recruited to the complex,
leading to FA remodeling in both cultured cell systems
and airway smooth muscle (Zhang et al., 2015). Thus,
paxillin provides a signaling hub in the vicinity of focal
adhesions that can have specific cytoskeletal outcomes.
Caveolin is an extensively studied protein but there
are still many mysteries regarding its function. A
caveolin-associated protein has also discovered and
named cavin (Liu and Pilch, 2008; Ding et al., 2014;
Kovtun et al., 2015). The exact way in which caveolin
and cavin interact and the role of cavin specifically in
smooth muscle is not yet clear; however, a cavin
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knockout mouse has been produced (Sward et al., 2014).
In this knockout animal not only were arterial expres-
sion of cavin-1, cavin-2, and cavin-3 reduced but also all
isoforms of caveolin were reduced. As a result, caveolae
were absent from both smooth muscle and endothelial
cells. An enhanced contractile response to an alpha 1
adrenergic agent was seen, but was likely to be due to
the increased thickness of the vascularwall. In contrast,
myogenic tone was essentially absent. Surprisingly,
blood pressure of the knockout mouse was well main-
tained, presumably due to opposing influences from
smooth muscle and endothelial effects.
Inhibition of caveolin function by a caveolin decoy
peptide or by methyl-beta-cyclodextrin has been shown
to disrupt ERK activation in vascular smooth muscle
(Je et al., 2004). Work using cultured vascular smooth
muscle cellmodels has suggested that caveolin-mediated
scaffolding of ERK leads to different functional outputs
than actin/calponin-mediated scaffolding (Vetterkind
et al., 2013). This concept has not yet been pursued in
contractile smooth muscle but illustrates the idea of
scaffold proteins regulating the output of kinase cas-
cades toward separate purposes and serving as traffic
cops for complex cellular signaling pathways.
IQGAP (IQ motif containing GTPase activating pro-
tein) is an ERK-binding and actin-binding protein that
has been extensively studied in nonmuscle systems but
little studied in smooth muscle systems. In cultured
vascular smooth muscle cells, knockdown of IQGAP
prevents the phosphorylation and activation of an actin-
associated pool of ERK in response to PKC activation.
Proximity ligation assays demonstrated direct tether-
ing of ERK1/2 to actin by IQGAP. Interestingly caveolin
is also required for activation of this pathway unless
ERK is already associated with actin. Caveolin appears
to be required specifically for upstream C-raf activation
(Vetterkind et al., 2013).
2. Myosin Phosphatase Scaffolds. Myosin regula-
tion is discussed in detail in section IV below, but
multiple pathways have been suggested to coordinate
signaling associated with myosin phosphatase (MP), and
hence,myosin activity (Pathway#2, Fig. 1), and it seems
likely that scaffolds play a role to regulate/facilitate these
pathways. One MP putative scaffold, M-RIP, also called
p116RIP, is thought to link active Rho/ROCK to the
inhibition of MP (Surks and Mendelsohn, 2003; Mulder
et al., 2004; Koga and Ikebe, 2005). Vetterkind and
Morgan (2009) reported that another scaffold/adaptor
protein, Par-4, also regulates myosin phosphatase activ-
ity in contractile smooth muscle. We have described a
“padlock” model to explain the actions of Par-4, whereby
binding of Par-4 to MYPT1 activates MP. This is
postulated to occur by the physical blockade by Par-4 of
theMYPT1 inhibitory phosphorylation sites. Conversely,
this model indicates that inhibitory phosphorylation of
MYPT1 by Zipper-interacting protein kinase requires
“unlocking” of the blockade by phosphorylation and
displacement of Par-4 (Vetterkind et al., 2010). Whether
M-RIP and Par-4 facilitate or antagonize each other’s
actions is not known.
The complexity of this system is impressive, but it is
expected that the multiple scaffolding proteins and
signaling molecules involved in regulating myosin
phosphorylation will lead to the development of rational
and selective therapeutic approaches to cardiovascular
disease.
C. Link to Hypertension
We describe here a number of pathways by which
vascular smooth muscle contraction and stiffness are
directly regulated and hence will affect blood pressure.
It should be mentioned that many other indirect
pathways are also involved, with a major mechanism
being the development of inflammation and subsequent
reduction-oxidation reaction (REDOX) signaling path-
ways (Sorescu et al., 2001; Loirand and Pacaud, 2014).
These pathways are triggered by angiotensin-induced
signaling, and as a result, inhibitors of the effects of and
production of angiotensin are major ways of regulating
blood pressure, including blood vessel contraction. For
further details, we refer you to Mehta and Griendling
(2007) for a review of this topic.
D. Potential Novel Therapeutic Targets/Approaches/
Critical Analysis of Pathway-Specific Inhibitors
1. Rho Kinase Inhibitors. Y27632, the first ROCK
inhibitor described, decreases blood pressure in
11-Deoxycorticosterone acetate (DOCA)-salt rat model
of hypertension. A similar effect was obtained with the
newer ROCK inhibitors fasudil, SAR07899, in other
animal models of hypertension, including the sponta-
neously hypertensive rat (SHR), angiotensin II-induced
hypertension in several animals, and L-NG-Nitroarginine
Methyl Ester (L-NAME)-induced hypertension (Uehata
et al., 1997; Mukai et al., 2001; Kumai et al., 2007; Lohn
et al., 2009). Of note, this class of inhibitors also has a
major part of their effect on hypertension through in-
hibition of inflammatory pathways and cardiovascular
remodeling. For more details we refer you to a recent
review by Loirand and Pacaud (2014).
2. Endothelin Inhibitors. The endothelin pathway,
linked to PLC and ERK signaling, has been identified as
an effective antihypertensive target (Sandoval et al.,
2014).
3. Beta Adrenergic Receptor Mediated Inhibition.
Of interest is the fact that beta receptor mediated
relaxation of vascular smooth muscle has been reported
to decline with age in both the human and animal
models. In aortas from Fischer 344 rats, an increase in
the level of G-protein receptor kinase-2, which desensi-
tizes the beta adrenergic receptor by phosphorylation of
the receptor has been reported to increase with age
(Schutzer et al., 2005), and thus inhibitors of G-protein
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receptor kinase-2 may promote beneficial restoration of
beta receptor mediated vasodilation.
IV. Regulation of Smooth Muscle Myosin
A. Overview of Regulation of the Smooth Muscle
Actomyosin ATPase and 20kda light chain
Phosphorylation/Smooth Muscle Activation
The crossbridge cycle describes the development of
force through a series of complexes between actin (A),
myosin (M), ATP, and its hydrolysis products, ADP and
Pi (Sweeney and Houdusse, 2010) (Fig. 4 and the
termination of Pathway #1; Fig. 3). Beginning in the
rigor state (AM), ATP binding to AM results in rapid
dissociation of AM, forming an A+M-ATP state, and
then ATP is hydrolyzed by myosin. After hydrolysis, the
crossbridge enters a weakly attached, pre-powerstroke
AM-ADP-Pi state, and then transitions to a strongly
bound, force producing AM-ADP-Pi state. After Pi
release from the AM-ADP-Pi state, the crossbridge
enters a AM-ADP state, which then isomerizes to a
high force generating state (AM-ADP) followed by ADP
release and returning to the rigor state (AM). MgATP
subsequently binds to the AM state, causing rapid
crossbridge detachment, and then another crossbridge
cycle commences. The duty cycle is defined as the
proportion of time crossbridges spend in strongly at-
tached states divided by the time for the total cross-
bridge cycle (De La Cruz and Ostap, 2004); high duty
cycle motors are capable of processive movement
(i.e., dynein,myosin V), whereas skeletalmusclemyosin
has a low duty cycle that prevents the development of an
internal load from strongly bound crossbridges, which
would decrease shortening velocity. Although the cross-
bridge cycle for all types of myosin is frequently de-
scribed in this generic manner, differences exist
between the kinetics of skeletal, cardiac, and smooth
muscle and even within different smooth muscle tis-
sues, requiring changes in the crossbridge cycle to
explain the differences in AMATPase rates (Rosenfeld
et al., 2000).
The smooth muscle AMATPase is similar to that of
striated muscle, albeit the kinetics are slower. The
kinetics and individual rate constants of the steps in
the actomyosin ATPase have been defined in a number
of studies (Rosenfeld et al., 2000; Baker et al., 2003;
Haldeman et al., 2014), and similar to other myosin IIs,
the ATPase is limited by phosphate release or the tran-
sition from weak to strong binding states (Haldeman
et al., 2014). Both cardiac and skeletal muscle myosin is
functionally on, i.e., myosin will hydrolyze ATP in the
presence of actin. Smooth muscle (SM) myosin will
hydrolyze ATP in the presence of actin, albeit very
slowly; however, after phosphorylation of the 20-kDa
regulatory myosin light chain (RLC), the rate of hydro-
lysis is increased (Chacko et al., 1977; Ikebe and
Hartshorne, 1985; Ikebe and Morita, 1991; Ellison
et al., 2000) due to an ;1000-fold increase in the rate
of product release (Sellers and Adelstein, 1985). Thus,
changes in RLC phosphorylation regulate smooth mus-
cle activation and relaxation.
In smooth muscle, in addition to RLC phosphoryla-
tion regulating the AMATPase, it also controls the
structure of SM myosin and filament formation (Ikebe
and Hartshorne, 1985). In the absence of RLC phos-
phorylation, myosin is in the 10S conformation [high
sedimentation velocity and low ATPase (Ikebe and
Hartshorne, 1985), with the tail of myosin bending back
over the head neck junction interacting with the
regulatory light chain (Jung et al., 2011; Salzameda
et al., 2006)]. After RLC phosphorylation, the interac-
tion of the myosin tail with the RLC is perturbed (Jung
et al., 2011), and myosin exists in an extended confor-
mation [6S, low sedimentation velocity, high ATPase
Fig. 4. AMATPase: Actomyosin ATPase cycle; ATP is hydrolyzed by myosin (M) and the subsequent interaction of myosin with actin (A) produces force
and/or displacement (see text for details).
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(Ikebe and Hartshorne, 1985)] and also forms filaments
(Applegate and Pardee, 1992). Other investigators have
suggested that in the absence of RLC phosphorylation,
the interaction of the NH2-terminal region of caldesmon
(see Fig. 3 and section III.A.1) with the myosin cross-
bridge disrupts the interaction of the myosin head with
its neck-tail region to promote a transition from the 10S
to the active, 6S conformation (Wang, 2008). Nonethe-
less, in human smooth muscle, there is significant pool
of 10S myosin that can be converted by changes in
cellular conditions to 6S myosin that can then assemble
into side polar thick filaments (Milton et al., 2011).
These data could suggest that in addition to the regu-
lation of the AMATPase, changes in RLC phosphoryla-
tion could regulate the formation of myosin filaments
within the smooth muscle during activation and re-
laxation (Pratusevich et al., 1995; Ali et al., 2007; Liu
et al., 2013; Seow, 2013; Lan et al., 2015); however in
vivo, the ability of RLC phosphorylation to regulate
filament formation is controversial (Seow, 2015; Som-
lyo, 2015).
The level of RLC phosphorylation is defined by the
relative activities of myosin light chain kinase (MLCK)
and MLC phosphatase (Gong et al., 1992), i.e., RLC
phosphorylation is related to MLCK/(MLCK+MLC
phosphatase). Thus, changes in the activity of either
MLCK orMLC phosphatase will change RLC phosphor-
ylation and force or vascular tone. MLCK is regulated
by Ca2+-calmodulin (Ikebe and Hartshorne, 1985),
whereas MLC phosphatase activity is regulated by a
number of signaling pathways (Hartshorne et al., 1998).
At a constant [Ca2+], a decrease in MLC phosphatase
activity increases SMRLC phosphorylation and force to
produce Ca2+ sensitization (Somlyo and Somlyo, 2003),
whereas an increase in MLC phosphatase activity
decreases SM RLC phosphorylation and force to pro-
duce Ca2+ desensitization (Somlyo and Somlyo, 2003).
MLC phosphatase is a holoenzyme (Hartshorne et al.,
1998) consisting of a catalytic subunit, a 20-kDa subunit
of unknown function, and a myosin targeting subunit
(MYPT1). Alternative splicing of a 123-bp central exon
results inMYPT1 isoforms that differ by a 41-aa central
insert (CI), referred to as M130 and M133 (Hartshorne
et al., 1998). Additionally, alternative splicing of the 39
exon (Khatri et al., 2001) is responsible for generating
MYPT1 isoforms that differ by the presence or absence
of a carboxy-terminal leucine zipper (LZ). Thus in
humans and other species, alternative splicing gener-
ates four MYPT1 isoforms that differ by the presence
or absence of a CI and LZ: CI+LZ+, CI-LZ+, CI+LZ2,
CI-LZ2 (Hartshorne et al., 1998).
B. Guanine Nucleotide Exchange Factor Signaling,
Rac/Rho, and Analysis of Inhibitors
The Rho GTPases are within the RAS superfamily of
small G proteins (Jaffe and Hall, 2005), which exist as
either active GTP-bound and inactive GDP-bound
forms. The conversion between active and inactive
forms is controlled by guanine nucleotide exchange
factors (GEFs), GTPase activating proteins (GAPs),
and guanine dissociation inhibitors. The role of RhoA
for the regulation of smooth muscle tone has been well
described (Fig. 5; Ca2+ sensitization and Pathway #2,
Fig. 3). RhoA/Rho kinase signaling is activated by G
protein-coupled receptors, and the role of this pathway
for the inhibition of MLC phosphatase and Ca2+ sensi-
tization has been the subject of a number of reviews
(Arner and Pfitzer, 1999; Somlyo and Somlyo, 2003;
Puetz et al., 2009). The activation of Rho kinase has
been demonstrated to phosphorylate CPI-17 at Thr38
(Eto et al., 1995; Kitazawa et al., 2000), PHI-1 at Thr57
(El-Touhky et al., 2005, 2006), and MYPT1 (Trinkle-
Mulcahy et al., 1995) at both T696 and T850 (Muranyi
et al., 2005). MYPT1 phosphorylation at T696 has been
Fig. 5. Ca2+ sensitization: Agonist activation of G-protein coupled receptors activates several signaling pathways (IP3, RhoA/Rho kinase, PKC, RAC1)
that modulate Ca2+ release from the SR and/or lead to Ca2+ sensitization of the contractile filaments (see text for details).
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demonstrated to decrease MLC phosphatase activity to
increase force at a constant Ca2+ (Kitazawa et al.,
1991a), whereas the phosphorylation of MYPT1 at
T850 dissociates the holoenzyme, which results in a
decrease in MLC phosphatase activity (Velasco et al.,
2002), which produces Ca2+ sensitization. Similarly,
agonist activation of G-protein-coupled receptors has
been demonstrated to lead to the activation of PKC,
which phosphorylates both CPI-17 at Thr38 (Eto et al.,
1995; Kitizawa et al., 1991b) PHI-1 at Thr57 (Eto et al.,
1999). When phosphorylated, these proteins will bind to
the catalytic core of the catalytic subunit of MLC
phosphatase to decrease phosphatase activity (El-
Toukhy et al., 2006; Eto et al., 2007). In addition to
Rho kinase, Zip kinase will phosphorylate MYPT1
(MacDonald et al., 2001a) as well as CPI-17 (MacDonald
et al., 2001b), and integrin-linked kinase will phosphor-
ylate MYPT1 (Kiss et al., 2002; Muranyi et al., 2002) as
well as CPI-17 and PHI-1 (Deng et al., 2002).
There are a number of studies demonstrating Rho
kinase signaling mediates both MYPT1 phosphoryla-
tion and Ca2+ sensitization (Somlyo and Somlyo, 2003;
Puetz et al., 2009). However, in smooth muscle of the
guinea pig ilium, although inhibition of Rho kinase
decreased the carbachol-induced increase in Ca2+ sen-
sitivity, it had no effect on MYPT1 phosphorylation
(Pfitzer, 2001). In this study, although staurosporin
prevented MYPT1 phosphorylation, specific PKC inhib-
itors had no effect on the phosphorylation of MYPT1,
which could suggest in this tissue Zip kinase is involved
in a physiologically important signaling pathway for
Ca2+ sensitization. In bladder smooth muscle, others
have demonstrated that there is constitutive phosphor-
ylation of MYPT1 at T696, which was unaffected by
inhibition of either Rho kinase or PKC, whereasMYPT1
phosphorylation at T850 was primarily mediated by
Rho kinase (Chen et al., 2015). These investigators
generated T696A and T850A MYPT1 mutant mice to
demonstrate that the MYPT1 phosphorylation at T696,
but not T850, is important for increasing RLC phos-
phorylation andCa2+ sensitization during the sustained
phase of force maintenance. These results demonstrate
that during activation of smooth muscle, the physiolog-
ically important signaling pathways mediating both
MYPT1 phosphorylation as well as Ca2+ sensitization
are agonist as well as tissue specific.
Although the role of RhoA in the regulation of Ca2+
sensitization of smoothmuscle is established, the role of
other Rho GTPases for force regulation in smooth
muscle is not well defined. Pak1, a downstream target
of Rac1, has been demonstrated to inhibit MLCK and
relax permeabilized intestinal smooth muscle (Wirth
et al., 2003). However in airway smooth muscle, both
the knockout or inhibition of Pak reduces tone (Hoover
et al., 2012), and Pak3 has been shown to induce a Ca2+-
independent contraction of permeabilized smooth
muscle (Van Eyk et al., 1998; McFawn et al., 2003).
Furthermore, Pak also has been demonstrated to
phosphorylate CPI-17 (Takizawa et al., 2002). Recently,
the role of Rac1 in force regulation has been further
delineated (Rahman et al., 2014). Using a smooth
muscle-specific, conditional Rac1 KO, these investiga-
tors demonstrated that the decrease in Rac1 reduced
force in both bladder and saphenous arterial smooth
muscle. Furthermore, the inhibition of Rac1 with
EHT1864, which affects nucleotide binding, decreased
the Ca2+ transient and force produced in response to
depolarization, agonist activation, and activation of
PKC. However, inhibition of Rac1 with NSC23766,
which blocks the interaction of Rac1 with GEFs, de-
creased force for phenylephrine (a-agonist) activation
but increased the force produced by stimulation with
both prostaglandin F2a and thromboxane (U46619).
These results suggest that Rac1 signaling is agonist
dependent and can result in either an enhancement of
the Ca2+ transient and force or an inhibition of Ca2+
sensitization.
The well documented role of RhoA/Rho kinase signal-
ing for the inhibition of MLC phosphatase and Ca2+
sensitization (Somlyo and Somlyo, 2003) could suggest
that Ca2+ sensitization of vascular smooth muscle cells
contributes to themolecularmechanism for the increase
in vascular tone and/or systemic vascular resistance
that produces hypertension. Consistent with this hy-
pothesis are the results demonstrating that in SHR
compared with control rats, both the sensitivity to
G-protein-coupled agonists and the magnitude and sen-
sitivity of Ca2+ sensitization are increased (Satoh et al.,
1994) as well as studies defining the role of G12-G13-
induced activation of Rho kinase-mediated Ca2+ sensiti-
zation for the development of DOCA salt-sensitive
hypertension (Wirth et al., 2008). Furthermore, the
infusion of the Rho kinase inhibitor Y-27632 reduced
blood pressure in normal Wistar rats, as well as several
animal models of hypertension including the SHR and
DOCA salt-sensitive rat models of hypertension
(Uehata et al., 1997), as well as L-NG-Nitroarginine
Methyl Ester (L-NAME)-induced hypertension (Seko
et al., 2003). Additionally, the expression and activity of
Rho kinase are higher in vascular smooth muscle
isolated from the SHR compared with controls (Mukai
et al., 2001), and the specific Rho kinase inhibitor
fasudil (Uehata et al., 1997) reduced blood pressure in
the SHR model of essential hypertension (Mukai et al.,
2001).
Rho/Rho kinase signaling has also been implicated as
an important contributor for the regulation of vascular
tone in other mammals; the Rho kinase inhibitor
HA1077 has been shown to dilate canine coronary
arteries (Asano et al., 1989). Furthermore, Rho kinase
is upregulated in a porcine model of coronary vaso-
spasm, and in this model, inhibition of Rho kinase with
Y-27632 decreases coronary vasospasm (Kandabashi
et al., 2000). In humans, fasudil has been demonstrated
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to be effective in treating the cerebral vasospasm
associated with subarachnoid hemorrhage (Tanaka
et al., 2005; Kim et al., 2006), and fasudil is approved
for treating patients with pulmonary hypertension
(Archer et al., 2010). In humans, Masumoto et al.
(2001) demonstrated that brachial artery infusion of
fasudil did not decrease systemic blood pressure, but did
produce a dose-dependent increase in forearm blood
flow in hypertensive patients, but not controls without
hypertension. Sodium nitroprusside, on the other hand,
resulted in comparable increases in forearm blood flow
in both hypertensive and normal humans. These results
suggest that an increase in RhoA/Aho kinase signaling
may be involved in the molecular mechanism that
produces essential hypertension, and development of
drugs that target this pathway could represent an
effective, novel class of therapeutic agents.
C. Phenotypic Switching of Contractile Proteins
during Development and Disease: Role of MYPT1 in
Ca2+ Sensitization/Desensitization
1. Smooth Muscle Myosin Heavy Chain. Four iso-
forms of the smooth muscle myosin heavy chain (SM
MHC) are produced by alternative splicing of a single
gene. Alternative splicing of a 59-site produces two
isoforms that express a unique aa sequence of either
43 (SM1, 204 kDa) or 9 (SM2, 200 kDa) residues at the
carboxy terminus of the SM MHC tail (Babij and
Periasamy, 1989; Nagai et al., 1989), whereas alterna-
tive splicing of a 21-bp insert produces a difference of 7
aa near the ATP binding site of the SM MHC (Kelley
et al., 1993). Although SM1 or SM2 homodimers are
more common than herterodimers in a single myosin
rod, SM1 and SM2 homodimers will copolymerize and
assemble into side polar thick filaments (Rovner et al.,
2002). Estrogen has been demonstrated to increase the
ratio of SM1/SM2 expression, and this shift in the
expression of SM1 MHC isoform has been suggested to
contribute to changes in the sensitivity to the agonist
norepinephrine and KCl depolarization (Paul et al.,
2007). However, others have demonstrated in the
motility assay, there is no difference in the ability of
SM1 and SM2 to translate actin (Rovner et al., 2002).
These investigators also demonstrated that although
there is no difference in the length of SM1 and SM2
filaments, the differences in SM1 and SM2 at the
carboxy terminus of the myosin tail influenced filament
packing and stability; SM1 filaments have greater
stability (Rovner et al., 2002). Consistent with these
results, others have demonstrated that the smooth
muscle thick filaments of the SM2 KO are similar in
length to that of WT mice, but the SM1 thick filaments
isolated from SM2KOmice are smaller in diameter and
there are fewer thick filaments per high-powered field
(Chi et al., 2008). However, despite the decrease in the
number of smooth muscle myosin thick filaments and a
concomitant decrease in the expression of SM1, the
force produced by both KCl depolarization and carba-
chol activation was higher in the SM2 KO (Chi et al.,
2008).
The other SM MHC isoform is due to a 7-aa insert at
the amino terminus, near the ATP binding site of the
SM MHC (Kelley et al., 1993). The 7-aa insert is
expressed in both SM1 and SM2 SM MHCs, and the
SM MHC with the 7-aa insert has been referred to as
SMB, whereas SM MHC lacking the insert is SMA
(Kelley et al., 1993). SMB, when compared with SMA,
has been demonstrated to have a twofold higher
AMATPase activity and a 2.5-fold faster velocity of
actin translation in the in vitro motility assay (Kelley
et al., 1993). Whether the presence of the insert confers
a functional difference to the mechanical properties of
smooth muscle was assessed using bladder smooth
muscle isolated from a transgenic mouse line; the
maximum velocity of muscle shortening of bladder
smooth muscle strips fromWT (SMB+/+) is higher than
that of either of heterozygous (SMB+/2) animals or the
SMB KO mice (Babu et al., 2001; Karagiannis et al.,
2004). Further analysis of the mechanical responses of
Ca2+-activated skinned bladder strips to elevated Pi
and ADP suggested that the lower shortening velocity of
the SMA isoform is due to a slower rate of ADP
dissociation or an additional force producing isomeriza-
tion of the AM-ADP state in the crossbridge cycle
(Karagiannis et al., 2003). These results demonstrate
that the insert near the SMMHC ATP binding site will
alter the mechanical properties of smooth muscle, and
the duty cycle of SMA should be higher than SMB,
which would be predicted to increase vascular tone and/
or vascular resistance and thus blood pressure. Consis-
tent with this prediction are the results demonstrating
that compared with WT mice, the isometric force for
mesenteric vessels of SMB KO mice was increased
(Babu et al., 2004). However, the blood pressure of
SMB KO animals compared with WT controls has not
been reported, and whether SMA/SMB isoform expres-
sion is altered during hypertension has not been
investigated.
2. ELC17. For the 17-kDa essential myosin light
chain (ELC17), alternative splicing of exon six, which
encodes 44 bp, also produces two isoforms, which differ
in the expression of 9 aa at the carboxy terminus of the
ELC17 (Nabeshima et al., 1987; Lenz et al., 1989;
Hasegawa and Morita, 1992). Exon 6 is excluded in
the nonmuscle, more basic isoform (ELC17a), whereas
exon 6 is included in the smooth muscle, more acidic
isoform (ELC17b) (Hasegawa and Morita, 1992; Kelley
et al.,1993). Changes in the ELC17 could affect the
stiffness of the SM MHC lever arm, and thus myosin
step size and or unitary force. However for ELC17
isoforms, the motility assay does not show any differ-
ence in the velocity of actin translocation (Kelley et al.,
1993; Quevillon-Cheruel et al., 2000). Nonetheless in
fast smoothmuscle, the expression of ELC17a and SMA
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is higher than in slow smooth muscle (Malmqvist and
Arner, 1991).
3. MYPT1. Alternative mRNA splicing produces
four splice variant MYPT1 isoforms, formed by the
presence or absence of a 43 aa central insert (CI+/2)
and carboxy-terminal leucine zipper (LZ+/2). The ex-
pression of the CI (residues 512–552) (Shimizu et al.,
1994) is both developmentally regulated and tissue
specific (Dirksen et al., 2000), and phosphorylation of
MYPT1 at Thr696 has been demonstrated to inhibit
phosphatase activity (Ichikawa et al., 1996). Although
there is evidence that the CI+ MYPT1 isoform may be
preferentially phosphorylated during Ca2+ sensitiza-
tion (Richards et al., 2002), a role for the CI for the
regulation of smooth muscle contractile properties has
not been established. The MYPT1 LZ+ isoform is
generated by the exclusion of a 39- to 31-bp exon, whereas
exon inclusion generates a LZ2MYPT1 isoform (Khatri
et al., 2001). The aa sequence of theMYPT1 LZ domain is
identical from avians to mammals and 75% identical in
mammals and worms (Khatri et al., 2001), which could
suggest that this domain is important for the regulation
ofMLC phosphatase activity. Surks et al. (1999) were the
first to demonstrate an important functional role for the
MYPT1 LZ domain. These investigators demonstrated
that the LZ MYPT1 domain was important for the
interaction of MYPT1 and PKG (Surks et al., 1999; Surks
and Mendelsohn, 2003). Subsequently it has been dem-
onstrated that PKG interacts with the LZ domain (Lee
et al., 2007; Sharma et al., 2008) as well as a MYPT1
domain between aa 888 and 928 (Given et al., 2007;
Sharma et al., 2008), but the LZ domain is necessary for
the PKG-mediated activation of the MLC phosphatase
during Ca2+ desensitization (Fig. 6,; Ca2+ desensitization)
and/or nitric oxide (NO)-mediated vasodilatation (Huang
et al., 2004). PKG phosphorylates MYPT1 at Ser695 and
Ser849, which excludes the Rho kinase-mediated
MYPT1 phosphorylation at Thr696 and Thr850, to
prevent a Rho kinase-mediated decrease in MLC phos-
phatase activity (Wooldridge et al., 2004; Nakamura
et al., 2007), but MYPT1 phosphorylation at these sites
by PKG does not increase MLC phosphatase activity
(Nakamura et al., 2007). The mechanism for the in-
crease in MLC phosphatase activity during NO/cGMP-
mediated Ca2+ desensitization was recently defined;
PKG phosphorylates only LZ+ MYPT1 isoforms at
Ser668 (Yuen et al., 2011, 2014), and the Ser668MYPT1
phosphorylation increases the activity of MLC phos-
phatase (Yuen et al., 2011; Yuen et al., 2014). MYPT1
LZ+/2 isoform expression is developmentally regu-
lated, tissue specific (Khatri et al., 2001; Payne et al.,
2006), and modulated in animal models of heart failure
(Karim et al., 2004; Chen et al., 2006; Ararat and
Brozovich, 2009; Han and Brozovich, 2013), pre-
eclampsia (Lu et al., 2008), portal hypertension (Payne
et al., 2004; Lu et al., 2008), pulmonary hypertension
(Konik et al., 2013), nitrate tolerance (Dou et al., 2010),
and sepsis (Reho et al., 2015). Furthermore, a decrease
in LZ+ expression decreases the sensitivity to NO-
mediated vasodilatation (Huang et al., 2004; Yuen
et al., 2011, 2014). Thus, the molecular mechanism that
underlies the differential response of the vasculature to
NO and NO-based vasodilators is in part due to
differential expression of LZ+/2 MYPT1 isoforms, and
furthermore, changes in the relative LZ+/2 expression
could tune the vasculature between a low-resistance
vascular bed (relatively vasodilated), which is NO
responsive and Rho kinase/PKC resistant, and a high-
resistance vascular bed (relatively vasoconstricted) that
is resistant to NO but responsive to Rho kinase/PKC.
Fig. 6. Ca2+ desensitization: ACh stimulation of muscarinic receptors on the vascular endothelium leads to the production of NO, and NO diffuses into
smooth muscle cells to activate guanylate cyclase. The NO/cGMP signaling pathway relaxes smooth muscle by both decreasing intracellular Ca2+ and
activating MLC phosphatase, which results in Ca2+ desensitization of the contractile filaments (see text for details).
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The importance of the LZ domain of MYPT1 for the
regulation of vascular tone has been established using
two different transgenic mice. Michael et al. (2008)
produced a transgenic mouse with mutations in the LZ
domain of PKG, which disrupts the interaction of PKG
with MYPT1. Compared with control littermates, the
vascular smooth muscle isolated from these mice were
less sensitive to NO-mediated vasodilatation, and thus
these mice were hypertensive. In addition and also
consistent with an important role for LZ+ MYPT1
isoform expression for the regulation of vascular tone
are the results demonstrating that transgenic mice
expressing only the LZ+ MYPT1 isoform are more
sensitive to NO-mediated relaxation and hypotensive
compared with WT littermates (Reho et al., 2015).
Because NO-mediated vasodilation is a fundamental
property of the vasculature (Furchgott and Zawadzki,
1980; Furchgott, 1999), preservation of the normal
response to NO by maintaining the normal LZ+MYPT1
isoform expression could improve the outcome for the
treatment of diseases of the vasculature. For the
treatment of heart failure, both ACE inhibitors (Chen
et al., 2006; Chen and Brozovich, 2008) and ARBs
(Ararat and Brozovich, 2009) have been demonstrated
to preserve both LZ+ MYPT1 expression and the
sensitivity to NO-mediated vasodilatation, which could
underlie the beneficial effects of inhibition of angioten-
sin II signaling in the treatment of heart failure
compared with other vasodilators (Pfeffer et al., 1992;
Yusuf et al., 1992, 2000; Pitt et al., 2000; Granger et al.,
2003). Additionally, differential expression of LZ+/2
MYPT1 isoforms in patients with heart failure could
underlie the mortality benefit of ACE inhibitors in
white compared with black patients. ACE inhibitors
reduced mortality in white patients, whereas in black
patients, although ACE inhibitors did not show a
benefit, treatment with the combination of hydralazine
and isosorbide dinitrate reduced mortality (Carson
et al., 1999).
The regulation for LZ+/2 MYPT1 expression is un-
known, but LZ+/2 MYPT1 expression is both develop-
mental regulated and tissue specific (Khatri et al., 2001;
Payne et al., 2006), as well as modulated during disease
states (Karim et al., 2004; Payne et al., 2004; Lu et al.,
2008; Fisher, 2010). During heart failure (HF), p42/
44 MAP kinase is activated and the expression of
LZ+ MYPT1 decreases (Ararat and Brozovich,
2009), and further losartan therapy prevents the acti-
vation of p42/44MAP kinase and preserves LZ+MYPT1
expression (Ararat and Brozovich, 2009). Additionally,
the expression of LZ+MYPT1 isoforms aswell as Tra-2b,
an atypical member of RNA binding proteins, are higher
in fast (phasic) compared with slow (tonic) smooth
muscle, and in an animal model of portal hypertension,
Tra-2b is downregulated coincident with the decrease in
LZ+ MYPT1 expression (E23 exon exclusion) and the
shift to the expression of LZ2MYPT1 isoforms (Shukla
and Fisher, 2008). These investigators demonstrated
both that Tra-2b binds to E23 and transactivates E23
splicing (exon inclusion) to generate a LZ2 MYPT1
isoform and deletion or mutation of the Tra2b binding
site abolished E23 splicing (exon exclusion) to produce a
LZ+ MYPT1. These investigators also showed that an
siRNA-induced decrease of Tra-2b decreased E23 splic-
ing to produce an increase in LZ+ MYPT1 expression,
which is consistent with Tra-2b expression regulating
E23 splicing and LZ+/2MYPT1 expression (Shukla and
Fisher, 2008). Further investigation of the signaling
pathway for the regulation of LZ+/2 MYPT1 isoform
expression could reveal novel targets in this pathway.
Small molecules could be designed to modulate either
total MYPT1 or LZ+ MYPT1 expression, which would
both improve both the vascular response to endogenous
NO and pharmacological response during the treatment
of hypertension as well as a number of other diseases of
the vasculature.
D. Implications for Disease and Treatment
1. Pressurized Resistance Vessels, Implications of the
Myogenic Response for Hypertension, and Critical
Analysis of Inhibitors. In most systems, flow and
pressure are linearly related; as pressure increases, so
does flow. However, small arteries vasoconstrict in
response to an increase in pressure and vasodilate
in response to a decrease in pressure, and the change
in vessel diameter in response to changes in intravas-
cular pressure is referred to as the myogenic response
(Bayliss, 1902; Lassen, 1959; Davis and Hill, 1999). The
myogenic response is an intrinsic property of the small
resistance vessels and does not require flow (Davis and
Hill, 1999). Furthermore, because of the intrinsic
myogenic response as well as the modulatory actions
of vasoactive substances (Bayliss, 1902; Lassen, 1959;
Davis and Hill, 1999; Walsh and Cole, 2013), the
resistance vessels maintain a constant blood flow over
a wide range of perfusion pressures, and this property is
termed the autoregulation of blood flow (Bayliss, 1902;
Lassen, 1959; Davis and Hill, 1999).
Hypertension is associated with abnormalities of the
myogenic response (Immink et al., 2004; Jarajapu and
Knot, 2005; Kim et al., 2008b), and thus, themechanism
underlying the myogenic response is important in both
health and disease. There are significant regional as
well as vessel dimension differences in the magnitude
and mechanism governing the autoregulation of blood
flow (Jones et al., 1995; Davis and Hill, 1999). Further
complicating investigation of the mechanism(s) respon-
sible for the myogenic response are the small size (,200
mm diameter) of the resistance vessels; until recently,
investigation of the signaling pathways regulating the
myogenic response of the small resistance arteries was
not possible. But, recent improvements in the sensitiv-
ity of protein phosphorylation levels have allowed for
direct investigation of signaling pathways that regulate
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the myogenic response (Takeya et al., 2008; Johnson
et al., 2009; El-Yazbi et al., 2010; Moreno-Dominguez
et al., 2013).
Although the signaling pathway for the myogenic
response is still being investigated, the first element is
the mechanosensor that responds to the changes in
intraluminal pressure. Martinez-Lemus et al. demon-
strated that blocking integrin function with either anti-
integrin antibodies (Martinez-Lemus et al., 2005) or
integrin-specific peptides (Martinez-Lemus et al., 2003)
results in a significant inhibition of the myogenic
response. Furthermore, both the activation of integrins
and the myogenic response are associated with tyrosine
phosphorylation and the activation of focal adhesion
kinase (FAK) and Src family tyrosine kinases (Murphy
et al., 2001; 2002). Additionally, agonist stimulation of
smooth muscle lead to a tyrosine phosphorylation of the
protein paxillin (Pavalko et al., 1995) as well as
activation of p42/44 MAPK (Spurrell et al., 2003) and
the L-type Ca2+ channel (Chan et al., 2010). These data
suggest that because of their ability to link the extra-
cellular matrix to the cytoskeleton of the smoothmuscle
cell, integrins participate in the sensing and trans-
mission of changes in intravascular pressure.
There are a number of studies that have demon-
strated an important role for TRP channels Earley and
Brayden (2015), specifically TRPC6 and TRPM4 in the
myogenic response. Gonzales et al. (2014) demonstrated
that selective inhibition of TRPM4 decreased the tran-
sient inward cation current induced by membrane
stretch. These investigators demonstrated that the
generation of IP3 by PLCg1 and the subsequent Ca
2+
release from internal stores is required for both TRPM4
activity and myogenic tone. Furthermore, both TRPC6
inhibitors and antibodies that bind to an extracellular
epitope of TRPC6, which block TRPC6 currents, atten-
uated the stretch-induced activation of TRPM4 current.
These investigators also demonstrated that the inhibi-
tion of Src nonreceptor tyrosine kinases, which signal
through PLCg, decreased myogenic tone. These results
suggest that Src tyrosine kinase activity is important in
the stretch-induced increases PLCg, which generates
IP3. Subsequently, IP3 binds to the IP3 receptor, which
stimulates Ca2+ release from the SR. Thus, in response
to stretch, a local increase in Ca2+ generated by both
TRPC6 and IP3 are important for the activation of
TRPM4, which changes membrane potential and in-
creases the conductance of voltage-dependent Ca2+
channels, which results in smooth muscle cell contrac-
tion to generate the myogenic response.
Additionally, both Ca2+ release and Ca2+ sensitiza-
tion of the contractile filaments contribute to the
myogenic response. The pressure-induced increase in
wall tension leads to depolarization of the smooth
muscle cells, which results in opening of voltage-gated
Ca2+ channels (Knot and Nelson, 1998; Davis and Hill,
1999) and an increase in intracellular Ca2+. However, in
addition to the pressure-induced increase in Ca2+, other
mechanisms contribute to the myogenic response (Wor-
ley et al., 1991; Osol et al., 2002). Using a highly
sensitive biochemical technique, El-Yazbi et al. (2010)
demonstrated that only in the presence of myogenic
tone, serotonin stimulation produced a Rho kinase-
mediated phosphorylation of MYPT1, which induced a
Ca2+ sensitization of the contractile filaments. Further-
more, this group has also demonstrated that both a Rho
kinase-mediated phosphorylation of MYPT1, as well as
a Rho kinase- and PKC-mediated increase in actin
polymerization are important determinants of the
myogenic response (Moreno-Dominguez et al., 2013;
El-Yazbi et al., 2015). The activation of the Ca2+-
dependent tyrosine kinase, Pyk2, has also been demon-
strated to occur with KCl depolarization, and although
the inhibition of Pyk2 did not change the rapid increase
in force and RLC phosphorylation in response to KCl
depolarization, Pyk2 inhibition did depress RLC phos-
phorylation, Thr-696, and Thr-850 MYPT1 phosphory-
lation and force during the sustained phase of the
contraction (Mills et al., 2015). These results suggest
that a Ca2+-induced activation of Pyk2 leads to an
activation of RhoA/Rho kinase and Ca2+ sensitization,
which is important for force maintenance, or the tonic
phase of smooth muscle contraction.
Because hypertension is associated with abnormali-
ties of the myogenic response (Immink et al., 2004;
Jarajapu and Knot, 2005; Kim et al., 2008b), antihyper-
tensive agents aimed at the signaling pathway for the
myogenic response should be effective for the control of
blood pressure. Drugs that decrease Ca2+ influx as well
as agents that decrease and/or block the activation of
Rho kinase signaling such as ACE inhibitors, ARBs,
Rho kinase inhibitors should be and are effective
antihypertensives. However, novel agents designed to
decrease the sensitivity of the mechanosensor such as
blocking the activation of integrins or decreasing tyro-
sine kinase activation could reduce blood pressure.
However, tyrosine kinase inhibitors used for the treat-
ment of carcinomas are known to be cardiotoxic (Chu
et al., 2007; Force et al., 2007), and hypertension is the
most common cardiovascular side effect (Chu et al.,
2007). The mechanism by which tyrosine kinase in-
hibition produces hypertension is not well understood,
but hypothesized to be due to fluid retention, endothe-
lial dysfunction, and an inhibition of NO (Cabanillas
et al., 2011). These data demonstrate the complex
interplay between the myogenic response, circulating
vasoactive substances, and the kidney in the regulation
of blood pressure.
2. Smooth Muscle Myosin versus Nonmuscle Myosin,
Implications for Force Maintenance and Vascular Tone.
There are three classes of nonmuscle (NM) myosin
(Golomb et al., 2004), NMIIA, NMIIB, and NMIIC,
and both NMIIA and NMIIB are expressed in smooth
muscle (Gaylinn et al., 1989; Morano et al., 2000;
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Lofgren et al., 2003; Eddinger et al., 2007; Yuen et al.,
2009; Guvenc et al., 2010; El-Yazbi et al., 2015),
whereas NMIIC is only expressed in neuronal tissue
(Golomb et al., 2004; Jana et al., 2009). BothNMIIA and
NMIIB are able to form bipolar thick filaments (Bill-
ington et al., 2013), and similar to SM, myosin RLC
phosphorylation promotes filament formation (Ikebe
and Hartshorne, 1985; Applegate and Pardee, 1992).
In smooth muscle, NM myosin expression represents
;10–15% of total myosin (Yuen et al., 2009; Konik et al.,
2013). Furthermore, NMIIA has been demonstrated to
formmixed bipolar filamentswithmyosin 18A (Billington
et al., 2015), and SM1 and SM2 will copolymerize to
form filaments (Rovner et al., 2002). However, it is
unclear if NM myosin and SM myosin copolymerize to
form mixed filaments or whether two distinct pools of
SM and NM myosin thick filaments exist within the
smooth muscle cells.
The kinetics of the individual steps of the AMATPase
of NMIIB (Wang et al., 2003) and NMIIA (Kovacs et al.,
2003) are slower than other types of class II myosin.
NMIIA and NMIIB have a high ADP affinity, and for
NMIIB, the rate of ADP release is similar to that of the
steady-state ATPase. Additionally for NMIIB, actin
augments ADP binding rather than accelerating ADP
release (Wang et al., 2003), which results in NMIIB
spending the majority of its kinetic cycle in states that
are strongly bound to actin (Rosenfeld et al., 2003;Wang
et al., 2003). On the other hand, the rate of ADP release
for NMIIA is one order of magnitude faster than the
ATPase, which results in NMIIA spending much less of
its ATPase cycle in strongly actin bound states (Kovacs
et al., 2003). Although the slow kinetics of NMIIA
suggest that NMIIA could contribute to force mainte-
nance, the high duty ratio make NMIIB an ideal
candidate for the so called “latch crossbridge” (Dillon
et al., 1981; Dillon and Murphy, 1982; Hai and Murphy,
1989), and NMmyosin may be an important component
for the sustained phase of smooth muscle contraction.
Kovacs et al. (2007) recently extended his kinetic
studies and demonstrated that ADP release from
NMIIB is slow and strain dependent; positive strain
increases the rate of ADP release by a factor of fourfold,
whereas negative strain decreases ADP release by 12-
fold. Load dependence of ADP release prevents NMIIB
from slowing either shortening or the rate of force
generation by smooth muscle myosin. However for
NMIIB, negative strain increases the duty ratio, which
would contribute to force maintenance (Kovacs et al.,
2007); i.e., for NMIIB, rapid ADP binding and load-
dependent ADP release prolongs the attachment of
NMIIB to actin at 10–100 mMADP (at normal MgATP),
which would decrease the rate of ATP usage to ,0.01
ATP per head per second during force maintenance
(Kovacs et al., 2007). Furthermore, during force main-
tenance both heads of the NMIIB would be attached to
actin, which is ideal for a crossbridge that maintains
tone.
Similar to NM myosin, the kinetics of SM myosin
have been demonstrated to depend on load (Veigel et al.,
2003). Using optical tweezers, these investigators dem-
onstrated that the displacement of the SM crossbridge
occurs in successive steps of 4 and 2 nm. The duration of
the first phase (4-nm displacement) is strain dependent,
increasing by twofold with a negative strain and de-
creasing by twofold with positive strain. These results
could suggest that the increase in attachment time of
SM myosin due to the negative strain on the SM
crossbridge during force maintenance could contribute
to the latch state. Furthermore, recent data from optical
trap experiments demonstrated that the attachment
time of smooth muscle myosin to actin varies with SM
RLC phosphorylation (Tanaka et al., 2008); when only
one of the two heads of smooth muscle myosin is
phosphorylated, the dwell time was fit with a double
exponential with rates of 24 second21 and 1 second21,
compared with a single rate of 29 second21 when both
heads were phosphorylated. These investigators sug-
gested that the long attachment time of the singly
phosphorylated myosin could explain the latch state,
or force maintenance, in smooth muscle. However,
experiments in the optical trap are performed at low
ionic strength to both promote actin-myosin interaction
and increase interaction times; at physiologic condi-
tions, rates are much faster. Tanaka et al. (2008) also
demonstrated that the ATP turnover rate of singly
phosphorylated myosin was 30% of that compared with
doubly phosphorylated myosin, which contrasts with
the results of Rovner et al. (2006) who demonstrated
that the ATP turnover rate of myosin with a single
phosphorylated head was over 50% of that when both
heads were phosphorylated. The reason for the discrep-
ancy between the results for the ATP turnover is
unclear. However, it is likely that the single molecule
mechanics of NM myosin with the RLC of one or both
heads phosphorylated would be similar to smooth
muscle myosin, although much slower, making NM
myosin a more attractive candidate for a latch
crossbridge.
The regulation of NM myosin has been studied in
nonmuscle cells (Kolega, 2003), and similar to smooth
muscle myosin, NM myosin is regulated by phosphory-
lation of its regulatory light chain (NM RLC); NM RLC
phosphorylation promotes NM myosin filament assem-
bly (Kolega, 2003) and also results in a 10-fold increase
in the Vmax of the NMmyosin AMATPase (Cremo et al.,
2001). In nonmuscle cells, Rho kinase phosphorylates
the NM RLC at Ser19 (Kolega, 2003), and in epithelial
cells, results are consistent with both MLCK and Rho
kinase as important for the phosphorylation of NMRLC
(Connell and Helfman, 2006). In epithelial carcinoma
cell lines, Rho kinase increases the phosphorylation of
the NM RLC at Ser19 phosphorylation of both NMIIA
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and NMIIB (Sandquist et al., 2006). During KCl de-
polarization of smooth muscle, both SM RLC and NM
RLC phosphorylation increase, and the increase in RLC
phosphorylation is not dependent on either Rho kinase
or PKC (Yuen et al., 2009). However for angiotensin II
(Ang II) activation, inhibition of either Rho kinase or
PKC blunted SM RLC phosphorylation, whereas only a
Rho kinase-dependent pathway regulated NM RLC
phosphorylation (Yuen et al., 2009). These results
demonstrate that similar to SM myosin, NM myosin is
regulated in smooth muscle, and both MLCK and Rho
kinase regulate the activation of NM myosin (Fig. 7).
Recent evidence from mechanical studies also sug-
gests that NM myosin contributes to the force mainte-
nance phase of smooth muscle tissue contraction.
Morano et al. (2000) showed that bladder smooth
muscle from transgenic mice lacking smooth muscle
myosin still contract, albeit with a very slow tonic
response, as opposed to the rapid phasic contraction
(with transient peaks in force and Vmax) characteristic
of wild-type bladder smooth muscle (Morano et al.,
2000; Lofgren et al., 2003). The force produced by NM
myosin in KO tissues is low (Lofgren et al., 2003), which
would suggest that NM myosin will not participate in
the rapid phase of force activation, but rather the
kinetics of NM myosin are tuned for force maintenance
(Kovacs et al., 2007). Consistent with this hypothesis
are results demonstrating that the inhibition of the NM
AMATPase with blebbistatin reduced force mainte-
nance (Rhee et al., 2006); for phasic smooth muscle,
blebbistatin did not affect the rapid rise in force, but
decreased maintained force, and for tonic smooth
muscle, blebbistatin decreased force maintenance.
However, although blebbistatin is thought to be specific
for the inhibition of the NM myosin AMATPase
(Straight et al., 2003), the specificity of blebbistatin for
the NM versus SM AMATPase has been questioned
(Eddinger et al., 2007). Nonetheless, consistent with a
role of NMmyosin for force maintenance are the results
with heterozygous NMIIB KO mice; when compared
with WT control mice, force maintenance is depressed
by 25% in smooth muscle of heterozygous NMIIB KO
(Yuen et al., 2009). Interestingly, Sward et al. (2000)
demonstrated for carbachol activation of guinea pig
ileum that inhibition of Rho kinase did not affect peak
force but decreased force maintenance, and Rho/Rho
kinase signaling regulates NM RLC phosphorylation
(Yuen et al., 2009). These results are consistent with
NMmyosin participating in force maintenance (Morano
et al., 2000; Lofgren et al., 2003; Rhee et al., 2006; Yuen
et al., 2009; Guvenc et al., 2010), and the inhibition of
Rho kinase would lead to a decrease in the activation of
NM myosin (Yuen et al., 2009), which results in a
reduction in both the force maintenance phase of
smooth muscle contraction and vascular tone (SVR). It
is also interesting to speculate on the contributions of
other pathways, which have been demonstrated to be
important contributors for changes in vascular tone for
the regulation of NM myosin including tyrosine kinase
(Moreno-Dominguez et al., 2013; El-Yazbi et al., 2015;
Mills et al., 2015).
3. Force Maintenance/Latch and the Regulation of
Vascular Tone: The Tonic versus Phasic Contractile
Phenotype and Contributions to Pathogenesis of
Hypertension. Smooth muscle contractile properties
have been classified as phasic or tonic (Somlyo and
Somlyo, 1968); after activation, for phasic smooth
muscle, force rises rapidly to a peak before falling to a
lower steady-state level, whereas for tonic smooth
muscle, force slowly increases to a sustained steady
state. Smooth muscle has also been termed “fast” and
“slow” because of the differences in Vmax. The molecular
mechanism that governs tonic and/or phasic contractile
properties has yet to be elucidated, although emerging
evidence suggests that there are tonic and phasic
contractile phenotypes (see Fisher, 2010). In general,
the fast isoforms of the SM MHC (SMB) and ECL17
(ECL17a) are expressed in phasic smooth muscle while
slow isoforms (SMA and ECL17b) expression predom-
inates in tonic smooth muscle (Malmqvist and Arner,
1991). Similarly, the expression of NM myosin is
significantly higher in tonic smooth muscle (Lofgren
et al., 2003; Rhee et al., 2006). In addition, there are
differences in the expression of the regulatory proteins
in phasic and tonic smooth muscle. The expression of
MLCK (Gong et al., 1992), MYPT1 (Woodsome et al.,
2001), and the LZ2 MYPT1 isoform (Dirksen et al.,
2000; Khatri et al., 2001) is higher in phasic compared
with tonic smooth muscle. Furthermore, in phasic
versus tonic smooth muscle, the expression of CPI-17
is lower (Woodsome et al., 2001), whereas telokin
expression is higher (Gallagher et al., 1991; Wu et al.,
1998; Herring et al., 2001). These results could suggest
that a gene program exists that governs the differential
expression of contractile proteins in fast (phasic) versus
slow (tonic) smooth muscle (Fisher, 2010), and the con-
tractile phenotype regulates systemic vascular resistance.
Resistance is inversely related to the vessel radius to
the forth power (1/r4), and thus, SVR is predominantly
regulated at the level of the small resistance arteries
with a diameter of 50–300 mm. Because of their small
size, the molecular contractile phenotype of the re-
sistance vessels have not been fully characterized, but
the small resistance vessels express a mixture of fast
and slow contractile proteins (Fisher, 2010) and exhibit
a mixture of tonic and phasic contractile activity, which
is referred to as vasomotion (Peng et al., 2001; Haddock
and Hill, 2005). The molecular basis of essential
hypertension is unknown, but the molecular contractile
phenotype is known to be modulated during disease in
both the large conduit vessels (Karim et al., 2004; Chen
et al., 2006; Ararat and Brozovich, 2009), as well
smaller resistance vessels (Zhang and Fisher, 2007;
Han and Brozovich, 2013). In the small resistance
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vessels, an increase in the relative expression of protein
isoforms associated with the tonic contractile phenotype
(i.e., an increase in NM myosin expression) or decrease
in LZ+ MYPT1 isoform expression would produce an
increase in vascular tone and/or SVR, which would
produce hypertension.
4. Autoregulation of Vascular Resistance/Flow-
Mediated Vasodilatation and Nitric Oxide Signaling
with Analysis of Current Inhibitors. Flow is governed
by the simple equation, flow = pressure/resistance, and
the ability of NO, or flow, tomediate changes in vascular
tone is considered a fundamental property of the
vasculature (Furchgott, 1999). The autoregulation of
blood flow to a vascular bed maintains a constant flow
over a wide range of pressures to ensure that perfusion
is maintained despite either hypo- or hypertension. The
mechanism governing the autoregulation of blood flow
has yet to be fully elucidated but is known to be
dependent on the intrinsic myogenic response as well
as the modulatory actions of vasoactive substances
(Lassen, 1959; Walsh and Cole, 2013), which impor-
tantly includes the vascular response to NO. NO is
produced by the vascular endothelium in response to
shear stress. The NO produced by the endothelium
diffuses into the smooth muscle cells where it activates
the soluble pool of guanylate cyclase and results in an
increase in cGMP. cGMP activates protein kinase G
(PKGI), which has a number of targets that produce
smoothmuscle relaxation (Lincoln, 1989; Schmidt et al.,
1993; Alioua et al., 1998; Fukao et al., 1999; Lincoln
et al., 2001), including myosin light chain (MLC)
phosphatase (Surks et al., 1999). As perfusion pressure
increases, the subsequent increase in blood flow will
increase shear stress on the endothelial cells, which will
stimulate NO production and a subsequent vasodilata-
tion to decrease flow. Conversely, a decrease in perfu-
sion pressure will decrease endothelial shear stress and
NO production, and the resulting vasoconstriction will
increase flow. Therefore, the NO-induced changes in
vascular resistance can be viewed as part of a negative
feedback loop that blunts the myogenic response; the
myogenic response generates a vasoconstriction with an
increase in pressure and vasodilatation with a decrease
in pressure (Bayliss, 1902; Lassen, 1959; Davis andHill,
1999; Walsh and Cole, 2013). Thus, NO production
regulates vascular resistance and is essential for the
normal regulation of blood flow.
The sensitivity and response of the vasculature to NO
and NO-based vasodilators are well known to be
heterogenous, and the molecular basis for this variable
response to NO is controversial. Nonetheless, during
NO signaling, activation of the MLC phosphatase
requires the expression of a LZ+MYPT1 isoform (Surks
et al., 1999, 2003; Huang et al., 2004; Yuen et al., 2011,
2014) and in both health (Khatri et al., 2001; Huang
et al., 2004; Payne et al., 2006) and disease (Karim et al.,
2004; Payne et al., 2004; Zhang and Fisher, 2007; Lu
et al., 2008; Dou et al., 2010; Han and Brozovich, 2013;
Konik et al., 2013). The sensitivity of the vasculature to
NO-mediated vasodilation is regulated by the relative
expression of LZ+/LZ2 MYPT1 isoforms; i.e., an in-
crease and/or decrease in LZ+ MYPT1 expression will
produce an increase and/or decrease in the sensitivity to
NO, respectively. Nitrates and nitrate-based vasodila-
tors are a well-known class of antihypertensive agents
that will decrease blood pressure in the acute setting.
However, tolerance to nitrates is a well-known phenom-
enon, which may limit the efficacy of nitrates for
the treatment of hypertension, and a decrease in
LZ+ MYPT1 expression has been demonstrated to
contribute to the molecular mechanism of nitrate
tolerance (Dou et al., 2010). In the treatment of heart
failure, both ACE inhibitors (Chen et al., 2006; Chen
and Brozovich, 2008) and ARBs (Ararat and Brozovich,
2009) have been demonstrated to maintain the normal
expression of LZ+ MYPT1 expression and sensitivity to
NO-mediated vasodilatation. In essential hypertension,
both whether changes in LZ+ MYPT1 expression con-
tribute to the molecular mechanism producing this
disease and strategies to improve LZ+ MYPT1 expres-
sion and the sensitivity toNO-based vasodilators for the
treatment of hypertension have not been investigated.
5. Mouse Models (Contractile Protein Knockout) and
Implications for Hypertension. Several strains of ge-
netically modified mice have been produced to evaluate
the contribution of abnormalities in the regulation of
vascular tone and/or vascular dysfunction to hyperten-
sion (Pfeifer et al., 1998; Brenner et al., 2000; Chutkow
et al., 2002; Zhu et al., 2002; Tang et al., 2003; Michael
et al., 2008; Wirth et al., 2008; Qiao et al., 2014), and
experimental results and their implications will be
discussed in this section.
Ca2+ signaling is well known to be important for the
regulation of vascular tone (Arner and Pfitzer, 1999);
the activation of voltage-gated Ca2+ channels increases
cytoplasmic Ca2+ and results in vasoconstriction. How-
ever, the increase in Ca2+ also activates Ca2+-activated
potassium channels (BK channels), and Ca2+ activation
of these channels results in a membrane hyperpolariz-
ing current that opposes vasoconstriction (Nelson et al.,
1995) and K+ channel openers, such as nicorandil,
hyperpolarize smooth muscle to produce vasodilatation
(Nelson et al., 1990). Brenner et al. (2003) deleted the b1
subunit of the BK channel in mice and demonstrated
that, compared with controls, the open probability of BK
channels was 100-fold lower and the BK current in
response to Ca2+ sparks was impaired in vascular
smooth muscle from the b1 KO animals. Furthermore,
myography demonstrated that cerebral arteries from
the b1 KO animals mice were more constricted at all
pressures, which resulted in hypertension in these
animals. Additionally, BK channels have been demon-
strated to increase their conductance in response to NO/
cGMP signaling (Alioua et al., 1998).
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In smooth muscle, contractile agonists have been
demonstrated to activate the G-proteins Gq and G11
and stimulate phospholipase C, which leads to an
increase intracellular Ca2+ and activation of MLCK to
increase RLC phosphorylation and force (Somlyo and
Somlyo, 2003). However, many vasoconstrictors also
couple with G12 and G13 to activate Rho kinase-
mediated signaling, which inhibits MLC phosphatase
to produce a Ca2+-independent increase in force (Somlyo
and Somlyo, 2003). Wirth et al. (2008) produced mice
with smooth muscle-specific ablation of Gq-G11 or
G12-G13 to investigate the relative contributions of
Gq-G11 versus G12-G13 on vascular tone and the devel-
opment of hypertension. In aortic smooth muscle iso-
lated from the Gq-G11 KOmice, the contractile response
to both phenylephrine and Ang II was completely
blocked, whereas the response to serotonin, endothelin,
vasopressin, and the thromboxane analog U46619 was
inhibited. Ablation of G12-G13 had no effect on the dose-
response relationship for phenylephrine or serotonin,
but it reduced the steady-state force produced by Ang II,
endothelin, vasopressin, and U46619. Furthermore,
compared with WT mice, blood pressure was no differ-
ent in the mice with ablation of G12-G13, but signifi-
cantly lower in the Gq-G11 KO mice, indicating that the
normal regulation of blood pressure requires Gq-G11
signaling. Additionally, ablation of either Gq-G11 or
G12-G13 attenuated the increase in blood pressure pro-
duced by DOCA-salt treatment, which suggests that
although G12-G13 signaling and the subsequent activa-
tion of a Rho kinase pathway leading to Ca2+ sensitiza-
tion is not required for maintenance of normotension, it
contributes to the development of DOCA-salt-dependent
hypertension. These investigators also demonstrated
that the RhoGEF protein LARG is important for the
G12-G13-mediated activation of Rho kinase and DOCA-
induced hypertension.
The importance of the NO/cGMP signaling pathways
for themaintenance of a normal blood pressure has been
established with several different models. In mice, the
disruption eNOS has been demonstrated to eliminate
ACh-mediated relaxation of aortic smoothmuscle rings,
and as would be predicted, the relaxation produced by
sodium nitroprusside was no different in eNOS KO and
WT animals. This defect in vascular reactivity resulted
in hypertension in the eNOS KO mice (Huang et al.,
1995). Similarly, PKGI KO mice were hypertensive
compared with WT littermates (Pfeifer et al., 1998).
These investigators demonstrated compared with WT,
that although the response to contractile agonist was
not different in aortic rings from the PKGI KO, ACh-
and 8Br-cGMP-mediated relaxation was significantly
attenuated. Further preincubation of aortic cells with
8Br-cGMP attenuated the Ca2+ transient in response to
NE in WT aortic smooth muscle cells, but had no effect
on the Ca2+ transient in the PKGI KO aortic smooth
muscle cells.
Most contractile agonists activate Gq-coupled recep-
tors, resulting in the activation of phospholipase C, the
generation of IP3, Ca
2+ release, and the activation of
MLCK as well as Rho/Rho kinase and a resulting
inhibition of the MLC phosphatase (Somlyo and Somlyo,
1994; Davis and Hill, 1999). Mendelsohn’s group (Tang
et al., 2003) demonstrated that the dose-dependent
increase in IP3 production by thrombin was inhibited
by both S-nitrosocysteine and 8Br-cGMP. Because NO
and cGMP inhibit thromboxane signaling via a PKG-
mediated phosphorylation of the cytoplasmic tail of the
thromboxane receptor (Wang et al., 1998) and RGS-2
terminates G-protein receptor signaling by accelerating
the GTP hydrolysis rate by Ga subunits (Watson et al.,
1996), these investigators (Tang et al., 2003) examined
the function of RGS-2 in NO/cGMP signaling cascade.
They demonstrated that phosphorylation of RGS-2 by
PKG resulted in a translocation of RGS-2 from the
cytosolic to particulate fractions and decreased Gaq
GTPase activity. These data show that NO/cGMP-
mediated activation of PKG results in a phosphoryla-
tion of RGS-2, which increases the activation of
Gq-coupled receptors. Consistent with these data are
the results that show agonist-induced force production
was increased and the vasodilatory response to NO was
reduced in aortic smooth muscle from RGS-2 KO mice,
and the resulting increase in vascular tone (relative
vasoconstriction) was responsible for the increase in
blood pressure in RGS-2 KO mice compared with WT
littermates (Tang et al., 2003). The importance of the
NO/cGMP signaling cascade for the regulation of vas-
cular tone and blood pressure has also been demon-
strated in three recent studies (Michael et al., 2008;
Qiao et al., 2014; Reho et al., 2015). Michael et al. (2008)
produced a knock-in mouse in which the initial four
leucine/isoluecine residues of PKGIa were replaced by
alanine. This PKGIa LZ mutant does not interact with
MYPT1 (Surks andMendelsohn, 2003), and as would be
predicted, when compared with WT, aortic rings iso-
lated from the PKGIa LZ mutant were less sensitive to
ACh- and 8Br-cGMP-mediated relaxation, which pro-
duced hypertension. Qiao et al. (2014) produced a
conditional MYPT1 KO, which were hypertensive com-
pared with WT controls. The lack of MYPT1, which
would disrupt the ability of the MLC phosphatase to
target to its substrate, the RLC, resulted in an increase
in the phosphorylation of the RLC as well as force in
response to both KCl depolarization and contractile
agonists. However, surprisingly, the sensitivity of re-
laxation produced byNO/cGMP signalingwas similar in
the control and MYPT1 KOmice. The lack of a decrease
in the sensitivity to NO of secondary branches of the
mesenteric arteries from MYPT1 KO animals could be
explained if the conditional KO of MYPT1 increased
RGS-2 expression or decreased NO/cGMP-mediated
PKG phosphorylation of RGS-2 or the functional re-
placement of MYPT1 by MBS85, which is a member of
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the MYPT family that is also expressed in smooth
muscle (Hartshorne et al., 2004). Reho et al. (2015)
generated a conditional deletion of MYPT1 E24 to
produce a LZ+ MYPT1 KI mouse. Vascular tissue
isolated for the LZ+ MYPT1 mice was more sensitive
to NO/cGMP-mediated relaxation, and as would be
expected, the mice were hypotensive compared with
controls. Of course, it must be kept in mind that NO,
cGMP, and PKG also can dilate vascular smoothmuscle
by more than one mechanism, thus pathways not
involvingMYPT1 are also possible but we are not aware
of appropriate animal models yet available to test those
possibilities.
Mendelsohn’s group has also demonstrated that NO
signaling is regulated by estrogens; Zhu et al. (2002)
compared the vascular responses in WT, iNOS KO, and
estrogen receptor b KO mice. Estrogen was found to
decrease PE-induced contraction of aortic smooth mus-
cle inWT, but not iNOSKOmice. Furthermore, iNOS is
upregulated by estrogen, as well as transfection with
estrogen receptor b. In vascular rings from estrogen
receptor b KO mice, compared with WT mice, the
contractile response to PE was reduced, which could
be the result of a decrease in iNOS in the estrogen
receptor b KO tissues. The sensitivity of smooth muscle
relaxation to sodium nitroprusside was similar in
estrogen receptor b KO and WT animals. Nonetheless,
in the estrogen receptor b KO animals, the abnormal-
ities in vascular tone produced hypertension.
The data presented in this section demonstrate the
importance of the regulation of vascular tone for the
regulation of blood pressure and consistently demon-
strate that disruption in the NO/cGMP signaling
pathway reduces the sensitivity to NO-mediated vaso-
dilatation, and this decrease in the vascular response
to NO and/or NO-based vasodilators produces
hypertension.
E. Summary of Contractile Phenotype and
Contributions to Pathogenesis of Hypertension with
Analysis of Current Therapies for Hypertension
Diuretics reduce blood pressure by decreasing in-
travascular volume, which mechanistically fits with a
Guytonian view for the regulation of blood pressure
(Guyton, 1991), and diuretics, as a class, are useful for
treating essential hypertension (ALLHAT and Coordi-
nators for the ALLHAT Collaborative Research Group,
2002; Rosendorff et al., 2007). Given the importance of
Ca2+ signaling for the regulation of vascular tone (Arner
and Pfitzer, 1999; Somlyo and Somlyo, 2003), the
benefit of CCB for treating humans with essential
hypertension is not surprising (ALLHAT Officers and
Coordinators for the ALLHAT Collaborative Research
Group, 2002). Similarly, ACE inhibitors and ARBs will
decrease the activation of the Ang II G-protein-coupled
receptor and inhibit Ang II-stimulated increase in
intracellular Ca2+ and activation of Rho kinase
signaling to decrease vascular tone (Somlyo, 1997).
Crowley et al. (2005) demonstrated that the KO of the
AT1 receptor in only the peripheral vasculature de-
creases SVR and blood pressure, and thus, these agents
would be expected to and have been demonstrated to be
effective therapies of essential hypertension (Guyton,
1991; ALLHAT Officers and Coordinators for the
ALLHAT Collaborative Research Group, 2002). In fact,
drugs that block any G-protein-coupled receptor,
i.e., a-receptor blockers (Koshy et al., 1977), would be
expected to decrease vascular tone and lower blood
pressure. b-Blockers decrease the activation of the
cardiac b-adrenergic receptor, and the subsequent de-
crease in cAMP and PKA signaling produce negative
chronotropic and inotropic response, which decreases
blood pressure (Rosendorff et al., 2007). However, in the
vascular smooth muscle, an increase PKA activity
produces a vasodilatation ((Nakamura et al., 2007;
Wooldridge et al., 2004), and b-blocker therapy could
potentially result in an increase in vascular tone, but
because of the inhibition of central sympathetic output,
SVR decreases with b-blocker therapy (Man in’t Veld
et al., 1988). Drugs designed to increase K+ channel
conductance produce smooth muscle hyperpolarization
and a resulting vasodilatation of vascular smooth
muscle (Nelson et al., 1990; Sobey, 2001; Barbato,
2005), and these agents have been demonstrated to
both decrease blood pressure (Wang et al., 2005) and be
effective treating angina (Group, 2002). Although NO
and NO-based vasodilators will result in a decrease in
vascular tone (Furchgott, 1999) and are effective for
treating angina (Rosendorff et al., 2007), they have not
been demonstrated to be useful in treating essential
hypertension (Rosendorff et al., 2007), possibly because
of the phenomenon of nitrate tolerance (Munzel et al.,
2005).
Although there are a number of effective classes of
antihypertensives (Rosendorff et al., 2007), when treat-
ing patients with essential hypertension, the selection
of an antihypertensive agent does not consider the
possible changes in the smooth muscle contractile
phenotype that may contribute to the molecular mech-
anism for essential hypertension. This could explain the
variable racial and individual response to drug classes
(Cushman et al., 2000; Johnson, 2008; Gupta, 2010).
Thus, a critical need for a personalized approach for the
treatment of essential hypertension exists.
F. Potential Novel Targets for Treatment of
Essential Hypertension
Despite the effectiveness of current antihypertensive
(Rosendorff et al., 2007), many patients with essential
hypertension either do not respond to one or more
therapeutic agents or have a resistant hypertension
that requires treatment with multiple classes of anti-
hypertensives for adequate control of blood pressure.
Other than the well-known racial and regional
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differences in response to various classes of antihyper-
tensives (Cushman et al., 2000; Johnson, 2008; Gupta,
2010), there is no known method to determine for any
individual drug class whether a patient with essential
hypertension will have a therapeutic response or the
magnitude of the response to therapy. Because the
molecular mechanism that produces essential hyper-
tension is unknown, the diversity in the response to
treatment is not unexpected and demonstrates the
importance of identifying the mechanism producing
hypertension in each individual. As outlined in the
preceding sections, there are a number of changes in the
contractile phenotype that could contribute to hyper-
tension, and the contribution of the contractile pheno-
type could be variable among patients.
NO-mediated vasodilatation is a fundamental prop-
erty of the vasculature (Furchgott, 1999), and studies of
transgenic mice have demonstrated the importance of
NO/cGMP signaling for maintenance of normal SVR
and blood pressure (Huang et al., 1995; Pfeifer et al.,
1998; Brenner et al., 2000; Zhu et al., 2002; Michael
et al., 2008; Qiao et al., 2014; Reho et al., 2015).
However, nitrate-based vasodilators have not been
demonstrated to be effective for the treatment of
essential hypertension (Rosendorff et al., 2007), possi-
bly because of nitrate tolerance (Munzel et al., 2005). A
number of mechanisms contribute to this phenomenon,
but recently a decrease in LZ+MYPT1 isoform has been
suggested to play a role in the molecular mechanism for
nitrate tolerance (Dou et al., 2010). Because PKG-
induced phosphorylation of LZ+ MYPT1 isoforms and
subsequent activation of the MLC phosphatase (Yuen
et al., 2011; Yuen et al., 2014) is a key component in the
NO/cGMP signaling pathway leading to vasodilatation
(Lincoln, 1989), increasing MYPT1 LZ+ expression
should be effective for both for reversing nitrate toler-
ance and the treatment of essential hypertension. The
regulation for LZ+/LZ2MYPT1 expression is unknown,
but investigators have demonstrated that Tra-2b ap-
pears to be an important regulator for LZ+/LZ2MYPT1
expression (Shukla and Fisher, 2008). Furthermore,
both ACE-inhibitors (Chen et al., 2006) and ARBs
(Ararat and Brozovich, 2009) were demonstrated to
preserve both the normal LZ+ MYPT1 expression and
sensitivity to NO-mediated vasodilation in heart fail-
ure, which may explain the benefit of these agents in
treating heart failure (Pfeffer et al., 1992; Yusuf et al.,
1992; Pitt et al., 2000; Yusuf et al., 2000, 2003; Granger
et al., 2003) compared with other vasodilators (Awan
et al., 1977), as well as the mortality differences for
treatment of heart failure with hydralazine and iso-
sorbide dinitrate versus enalapril in white and black
patients (Carson et al., 1999). Investigation of the
signaling pathway for the regulation of total MYPT1
as well as LZ+/2 MYPT1 isoform expression could
reveal novel targets in this pathway that would increase
LZ+ MYPT1 expression. Small molecules could be
designed to modulate either total MYPT1 or LZ+
MYPT1 expression in vascular smooth muscle, and
therapies designed to increase LZ+ MYPT1 expression
in vascular smooth muscle would improve both the
vascular response to endogenous NO and pharmacolog-
ical response during the treatment of hypertension.
Other targets in theNO signaling pathway could also be
exploited for the treatment of essential hypertension;
i.e., novel activators of RGS-2 would be expected to
decrease the activation of Gq-coupled receptors (Tang
et al., 2003; Watson et al., 1996) and ultimately de-
crease vascular tone and blood pressure.
NM myosin could represent another novel target for
drug development for the treatment of hypertension.
The inhibition (Rhee et al., 2006), as well as the KO
(Yuen et al., 2009) of NM myosin has been demon-
strated to decrease force during the tonic phase of
smooth muscle contraction, and thus inhibition of NM
myosin would be expected to decrease both vascular
tone and blood pressure. As outlined above, there are
significant differences in the expression of contractile
proteins between tonic and phasic smooth muscle
(Fisher, 2010), and resistance vessels express a mixture
of fast and slow contractile proteins (Fisher, 2010), as
well as tonic and phasic contractile properties (Peng
et al., 2001; Haddock and Hill, 2005). The contractile
phenotype is known to be modulated during disease in
both the large conduit vessels (Ararat and Brozovich,
2009) and smaller resistance vessels (Zhang and Fisher,
2007; Han and Brozovich, 2013), and thus essential
hypertension could be due to changes in the gene
program governing the contractile phenotype and a
resulting change in the contractile properties of the
resistance vessels from a phasic to more tonic pheno-
type. This could suggest that targeting the gene pro-
gram to enhance the expression of phasic contractile
proteins would decrease blood pressure and represent a
novel therapy for essential hypertension.
V. Cytoskeletal Regulation
Regulation of smooth muscle function by myosin
isoforms, particularly nonmuscle myosin isoforms is
discussed above in section IV. Here we will discuss the
cytoskeletal proteins that until recently were assumed
to serve a primarily structural role in smooth muscle.
There are three types of cytoskeletal proteins in this
category: intermediate filaments, microtubules, and
actin filaments.
A. Intermediate Filaments, Dystrophin, Utrophin,
and Microtubules
Intermediate filaments have been studied relatively
little in contractile smooth muscle but of note is
literature that suggests that intermediate filaments
may be the glue that sticks together different functional
domains of the smooth muscle cellular cytoskeleton.
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This is based on anatomic studies of several types of
smooth muscle (Devine and Somlyo, 1971; Ashton et al.,
1975; Small et al., 1986; Siegman, 2014) showing that a
population of actin filaments that are not directly
contacting myosin surround the actomyosin filament
bundles and insert into cytoplasmic “dense bodies.”
These cytoplasmic dense bodies in turn are connected
to “dense bodies” at the surface of the cell (focal
adhesions) by intermediate filaments. Studies on air-
way smooth muscle have also indicated that interme-
diate filaments form cable-like structures that connect
dense bodies and that these structures have a func-
tional plasticity due to mechanisms, yet to be defined,
by which the cable length can be adjusted in a regula-
tory manner (Zhang et al., 2010). Intermediate fila-
ments in contractile vascular smooth muscle have also
been suggested to serve functional roles that are not
simply structural. For example, these filaments bind
CaMKII and are phosphorylated by this kinase
(Marganski et al., 2005), but whether the intermediate
filaments are serving a signaling scaffolding role or
whether CaMKII is somehow changing the function of
the intermediate filaments is not known. Similarly, in
airway smooth muscle, PAK has been shown to phos-
phorylate intermediate filaments (Wang et al., 2006,
2007). Interestingly, antisense knockdown of vimentin
in smooth muscle inhibits agonist-induced force devel-
opment (Tang, 2008), but, again, the exact molecular
mechanism involved is not clear.
1. Dystrophin/Utrophin. Of interest is the fact that
smooth muscle contains large quantities of dystrophin
and utrophin. These proteins have been little studied in
smooth muscle, but in lung and vascular smooth muscle
they and the dystroglycan complexes they form connect
with caveolin and cavin in caveoli as well as the actin
cytoskeleton (Palma-Flores et al., 2014; Sharma et al.,
2014). Knockout of dystrophin in amousemodel decreases
contractility of tracheal rings (Sharma et al., 2014).
With respect to microtubules, as expected, the micro-
tubular network is sparse in nonproliferative, non-
dividing smooth muscle (Somlyo, 1980). They could
serve a transport purpose, but we are unaware of such
functions yet being demonstrated in contractile smooth
muscle.
B. Actin
A far more extensive literature has developed with
respect to actin in smooth muscle. The actin in contrac-
tile smooth muscle can be divided into that associated
with smooth muscle myosin, generally called the thin
filaments, and the nonmuscle actin cytoskeleton. The
mechanisms of regulation of actomyosin have been
discussed above. Here we will focus on the emerging
role of the nonmuscle cytoskeleton in the regulation of
vascular function.
Several groups have demonstrated that vasoconstric-
tors and myogenic contractions (Cipolla et al., 2002;
Rembold et al., 2007; Kim et al., 2008a, 2010; Tejani
et al., 2011) regulate the structure of the actin cytoskel-
eton and its connection to focal adhesions (FAs) (Poythr-
ess et al., 2013; Saphirstein et al., 2013, 2015)
(Pathway #4, Fig. 3). These smoothmuscle FAs appear
to be essentially identical FAs in cultured cells except
for their less dynamic nature (Poythress et al., 2013).
Increasing evidence (Hill et al., 2001; Gunst and Zhang,
2008; Sun et al., 2008; Saphirstein et al., 2015) indicates
that tension modulates the function of signaling path-
ways in the smooth muscle tissue/cell and that these
biomechanical functions are mediated by remodeling of
the smooth muscle focal adhesions and its nonmuscle
actin cytoskeletal connections. It is important to em-
phasize that smooth muscles generally lack tendons for
the transmission and summation of contractile forces
generated by the muscles. In contrast, in smooth
muscles the extracellular matrix (ECM) forms a sort of
“intramuscular tendon” to which the integrins attach. It
is one function of the focal adhesions, then, to channel,
somehow, all contractile force generated by the contrac-
tile apparatus through the integrins and to the ECM.
The exact mechanisms involved are now an active area
of investigation in smooth muscle cells.
Moreno-Dominguez et al. (2014) have reported that a
decline in G-actin content occurs in response to pres-
surization or agonist activation of cerebral resistance
arteries, resulting in an increase in contractility in the
absence of detectable myosin or actin phosphorylation
that could be blocked by Rho kinase and PKC inhibitors.
These results pointed to cytoskeletal remodeling con-
tributing to the contractile responses observed. Smooth
muscle actin exists as four different isoforms. Alpha
smooth muscle actin and gamma smooth muscle actin
are the dominant actins associated with myosin in the
contractile filaments, what has been called “mini sar-
comers,” (Fatigati and Murphy, 1984; Kargacin et al.,
1989; Herrera et al., 2005) in vascular and gastrointes-
tinal smooth muscle, respectively. Beta nonmuscle and
gamma nonmuscle actins are thought to be present in
all smooth muscles (Fatigati and Murphy, 1984; Drew
et al., 1991; Kim et al., 2008a). These four isoforms are
separate gene products and clearly have different
functions and different expression patterns, but in-
terestingly they have highly similar protein sequences
with no isoform sharing less than 93% identity with any
other isoform (Perrin and Ervasti, 2010). Kim et al.
(2008a) mapped the individual actin isoforms in vascu-
lar smooth muscle during contraction in response to an
alpha agonist and found that the overall F/G ratio
increases by about twofold in response to the alpha
agonist phenylephrine, but only gamma nonmuscle
actin displays a statistically significant increase in
polymerization. Interesting, in response to a phorbol
ester, 12-deoxyphorbol 13-isobutyrate 20-acetate, only
beta nonmuscle actin showed significant evidence of
remodeling.
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The actin isoforms also appear to define distinct sub-
cellular domains within the geography of the cell. It has
been found that alpha smooth muscle actin is associated
with contractile filaments, beta nonmuscle actin is associ-
ated with cytoplasmic dense bodies and focal adhesions
and gamma nonmuscle actin describes in interesting
submembranous cortical domain in vascular smooth
muscle (Parker et al., 1994, 1998; Gallant et al., 2011).
Truly specific gamma nonmuscle antibodies have only
recently become available, but earlier studies described
qualitatively similar organizations in gut smooth muscle
(Furst et al., 1986; Small et al., 1986;North et al., 1994a,b).
C. Focal Adhesion Remodeling
The smooth muscle FA, by connecting with the non-
muscle actin and intermediate filament cytoskeleton, is
thought to serve the purpose of transmitting force
generated in the contractile filaments through the
integrins to the extracellular matrix and the tissue as
a whole. FAs in contractile smooth muscle, like those in
cultured, migrating cells, are thought to undergo con-
siderable plasticity and remodeling in response to bio-
mechanical forces, agonists, and hormones. When this
has been directly investigated in contractile VSMCs,
some, but not all, proteins have been shown to dissociate
from the bulk of the FA during vasoconstrictor stimu-
lation. Zyxin and vasodilator-stimulated phosphopro-
tein (VASP), but notably not FAK, undergo Src-dependent
endosomal processing and regulate, throughprocesses not
yet fully understood, vascular contractility and stiffness
(Poythress et al., 2013). In contrast, in airway smooth
muscle, FAK has been shown to be quitemobile, shuttling
between FAs at the plasmalemma and the cell interior
(Opazo Saez et al., 2004). This highlights differences not
only in organ function but also in cellular mechanisms
between different types of smooth muscle.
Zyxin and vasodilator-stimulated phosphoprotein
(VASP) are FA proteins associated with regulation of
actin polymerization. This is consistent with a model
whereby in VSMCs, only proteins at the edge of the focal
adhesion, furthest from the plasmalemma, are capable
of breaking off and undergoing remodeling in smooth
muscle. This model is consistent with recent nanoscale
super-resolution imaging of cultured fibroblast focal
adhesion function described by Kanchanawong et al.
(2010). In theKanchanawongmodel, their data describe
three sublayers within individual FAs: 1) the “integrin
signaling layer,” containing integrin and its direct
connections such as FAK closest to the plasmalemma;
2) the “force transduction layer,” including vinculin and
talin, which are more interior; and 3) the “actin
regulatory layer,” containing alpha actinin and zyxin,
which is deepest into the cytoplasm.
D. Link to Hypertension
An interesting scenario occurs immediately after
birth when there is a drastic demand for a decrease in
pulmonary vascular resistance. This triggers a transi-
tion from the intrauterine pulmonary vascular require-
ment for only 8–10% of cardiac output, whereas the
placenta performs the function of the primary site of gas
exchange to the independent support of the newborn’s
lung function. As a result, in the first days to weeks of
the newborn’s life, dramatic vascular remodeling is
required. If this fails it is associated with the disorder
of persistent pulmonary hypertension of the newborn.
Interestingly, the remodeling is not just of the cells of
the vascular tissue but also a subcellular remodeling of
the actin isoforms within the vascular cells with a
persistence of excessive gamma actin being a marker
of persistent pulmonary hypertension of the newborn
(Fediuk and Dakshinamurti, 2015). Cortical gamma
actin polymerization is reported to prevent nuclear
translocation of the transcription factor YY1, which
downregulates SM22, important for smooth muscle
specific differentiation (Sotiropoulos et al., 1999).
A similar link between actin polymerization at a
subcellular level within the vascular smooth muscle
cell and blood pressure has been suggested by the effect
of vasoconstrictor agonists to cause both actin polymer-
ization and inward remodeling of resistance vessels
associated with many forms of hypertension. Further-
more, inhibition of actin polymerization prevented the
agonist-induced inward remodeling of the resistance
vessels (Staiculescu et al., 2013). It is well known that
increased intraluminal pressure elicits a myogenic
vasoconstriction from resistance vessels and a further
increase in blood pressure. This myogenic response has
been associated with increased Ca2+ entry to the cell,
activation of myosin light chain kinase, as well as
increased activation of ROCK and protein kinase C
pathways that regulate actin polymerization (Moreno-
Dominguez et al., 2013).
Further investigation of the signaling pathway for the
myogenic response has implicated integrins as the link
between the extracellular matrix and the cytoskeleton
that senses changes in pressure (Martinez-Lemus et al.,
2003, 2005). Because the activation of integrins and the
myogenic response is associated with tyrosine phos-
phorylation and the activation of focal adhesion kinase
(FAK) and Src family tyrosine kinases (Murphy et al.,
2001, 2002), blocking the activation of integrins or
decreasing the activation of tyrosine kinase could be
novel targets for treating essential hypertension. Al-
though nonreceptor tyrosine kinases can phosphorylate
paxillin and induce actin polymerization (Ohanian
et al., 2005) and a PKC-mediated pathway will lead to
the phosphorylation, or activation, of PYK2 and Src
tyrosine kinases (Hodges et al., 2007; Chang et al.,
2012), there is also evidence that receptor tyrosine
kinases participate in the regulation of vascular tone.
ephrin (EPH) kinases are the largest family of receptor
tyrosine kinases, and the ligand for EPH tyrosine
kinases are ephrins. Ephrins are also cell surface
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molecules that transduce signals into cells, and multiple
EPHs will interact with multiple ephrins (Pasquale,
2008). Recently, the smooth muscle-specific deletion of
the tyrosine kinaseEPHB4was demonstrated to result in
decreased contractile responses to the agonist phenyl-
ephrine and hypotension in male, but not female, mice
(Wang et al., 2015). Contrasting with these results are
those demonstrating that blood pressure was unaffected
by deletion of the tyrosine kinase EPHB6 in male and
female mice, but blood pressure was elevated and the
contractile response to phenylephrine was enhanced in
castrated male EPHB6 KO mice (Luo et al., 2012; Wu
et al., 2012). These results demonstrate that there is
interplay between the various members of the non-
receptor and receptor tyrosine kinase families as well as
other factors that ultimately contribute to the regulation
of blood pressure that may provide untapped targets for
the development of novel antihypertensive therapeutics.
VI. Identifying Therapeutic Targets in Vascular
Smooth Muscle through Biomechanical Studies
A. Arterial Stiffness as a Predictor of Negative
Cardiovascular Events with Aging
Increased arterial stiffness is a prominent concept in
studies of cardiovascular disease (CVD), especially in the
context of aging, as an independent biomarker and pre-
dictor of hypertension and atherosclerosis, which are
associated with increased mortality rates and severe
damage to organ systems via stroke, renal failure, and
heart disease (Ross, 1993, 1999;Dustanet al., 1996;Blacher
et al., 1999; Guerin et al., 2001; Laurent et al., 2001;
Cruickshanketal., 2002;Mattace-Rasoetal., 2006;Laurent
and Boutouyrie, 2007). Given the overwhelming predomi-
nance and persistence of CVD as the leading cause of
humandeathworldwide, there is great interestandurgency
to develop a thorough understanding of arterial stiffness as
a possible cause of, and thus a potential therapeutic target
for preventing or treating, CVD in humans.
Assessment of arterial stiffness exists on multiple
scale levels. Macroscale techniques that characterize
the hemodynamics of pulsatile blood flow are available
clinically in humans and more easily interpretable,
whereas microscale techniques better elucidate the
underlying mechanisms causative of changes in the
physical properties of blood vessels (Kohn et al., 2015).
In studying arterial stiffness, the predominant chal-
lenge moving forward is to establish an integrated
model of increased arterial stiffness across macro- and
microscopic scales that enable the development of
treatments to alleviate or prevent later-onset CVD.
Recent studies suggest that vascular smooth muscle
represents an attractive therapeutic target for such
designs.
1. Pulse Wave Velocity: The Clinical Standard.
In vivo arterial stiffness can be measured representa-
tively and noninvasively as pulse wave velocity (PWV).
This measurement of the pulse wave generated by
cardiac systole is the ratio of the distance it travels
along the vascular wall to the time delay between its
arrivals at different points along the circulatory path-
way. Most commonly, PWV is measured via ultrasound
between the carotid and femoral arteries as represen-
tative of aortic stiffness. As the current “gold standard”
of arterial stiffness measurements, increased PWV is
strongly correlated to both aging and CVD (Mitchell
et al., 2007; Willum-Hansen et al., 2006; Ben-Shlomo
et al., 2014).
The validity of PWV as an in vivo approximation of
aortic stiffness is described by the Moens-Korteweg
equation:
PWV ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Eh=2ra
q
where E is the incremental Young’s modulus of the
vessel, h and a are the thickness and radius of the aortic
wall, respectively, and r is blood density. The value of E
represents a material stiffness of the wall that is more
precisely descriptive of its biomechanical properties.
The Moens-Korteweg equation is itself dependent upon
key assumptions: that the aortic wall is isotropic and
homogeneous and that the aorta undergoes small
isovolumetric changes in response to pulse wave prop-
agation. Unfortunately, these assumptions do not hold,
as demonstrated by previous studies (Clark andGlagov,
1985; Gosling and Budge, 2003); therefore, whereas
PWV is an undoubtedly useful prognosticative tool, its
accuracy as a biomechanical indicator is unclear.
2. The Importance of Ex Vivo Material Stiffness.
It is appropriate here to distinguish between “functional
stiffness”—a relation between pulse pressure applied to
a vessel and its resultant deformation, or strain—and
“material stiffness,” the normalization of functional
stiffness to vessel geometry, most notably vessel di-
ameter and wall thickness (Greenwald, 2007). Material
stiffness corresponds most directly to the value of E in
the Moens-Korteweg relation and is the most indepen-
dent representation of an intrinsic property to resist
deformation in response to an applied force (O’Rourke,
1990; Gamble et al., 1994).
Therefore, PWV can more accurately be described as
a standard for functional but not material stiffness.
Functional stiffness is derived from material stiffness,
but the opposite is not true. In understanding this
subtle difference, the diverse terminology used in
reference to aortic biomechanical properties may pre-
sent significant difficulties, compounded by the preva-
lence of terms reciprocal to stiffness such as
“compliance” and “distensibility,” which are sometimes
used interchangeably among studies in the context of
independence from vessel geometry. The most concise
discussion of this complicated canvas is provided by
Bank and Kaiser (1998), who cite conflicting results
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attributable to imprecise terminology and summarize
their own study, showing that changes to PWV in
brachial arteries, in response to smooth muscle re-
laxation, are not necessarily predictive of any corre-
sponding change in material stiffness.
Analysis of arterial mechanical properties is integral
to understanding more broadly the epidemiologic link
between arterial stiffness and negative cardiovascular
outcomes. Although arterial PWV is an easily demon-
strable and a clinically valuable measure of functional
stiffness, there is also a strong impetus to evaluate
material stiffness of the aortic wall directly to explain
how different components of the aortic wall, a highly
complex and layered network of interconnected cellular
and extracellular elements, contribute to altered or
defective mechanisms in disease models. This is most
conveniently and commonly done ex vivo by subjecting
arterial tissue to mechanical stretch.
B. Regulation of Arterial Stiffness by Vascular
Smooth Muscle
Although numerous studies and quantitative models
have highlighted the extracellular matrix as the pri-
mary effector of dramatic changes in arterial stiffness
due to aging or other cardiovascular defects (Greenwald,
2007; Zulliger and Stergiopulos, 2007; Fleenor et al.,
2010, 2012; Holzapfel and Ogden, 2010; Valentin et al.,
2011; Wagenseil and Mecham, 2012), vascular smooth
muscle cells (VSMCs) are implicated to be major regu-
latory factors of arterial stiffness overall.
1. Homeostatic Interactions between Cellular and
Extracellular Components of the Arterial Wall. All
major biologic components of the arterial wall play
integral roles in maintaining normal cardiovascular
function. Abnormalities in cellular mechanotransduc-
tion, which is regulated by cytoskeletal structures,
transmembrane receptors, matrix proteins, and cell-
cell and cell-matrix adhesions, have been linked to
changes in cell mechanics or sensory machinery, as well
as structural alterations in extracellular matrix, which
are commonly featured in a wide range of diseases
(Ingber, 2003, 2006). Indeed, there is a critical codepen-
dence between medial elastin and VSMCs in maintain-
ing structure and function in the arterial wall, with
studies showing both that elastin regulates VSMC
proliferation (Brooke et al., 2003) and that VSMC
knockout phenotypes result in severe degradation of
elastin (Fry et al., 2015). VSMCs have been implicated
in recruitment of both elastin (Dobrin, 1978) and
collagen (Bank and Kaiser, 1998) during their contrac-
tile response.
Physiologic factors such as aging and hypertension
induce observable physical changes in the wall due to
VSMC remodeling (Glagov et al., 1993; Intengan and
Schiffrin, 2000). With aging in particular, vascular
smoothmuscle cells (VSMCs) exhibit increased stiffness
(Qiu et al., 2010) and are capable of switching their
phenotype from contractile to synthetic, resulting in
fundamental changes to cellular function as well as wall
structure, because remodeled VSMCs migrate and pro-
liferate in concert with alterations to other wall compo-
nents, most notably elastin and collagen (Greenwald,
2007; Avolio et al., 2011).
The endothelium has also become an increasingly
visible nexus of aging-induced changes, with wide-
spread effects on cellular and extracellular processes
throughout the arterial wall and especially those linked
to VSM function. Nitric oxide (NO) produced by endo-
thelial cells induces vasodilation and relaxation in VSM
(Russell andWatts, 2000). NO bioavailability is reduced
with aging, which attenuates this benefit, increasing
VSM stiffness as a result. This downstream effect may
characterize a powerful positive feedback loop where
the increased stiffness leads to further reduction of NO
(Cannon, 1998; Avolio et al., 2011).
2. The Focal Adhesion and Actin Cytoskeleton as
Regulatory Sites of Arterial Material Stiffness.
Recently, attempts to quantify the constituency of total
arterial stiffness attributable to VSMC activity have
become more prevalent. Ex vivo studies have shown
that VSMCs contribute significantly to total stiffness,
potentially in conjunction with recruitment of collagen
(Barra et al., 1993; Bank et al., 1996). Under optimally
physiologic conditions for smooth muscle viability, up to
50% of maximal ex vivo aortic stiffness is observable
only after activating VSMCs by alpha agonist and
eliminating NO-mediated vasodilation (Gao et al.,
2014b), quantifiable as shown in Fig. 8.
Therefore, it is of great interest to probe the cellular
mechanisms that produce this effect to identify un-
derlying origins of dysfunction and degeneration. A
series of studies highlighting stimulated VSMCs have
found that focal adhesions connecting the cortical
cytoskeleton to the matrix play a critical role in the
regulation of signaling cascades triggered by smooth
muscle activation, independently of actomyosin cross-
bridges (Kim et al., 2008a, 2010; Min et al., 2012;
Poythress et al., 2013). In particular, disruption of the
FAK-Src signaling complex reduces contractility and
stiffness, as well as biochemical markers of focal
adhesion signaling, induced by smooth muscle activa-
tion (Saphirstein et al., 2013; Saphirstein and Morgan,
2014). Interestingly, these mechanisms are defective
with aging (Gao et al., 2014b), and may not be limited to
the focal adhesions, but are also processes inherent in
the cortical actin cytoskeleton (Saphirstein et al., 2015).
The normal plasticity of the cytoskeleton may be an
important sort of “shock absorber” for the aortic wall
that is lost with aging. A model for the focal adhesion
and actin cytoskeleton in the VSMC as core machinery
regulating arterial stiffness, which is compromised with
aging, has emerged from these findings, as shown in
Fig. 9.
Mechanisms of Vascular Smooth Muscle Contraction 507
It has become increasingly clear that VSMmay play a
major role in the regulation of arterial stiffness.
VII. Regulation of Vascular Smooth Muscle Cell
Function by Epigenetic Mechanisms
Epigenetic changes refer to the heritable alterations in
gene expression that occur without changes in genome
sequence (Jaenisch and Bird, 2003). The conventional
epigenetic mechanisms include DNA methylation and
histone modification, which alter the accessibility of
transcription factors at DNA regulatory regions, such as
promoters or enhancers (Kouzarides, 2007). Over the last
decade, RNA-based modifications, which alter the trans-
lation of genetic information, have emerged as important
regulators of development anddisease. Collectively, these
mechanisms likely play a role in the remarkable plastic-
ity exhibited by vascular smooth muscle cells (VSMCs).
This sectionwill discuss the role of epigenetics in vascular
smoothmuscle (VSM) biology and describeways bywhich
Fig. 7. Force maintenance involving either nonmuscle myosin or smooth muscle myosin: There are several proposed mechanisms for force
maintenance in smooth muscle including the interaction of actin with either smooth muscle or NM myosin (latch crossbridge) as well as changes in the
cytoskeleton (see text for details and see also Fig. 3).
Fig. 8. Separability of contractile components to the generation of aortic stiffness. Modified from Gao et al. (2014b).
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these changes may influence the risk of cardiovascular
diseases, such as hypertension.
A. DNA Methylation
DNA methylation involves the covalent addition of a
methyl group to the 59-position of the pyrimidine ring of
cytosine residues to form 5-methylcytosine (Lorenzen
et al., 2012). This process, catalyzed by DNA methyl-
transferases, leads to transcriptional repression by
blocking the access of transcription factors to response
elements in the promoter region of genes. DNA meth-
ylation had long been considered irreversible until the
recent discovery of the members of the ten-eleven
translocation (TET 1-3) family of proteins. TET proteins
oxidize 5-methylcytosine to 5-hydroxymethyl cytosine,
which ultimately revert to cytosine via the demethyla-
tion pathway (Boedtkjer et al., 2011; Lorenzen et al.,
2012).
Variable methylation patterns are observed in the
genes of VSMCs originating from different tissues
(Zhang et al., 2012). Abnormalities in DNAmethylation
patterns have been observed to associate with vascular
diseases and have been studied extensively in athero-
sclerosis (Dong et al., 2002; Castro et al., 2003; Hiltunen
and Yla-Herttuala, 2003). SMCs of atherosclerotic
lesions in humans and animal models exhibit reduced
levels of 5-methylcytosine. The resulting DNA hypome-
thylation enhanced switching of VSMCs from a contrac-
tile to synthetic phenotype (Laukkanen et al., 1999;
Ying et al., 2000; Hiltunen et al., 2002).
B. Histone Modifications
The modifications at protruding N-terminal tails of
histones act as an integral epigenetic tag for chromatin
remodeling. The histone tails can be modified by
acetylation, methylation, ubiquitylation, and phosphor-
ylation (Cheung et al., 2000; Kouzarides, 2007). The
unique pattern of histone modifications in SMCs can
alter chromatin packaging, which leads to the differen-
tial expression of crucial VSMC genes (Alexander and
Owens, 2012). For example, the chromatin structure of
the CArG-box [CC(A/T)6GG] motif, essential for tissue-
specific expression of SMC marker genes, exists in an
easily accessible euchromatin-like form in SMCs but not
in non-SMCs (Alexander and Owens, 2012). Various
histone modifications, such as dimethylation of H3K4
and H3K79 and acetylation of H4 and H3K9, have been
observed in the CArG elements of SM a-actin and SM
MHC in VSMC gene loci (McDonald et al., 2006). In
contrast, these histone modifications are associated
with transcriptional silencing in non-SMCs, such as
endothelial cells (ECs), embryonic stem cells, and
fibroblasts (McDonald et al., 2006). ECs exhibit high
levels of H4 acetylation and H3K4 dimethylation at the
EC-selective vascular endothelial cadherin gene locus.
Increased levels of H4K20 dimethylation of this locus in
VSMCs, however, are associated with transcriptional
silencing (McDonald et al., 2006). These studies
implicate histone modifications as important epige-
netic tags in the regulation of SMC determination and
differentiation.
Fig. 9. A diagrammatic model of how cytoskeletal remodeling could provide plasticity and an important “shock absorber” for the cardiovascular system
(modified from Gao et al., 2014b.)
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1. Histone Acetylases and Histone Deacetylases.
Histone acetylation is characterized by the posttrans-
lational modification of histones, which lead to chroma-
tin remodeling by loosening histone-DNA contacts
(Lorenzen et al., 2012). These modifications affect many
SMC processes, such as differentiation, phenotypic
switching, proliferation/apoptosis, and migration. Acet-
ylation and deacetylation of histones are catalyzed by
enzymes known as histone acetylases (HATs) and
histone deacetylases (HDACs), respectively. HATs are
classified into three families, including GNAT, MYST,
and CBP/p300 [cAMP response element-binding pro-
tein (CREB)]. HDACs are categorized into four classes
in mammals: class I (HDAC1-3, HDAC8), class II
(HDAC4-7, HDAC9-10), class III sirtuins (SIRT1-7),
and class IV (HDAC11) (Lorenzen et al., 2012). The
class I, II, and IV HDACs are Zn2+-dependent deacety-
lases, whereas the class III HDACs, sirtuins, possess
nicotinamide adenine dinucleotide (NAD)-dependent
deacetylase activity (Lorenzen et al., 2012).
HATs and HDACs work in a dynamic manner to
regulate cellular gene expression. Histone acetylation
by p300 HAT allows binding of serum response factor to
previously inaccessible CArG-containing regions of
SMC-specific genes enabling the recruitment of coac-
tivators, such as myocardin, to stimulate expression of
a-actin (Gabbiani et al., 1981), g-actin, calponin
(Duband et al., 1993), SM22a (Duband et al., 1993),
h-caldesmon (Frid et al., 1992), MLC, and SM MHCs
(SM1 and SM2) (Nagai et al., 1988). Retinoic acid
treatment of A404 cells, an SMC embryonic cell line,
enhances acetylation of histones H3 and H4 at SM
a-actin and SMMHCCArG-containing promoter regions
(Manabe and Owens, 2001). Unlike myocardin, KLF4
(Kruppel-like factor 4) is a transcription factor associated
with myogenic repression that regulates SMC pheno-
typic switching both in vitro and in vivo after vascular
injury. KLF4 acts through epigenetic mechanisms to
decrease histone H4 deacetylase by recruiting HDAC2
and HDAC5, which block the binding of serum response
factor to methylated histones and CArG box chromatin
during repression of SMC gene expression (McDonald
and Owens, 2007; Yoshida et al., 2008).
Although the studies identifying the role of HATs and
HDACs in the regulation of SMC functions warrant
further in vivo studies, they highlight the relevance of
inhibitors as epigenetic therapeutics in the treatment of
vascular diseases. One such study demonstrated that
inhibition of p300 HAT activity by Lys-CoA-TAT de-
creases the effects of retinoic acid on the differentiation
of A404 cells toward an SMC lineage (Spin et al., 2010).
In a separate study in A404 cells, overexpression of
HDACs increased CREB-CArG-dependent SM22 pro-
moter activity, whereas the HDAC inhibitor trichosta-
tin A had the opposite effect (Qiu and Li, 2002). In
contrast, HDAC inhibition after tributyrin treat-
ment inhibited migration of cultured VSMCs after
hyperacetylation of histone H3 and reduced expression
of HDAC7 (Qiu and Li, 2002). Pharmacological inhibi-
tion of HDAC activity or knockdown of HDAC expres-
sion with small interfering RNAs (siRNA) prevents
platelet-derived growth factor-induced VSMC prolifer-
ation (Findeisen et al., 2011).
Recently, HATs andHDACs have been found to act on
the lysine (K) residues of a wide range of nonhistone
proteins and are therefore also denoted as KATs and
KDACs, respectively (Europe-Finner et al., 2015). Non-
histone targets for KATs and KDACs include large
cellular macromolecular complexes involved in the
actin nucleation complex (Choudhary et al., 2009) and
other proteins participating in microfilament formation
and dynamics (Posern et al., 2004). A majority of
proteins involved in smooth and striated muscle con-
traction have been shown as substrates undergoing
acetylation (Karolczak-Bayatti et al., 2011; Lundby
et al., 2012). KDAC8 regulates the differentiation and
contraction of SMCs by interacting with a-actin
(Waltregny et al., 2005; Chen et al., 2013), tropomyosin,
and cortactin proteins (Chen et al., 2013; Li et al.,
2014a). KDAC6 is involved in the modulation of the
cytoskeleton, cell migration, and cell-cell interactions
by interacting with proteins such as SIRT2 (Valenzuela-
Fernandez et al., 2008). KDAC inhibition by trichostatin
A and hydroxamic acid was associated with increased
protein acetylation and reduction of agonist-stimulated
contractions in VSM tissues (Krennhrubec et al., 2007;
Karolczak-Bayatti et al., 2011; Chen et al., 2013). In a
separate study, during contraction, the cytoskeletal
proteins were dynamically regulated through
HDAC inhibition and activation, resulting in the
regulation of cytoskeletal structure (Kim et al.,
2006).
a. Histone deacetylases and link to hypertension.
Epigenetic mechanisms influence the changes in vascu-
lar structure that occur during hypertension (Lacolley
et al., 2012). Angiotensin II (Ang II) at least partially
influences vascular remodeling via HDACs in the
pathogenesis of hypertension (Xu et al., 2007). Specifi-
cally, HDAC5 and HDAC4, after phosphorylation by
Ang II, export from the nucleus where they activate
myocyte enhancer factor-2, leading to SMChypertrophy
(Xu et al., 2007; Li et al., 2010). Treatment of sponta-
neously hypertensive rats with HDAC inhibitors, such
as trichostatin A or valproic acid, reduced SMC hyper-
trophy, blood pressure, and vascular inflammation
(Cardinale et al., 2010; Bogaard et al., 2011; Usui
et al., 2012). All these studies highlight an important
therapeutic potential for HDAC inhibitors in the treat-
ment of vascular diseases.
2. Sirtuins. Sirtuins are a class of proteins that have
multiple functions including NAD+-dependent deacety-
lation. Currently, there are seven known mammalian
sirtuins (SIRT1-7), located in the nucleus (SIRT1, 6, and
7) (Michan and Sinclair, 2007), cytoplasm sirtuin
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(SIRT2), or mitochondria sirtuins (SIRT3, 4, and 5)
(Michishita et al., 2008). Because SIRTs are multifunc-
tional, they have a plethora of protein targets, including
p53, nuclear factor kB, Ku70, FOXO, tubulin, eNOS,
BAD, CytoC, Ndufa9, GDH, ACS2, and ISDH2 (Haigis
and Sinclair, 2010; Corbi et al., 2013). Extensive
reviews are available on the role of sirtuins in aging,
calorie restriction, mitochondrial biogenesis, and neu-
rodegenerative diseases (Gagnon et al., 2008; Pfister
et al., 2008; Haigis and Sinclair, 2010; Guarente, 2011),
Sirtuins have largely been shown to have protective
effects on the vasculature. For instance, SIRT1 modu-
lates vascular biology during hypoxia-induced redox
stress by deacetylating the transcription factor, HIF
(Hypoxia-inducible factor)-2a, which modulates vascu-
lar tone and enhances cell survival through induction of
antioxidant enzymes to promote angiogenesis (Dioum
et al., 2009). The deacetylase activity of SIRT1 has also
been shown to regulate the proliferation and migration
of VSMCs via the suppression of cellular senescence
mediator, p21 protein, and enhancement of senescence-
resistant cell replication (Stein and Matter, 2011).
Overexpression of SIRT1 increases the activity of
metalloproteinase-3 inhibitor, which inhibits cell mi-
gration. In addition, SIRT1 also deacetylates and
activates eNOS, which enhances NO-induced vasodila-
tion (Mattagajasingh et al., 2007).
Interestingly, recent studies implicated SIRT1 in
blood pressure regulation through targeting VSMCs.
Overexpression of SIRT1 in VSMCs has been found to
modulate blood pressure by downregulation of the Ang
II type 1a receptor gene (Miyazaki et al., 2008). More-
over, resveratrol treatment activated SIRT1, resulting
in the repression of Ang II type 1a receptor gene
transcription to counteract Ang II-induced hyperten-
sion inmice (Miyazaki et al., 2008). SIRT1 expression in
humanVSMCswas demonstrated to correlate inversely
with donor age (Thompson et al., 2014). This was
associated with functional defects, such as reduced mi-
gratory capacity and increased senescence (Thompson
et al., 2014). Interestingly, Ang II infusion significantly
decreased the expression of SIRT1 inmouse aorta, which
was associated with increased blood pressure and ele-
vated vascular remodeling. Importantly, aVSMC-specific
SIRT1 transgene attenuated both Ang II-induced in-
creases in blood pressure and vascular remodeling
(Gao et al., 2014a). These recent studies point to the
potential of therapeutically improving SIRT1 function
in VSMCs to treat hypertension.
C. Noncoding RNA
Noncoding RNAs comprise many functional RNA
transcripts that are not transcribed into proteins, but
regulate the transcription, stability, or translation of
protein-encoding genes (Ling et al., 2013). Noncoding
RNAs were once assumed only to regulate generic
functions of cells, such as transcription, translation,
and splicing. It is now recognized, however, that a wide
variety of noncodingRNA transcripts are transcribed and
have diverse biologic activity. The complex nature of this
RNA-based regulatory networkmay partially explain the
vast diversity of the characteristics of mammals, despite
possessing relatively similar proteomes (Mattick and
Makunin, 2006). In addition, epigenetic mechanisms,
such as DNA methylation, can regulate the expression
of noncoding RNAs, adding a further level of complexity
(Liang et al., 2009). This section discusses microRNAs
and long noncoding RNAs, which function in the broadly
termed RNA silencing machinery.
1. MicroRNAs. MicroRNAs (miRs) are a family of
short (21–25 nucleotide) RNAs, which typically nega-
tively regulate protein translation by direct binding to
the 39 untranslated (39 UTR) region of mRNA targets.
The first miR, lin-4, was discovered to have a role in
Caenorhabditis elegans larval development more than
20 years ago (Lee et al., 1993). To date, over 30,000miRs
have been discovered in 206 species, including 2578 in
humans (van Rooij and Kauppinen, 2014). It is now
certain that miRs play an important role in many
cellular and developmental processes. Crucially, miRs
are dysregulated in many pathophysiological condi-
tions, including cardiovascular disease.
MicroRNAs are transcribed in the nucleus by RNA
polymerase II to long primary transcripts (Lee et al.,
2002) (Fig. 10). They are subsequently processed by the
RNAse III enzyme Drosha (Lee et al., 2003) in the
nucleus to a 70 nucleotide hairpin structure termed
preliminary miRNAs (pre-miRNA). After export into
the cytoplasm, pre-miRNAs are further processed by a
separate RNAse III enzyme, Dicer (Hutvagner et al.,
2001), into a 21–25 nucleotide duplex. The mature miR
strand is then incorporated onto Argonaute protein
to form the RNA-induced silencing complex (RISC)
(Hammond et al., 2001; Hutvagner et al., 2001), leading
to unraveling and degradation of the complimentary
strand (Khvorova et al., 2003; Schwarz et al., 2003). The
miR then guides the RISC to complimentary sequences
in the 39 UTR of target mRNA (Lee et al., 1993). In
plants, the near-perfect complementarity between the
miR and target sequence promotes mRNA cleavage of
the target, akin to the mechanism for siRNA-induced
silencing (Hake, 2003). Inmammals, however, this level
of complementarity is rare. In contrast, association of a
6–8 nucleotide ("seed") sequence with the 39 UTR of
target mRNA (Lewis et al., 2005) leads to repression of
mRNA translation through inhibition of translation
initiation and/or promotion of mRNA decay (reviewed
by (Ameres and Zamore, 2013)).
a. Dicer knockout mice. There are several excellent
reviews that discuss the role of miRs in vascular
structure, function, and disease (Yu et al., 2014; Gupta
and Li, 2015; Maegdefessel et al., 2015a; Marques et al.,
2015). The current review will mainly focus on miRs
that have a role in regulating vascular smooth muscle
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cell (VSMC) contractility, thus influencing the risk of
hypertension. The importance of miRs in vascular
smooth muscle was demonstrated in experiments using
smooth muscle-specific Dicer KO mice. Knockout of
Dicer in vascular smooth muscle (VSM) induced embry-
onic lethality, which was associated with widespread
hemorrhaging, loss of contractile function, and reduced
VSMC proliferation (Albinsson et al., 2010). A further
study using a tamoxifen-inducible SMC-specific knock-
out of Dicer, suggested miRs are necessary for blood
pressure regulation and contractile function (Albinsson
et al., 2011). Blood pressure was reduced after Dicer
knockdown, with no change in cardiac dimensions. This
was associated with impairment of both receptor- and
calcium-mediated contraction of small mesenteric ar-
teries and reduction of expression of contractile proteins
(Albinsson et al., 2011). Furthermore, the stretch-
dependent increase in contractile gene expression in
the portal veins of mice was dependent on Dicer
expression (Turczynska et al., 2013). Loss of the miR-
143/-145 cluster is thought to be at least partially
responsible for this reduced vascular contractility
(Boettger et al., 2009; Norata et al., 2012; Dahan
et al., 2014). Pathways that promote the vascular
smooth muscle contractile phenotype, such as Notch
and bone morphogenic protein signaling, function par-
tially through promoting the expression of miR-143/-145
(Boettger et al., 2009; Albinsson et al., 2010; Boucher
et al., 2011; Davis-Dusenbery et al., 2011; Norata et al.,
2012; Turczynska et al., 2013; Dahan et al., 2014). In
addition tomiR-143/-145, the expression of miR-21 (Kang
et al., 2012) and miR-24 (Chan et al., 2010) is similarly
induced by bone morphologic protein (BMP) signaling,
promoting the contractile phenotype by targeting Pro-
grammed Cell Death 4 and Tribbles-like protein-3,
respectively.
Fig. 10. Summary of the main mechanisms of miR biogenesis and function and avenues for pharmacological intervention. (A) MiRs are first
transcribed in the nucleus, primarily from introns located in both coding and noncoding DNA, into long primary transcripts termed pri-miRNAs, then
are processed in the nucleus by the RNAse III enzyme Drosha into a shorter (;70 nucleotide) hairpin duplex termed pre-miRs. (B) After export to the
cytoplasm by the dsRNA-binding protein Exportin 5, pre-microRNAs are processed by an RNAse III enzyme, Dicer, into a short (21–25 nucleotide)
duplex. (C) The miR duplex is unwound, primarily leading to preferential incorporation of a single strand onto Argonaute protein to form the RNA-
induced silencing complex (RISC). A short sequence (6–8 nucleotides) at the 59 end of the miR, known as the "seed" sequence, targets the RISC to
complimentary sequences in the 39 UTR of target mRNAs. (D) Translational repression, through the blocking of translation initiation or recruitment of
translational blocking proteins, and/or (E) mRNA decay, via 59 to 39 decay and deadenylation of the poly (A) tail. (F) miR mimics are designed as RNA
duplexes composed of a passenger strand, chemically modified (e.g., phosphate addition) to permit entry to the cell and subsequent unwinding after
entry (i.e., by containing several nucleotide mismatches), and a guide strand, which consists of an identical sequence to the endogenous miR. (G) An
anti-miR is designed to be complimentary to the endogenous miR of interest, thus inhibiting target mRNA binding, which therefore increases
translation of the target mRNA. (H) A lipid nanoparticle delivery system can induce expression of a miR in specific cell types [e.g., in smooth muscle
cells by expressing the miR under the influence of a smooth muscle cell (SMC) promoter].
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The Dicer KO model has also demonstrated an
important role for miRs in the regulation of small
arterial myogenic tone, therefore modulating periph-
eral arterial resistance, which is raised in hypertension.
Myogenic tone of mesenteric arteries was abolished
from Dicer KOmice, which was associated with a loss of
calcium influx through the L-type calcium channel
(Bhattachariya et al., 2014). It is therefore possible that
the aberrant expression of miRs may increase the
development of myogenic constriction of small arteries,
thereby increasing peripheral resistance and systemic
blood pressure.
b. Regulation of vascular smooth muscle cell
contractility. Several miRs have been found to post-
transcriptionally modulate the expression of VSMC
contractile proteins. Overexpression of miR-143/-145
in VSMCs increases the expression of contractile pro-
teins, such as SM-MHC, calponin, and SM22a, through
the targeted downregulation of KLF4 and 5 (Albinsson
et al., 2010, 2011; Boucher et al., 2011; Davis-
Dusenbery et al., 2011; Norata et al., 2012; Turczynska
et al., 2013; Chettimada et al., 2014; Dahan et al., 2014;
Riches et al., 2014). VSMCs from Type 2 diabetic rats
(Chettimada et al., 2014) and humans (Riches et al.,
2014) display an increased expression of miR-145,
which contributes to the enhanced expression of vascu-
lar contractile proteins in Type 2 diabetes. Myocardin
increases the expression of miR-1 in human aortic
SMCs, which blocks the expression of the contractile
proteins a-SMA and SM22, possibly acting as a negative
feedback mechanism to counter myocardin-induced in-
crease in contractility (Jiang et al., 2010). Additionally,
although miR-21 may promote the contractile pheno-
type, it may also negatively regulate VSMC contraction
through the targeted downregulation of myosin phos-
phatase, Rho-interacting protein, and cofilin-2 (Kotlo
et al., 2011).
c. Regulation of vascular smooth muscle cell ion
channels. MicroRNAs have also been demonstrated to
posttranscriptionally regulate the expression of VSMC
ion channels, thereby influencing vascular contractility
and thus blood pressure regulation. For example, miR-
145 indirectly increases VSM contractility by targeted
downregulation of CamKIId, which results in increased
expression of the a1C subunit of the L-type calcium
channel (Turczynska et al., 2012). Similarly, miR-328
has been demonstrated to directly target the a1C sub-
unit of the L-type calcium channel (Guo et al., 2012).
Overexpression of the miR-424/322 resulted in decrease
in cyclin D1 and calcium-regulating proteins calumenin
and stromal-interacting molecule 1, which reduces
store-operated calcium entry in human and rat VSMCs
(Merlet et al., 2013). Further studies have elucidated a
role formiR-9a-3p (Li et al., 2015) andmiR-190 (Li et al.,
2014b) in the downregulation of the VSMC KATP and
potassium channel Kv7.5, respectively, causing an in-
crease in contractility.
d. Regulation of the extracellular regulated kinase
pathway. MicroRNAs have also been implicated in the
downregulation of proteins involved in the ERK 1/2
signaling pathway in proliferating, but not contractile,
VSMCs. The miRs-21 (Stein et al., 2014), -31 (Liu et al.,
2011), -132 (Choe et al., 2013), and -155 (Yang et al.,
2015) all affect ERK activation. It remains to be de-
termined if those miRs similarly affect ERK activation
in fully differentiated VSMCs.
2. Long Noncoding RNAs. Long noncoding RNAs
(LncRNAs), arbitrarily classified as longer than 200
nucleotides, have a role in regulating the expression of
neighboring genes. LncRNAs have a much more wide-
spread mode of action than miRs, and their function
cannot currently be inferred from sequence or structure
(Mercer et al., 2009; Rinn and Chang, 2012). LncRNAs
can recruit chromatin-remodeling complexes to epige-
netically regulate specific genomic loci. They can also
influence transcriptional regulation of genes by recruit-
ing RNA binding proteins to gene promoters, acting as
cofactors to modulate transcription factor and RNA
polymerase II activity. Finally, LncRNAs can also
regulate posttranscriptional processing events, by rec-
ognizing complimentary sequences of RNA. Like miRs,
they have the ability to bind to mRNA targets, affecting
their translation and degradation, but they can also
influence other posttranscriptional processes such as
splicing, editing, and transport. For a deeper descrip-
tion of LncRNA function the reader may refer to the
following references (Mercer et al., 2009; Rinn and
Chang, 2012).
Although the field is newer than that for miRs,
LncRNAs are emerging as potentially important play-
ers in cardiovascular disease (recently reviewed by
Uchida and Dimmeler, 2015 and Miano and Long,
2015). Through RNA sequencing approaches in human
coronary arteries, VSMCs have been demonstrated to
express several LncRNAs, including smoothmuscle and
endothelial cell-enriched migration/differentiation-
associated long noncoding RNA (Bell et al., 2014).
Depletion of endothelial cell-enriched migration/
differentiation-associated long noncoding RNA in
VSMCs was associated with decreased expression of
myocardin and other contractile genes and increased
expression of the promigratory proteins MDK and PTN,
suggesting a role in maintenance of the contractile
phenotype (Bell et al., 2014). The Lnc-Ang362 was
increased in Ang II-treated rats, which was associated
with an increased VSMC proliferation. Interestingly,
Lnc-Ang362 was cotranscribed with miR-221 and -222
andwas required for their expression (Leung et al., 2013).
This study provided evidence for the regulation of
LncRNAs by Ang II, which may have important implica-
tions in the pathogenesis of Ang II-associated cardiovas-
cular diseases, such as hypertension (Leung et al., 2013).
Recent evidence suggested the expression of
LncRNAsmay affect VSMC proliferation and apoptosis,
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therefore influencing the risk of aortic aneurysm (He
et al., 2015) and atherosclerosis (Congrains et al.,
2012a; Bayoglu et al., 2014; Li et al., 2014c; Vigetti
et al., 2014; Wu et al., 2014). For example, LncRNA-p21
was demonstrated to inhibit cell proliferation and neo-
intimal hyperplasia by releasing the mouse double
minute 2 repression of p53 (Wu et al., 2014). Impor-
tantly, this LncRNA was downregulated in atheroscle-
rotic plaques from ApoE2/2 mice (Wu et al., 2014).
Furthermore, the expression of the LncRNA ANRIL
was influenced by several atherosclerosis-associated sin-
gle nucleotide polymorphisms (SNPs) in the 9p21 locus
(Holdt et al., 2011; Congrains et al., 2012a,b; Bayoglu
et al., 2014). These data alert one to the possibility that
previous genome-wide association studies (GWAS) may
have misinterpreted SNPs in regions that encode non-
protein coding RNA as without effect on disease risk.
3. Strategies to Regulate microRNAs in Vascular
Disease. MicroRNAs continue to provide great thera-
peutic potential, and the strategies to altermiR function
will be discussed below. Because the functions of
LncRNAs in VSM biology are still being determined,
approaches to modify their function have not yet been
extensively examined in this setting.
One of the benefits of miRs is that they are strongly
conserved in species (albeit potentially targeting differ-
ing mRNA targets), thus aiding the design of preclinical
studies to determine their efficacy and safety. In
addition, miRs have the potential to target many
members of the same molecular pathway and as a
result having a greater combined effect than siRNAs,
which typically target only a single gene. For example,
the miR-200 family has been implicated in regulating
many targets that control actin filament organization
and dynamics (Bracken et al., 2014). Furthermore, miR
therapy will not completely knock down their target
protein’s expression. Rather, they will result in a "fine-
tuning" effect on target protein expression, making
them an attractive proposition for therapeutic
intervention.
There are two main techniques to modulate miR
activity in vivo (reviewed in Ling et al., 2013; van Rooij
and Kauppinen, 2014) (Fig. 10): 1) restoring the expres-
sion of a downregulated miR by use of a miR-mimic and
2) inhibiting the activity of an abnormally expressed
miR by use of an anti-miR. A miR-mimic is a synthet-
ically designed RNA duplex, containing a passenger
strand, chemically modified to enhance uptake and
disengage once inside the cell, and a guide strand,
which is identical to a miR of interest. Conversely, an
anti-miR is designed to be complementary to the
endogenous miR and therefore binds and inhibits it
from acting on its mRNA target. Several modifications,
such as locked nucleic acid and phosphodiester addi-
tions, have improved the in vivo stability of anti-miRs.
The great strength of miRs, their ability to target
multiple mRNAs, is also their greatest weakness
because they could potentially result in many off-
target effects. In addition, miR mimics often increase
the miR concentration to supraphysiologic levels, again
increasing the risk of off-target actions. To lower such
risk, viral constructs have been developed to re-express
the miRs to endogenous levels. Recently, lipid nano-
particle delivery has proved promising to deliver miR
regulators to target cells and reduced delivery to non-
target cells (Fig. 10). For instance, anti-miR-145 ther-
apy in ratswith Sugen-5416/hypoxia-induced pulmonary
arterial hypertension (PAH) using the Star:Star-mPEG
delivery system, reduced the severity of pulmonary
hypertension without significant off-target effects
(McLendon et al., 2015).
Extracellular vesicles, such as exosomes, microve-
sicles, and apoptotic bodies, allow long-distance de-
livery of cellular information, including noncoding
RNA. They recently emerged as important regulators
of cardiovascular diseases, such as atherosclerosis (re-
cently reviewed by Das and Halushka, 2015) and may
serve as important diagnostic and prognostic bio-
markers for these conditions.
a. Pulmonary hypertension. Several miRs have
been found to contribute to clinical and experimental
pulmonary hypertension, which is characterized by
enhanced proliferation and constriction of pulmonary
artery smooth muscle cells (PASMCs). For example,
miR-130a promotes PASMC proliferation through the
negative regulation of its targets CDKN1A and growth
arrest-specific homeobox (Wu et al., 2011; Brock et al.,
2015). Interestingly, the miR-130/-301 family also reg-
ulates the expression of peroxisome proliferation re-
ceptor gamma, which influences the expression of many
vasoactive factors, such as endothelin-1 (Bertero et al.,
2015). The expression of miR-190 was augmented in
PASMCs of the hypoxic rat, which acts as a model for
pulmonary hypertension. Vasoconstriction to both po-
tassium chloride and phenylephrinewas enhanced after
transfection of pulmonary arterial rings with amiR-190
mimic. The same study demonstrated that miR-190
downregulates the protein expression of the potassium
channel Kv7.5, which results in raised intracellular
calcium in PASMCs (Li et al., 2014b). The miR-328 has
been demonstrated to directly target the a1C subunit of
the L-type calcium channel and was reduced in the
pulmonary artery from patients with pulmonary hyper-
tension, thus enabling an increase in vasoconstriction
(Guo et al., 2012).
b. Systemic hypertension. There have been fewer
animal studies focusing on the role of miRs in the
development of essential hypertension. Clinical studies,
however, have highlighted the possibility of therapeutic
intervention to prevent or treat systemic hypertension.
A study from Greece found that the expression of miR-
145, -143, and -133 was upregulated, and miR-21 and -1
were downregulated in the peripheral blood of patients
presenting with essential hypertension (Kontaraki
514 Brozovich et al.
et al., 2014). These miRs are all important regulators of
VSMC phenotype plasticity. A further study in a
Chinese population identified the SNP rs12731181 (A
to G) in the prostaglandin F2a receptor that was more
prevalent in hypertensive individuals (Xiao et al., 2015).
This polymorphism reduces the likelihood of miR-590-
3p binding, thus increasing prostaglandin F2a receptor
expression and enhancing prostaglandin-mediated con-
tractility of VSMCs (Xiao et al., 2015).
c. Other vascular diseases. Several studies have
demonstrated the feasibility of miR therapies to slow
the development of abdominal aortic aneurysms. In
particular, the miR-29 family has been heavily impli-
cated in aneurysm development in mouse models.
Murine in vivo delivery of miR-29 was found to decrease
elastin mRNA and increase MMP activity and aneu-
rysm development (Boon et al., 2011; Jones et al., 2011;
Maegdefessel et al., 2012; Merk et al., 2012). Impor-
tantly, blockade of miR-29 reduced aneurysm develop-
ment in Ang II-infused mice (Boon et al., 2011), a
mouse model for Marfan syndrome (Merk et al.,
2012), and ApoE2/2 mice (Maegdefessel et al., 2012),
signifying its therapeutic potential. In addition,
miR-21 (Maegdefessel et al., 2012), -712/-205, and -195
(Zampetaki et al., 2014) have all been demonstrated to
promote aneurysm development, whereas miR-24
(Maegdefessel et al., 2015b) slows aneurysm progres-
sion in mouse models.
Interestingly, miR-29 was found to increase with
aging in the aorta from mice, which correlated with
aneurysm development (Boon et al., 2011). The targets
affected by miR-29 are strongly implicated in aortic
stiffness, which is also known to increase with age. Few
studies have focused on the role of miRs in vascular
stiffness. A clinical study found that two SNPs,
rs978906 (A allele) and rs9808232 (C allele), were
associated with high pulse wave velocity in 856 indi-
viduals in a Chinese population (Liao et al., 2015).
These polymorphisms rendered the expression of the
aortic stiffness-associated ROCK2 (Noma et al., 2007)
less responsive to changes inmiR-1183 expression, thus
enhancing ROCK2 expression (Liao et al., 2015). In
addition, miR-145 was strongly reduced in ApoE2/2
mice, which was associated with an increase in collagen
and stiffer arteries (Kothapalli et al., 2012).
These studies demonstrate the capacity of miR
therapeutics to improve treatments for vascular com-
plications such as hypertension, abdominal aortic an-
eurysm, and arterial stiffness. Indeed, anti-miR-33
(atherosclerosis, Regulus Therapeutics, (Carlsbad,
CA)), anti-miR-92 (peripheral artery disease, miRagen
Therapeutics Boulder, CO), and anti-miR-145 (vascular
occlusion, miRagen Therapeutics) have already reached
preclinical trials. Thishas clearly beena rapidly expanding
field and we expect to see many further developments,
including approaches to target LncRNAs, in the com-
ing years.
VIII. Vascular Smooth Muscle Diseases and
Their Treatments
A. Review of Current Therapies and Their Targets
Excess vasoconstriction and the resulting increase in
vascular tone and SVR are an important contributing
factor to the pathogenesis of essential hypertension.
CCBs, ACE inhibitors, ARBs, and direct vasodilators
(i.e., hydralazine) all target the smooth muscle cell to
decrease vascular tone and blood pressure. CCBs de-
crease the activation of SM myosin by decreasing
intracellular Ca2+, whereas ACE inhibitors and ARBs
will decrease the activation of the RhoA/Rho kinase
signaling pathway to reduce Ca2+ sensitization. K+
channel openers produce vasodilatation; nicorandil acts
on BK channels and hyperpolarizes smoothmuscle cells
(Nelson et al., 1990), whereas minoxidil opens ATP-
sensitive K+ channels and hyperpolarizes the smooth
muscle cells (Wickenden et al., 1991). Themechanism of
action for hydralazine, on the other hand, is unclear, but
evidence suggests that hydralazine both activates K+
channels and also stimulates NO production by the
vascular endothelium (Knowles et al., 2004).
In addition to essential hypertension, there are a
number of other diseases of the vasculature and dis-
eases with associated abnormal vascular reactivity.
These defects in vascular reactivity contribute to mor-
bidity and mortality. In this section, we will outline
these diseases, their mechanism, current therapies, and
suggest novel targets for both the treatment of essential
hypertension as well as these other diseases of the
vasculature (Table 1).
B. Other Major Vascular Diseases Including Analysis
of Current Therapies and Novel Targets
1. Heart failure. Considerable evidence from both
human subjects and animalmodels have shown thatHF
is associated with an impaired vasodilatory response to
acetylcholine, via an endothelium-dependent mecha-
nism, as well as to nitroglycerin, via an endothelial-
independent mechanism (Kaiser et al., 1989; Kubo
et al., 1991; Katz et al., 1993). Both MYPT1 LZ+
expression and the vasodilatory response to NO/cGMP
has been demonstrated to decrease in HF (Karim et al.,
2004; Chen et al., 2006; Ararat and Brozovich, 2009;
Han and Brozovich, 2013), which demonstrates that the
fall in LZ+ MYPT1 expression contributes to the de-
crease in sensitivity to NO-mediated vasodilatation
associated with HF. Additionally, treatment of HF with
either ACE inhibitors (Chen et al., 2006) or ARBs
(Ararat and Brozovich, 2009) has been demonstrated
to preserve the normal expression of the LZ+ MYPT1
isoform and sensitivity to NO/cGMP-mediated vasodi-
latation. These results are similar to those of Abassi
et al., 1997; this group demonstrated that both
endothelium-dependent and -independent responses
in renal blood flow were impaired in HF rats compared
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with control, and Ang II receptor blockade normalized
these vasodilatory responses.
The mechanism for the regulation of LZ+/LZ2
MYPT1 expression by Ang II-induced activation of the
AT1 receptor is unknown, but evidence suggests that
both the activation of p42/44 MAPK (Ararat and
Brozovich, 2009) and Tra2b (Shukla and Fisher, 2008)
are important. Ang II produces vasoconstriction
through its effect on both the endothelium and vascular
smooth muscle (Nickenig and Harrison, 2002). Addi-
tionally, Ang II activates nuclear factor kB to produce a
proinflammatory state by inducing expression of in-
terleukin (IL)-6 and tumor necrosis factor (TNF)-a
(Dzau, 2001; Nickenig and Harrison, 2002) and also
activates membrane NADH/NADPH oxidases, generat-
ing reactive superoxide anions, which increase NO
catabolism and therefore decrease NO bioavailability
(Griendling et al., 1994). In heart failure, inhibition of
Ang II signaling counter these deleterious effects and
could contribute to the reduction in cardiovascular
morbidity and mortality observed with ACE inhibitors
and ARBs (Pfeffer et al., 1992; Yusuf et al., 1992).
Furthermore, similar beneficial effects on survival have
not been observed with other vasodilators such as
prazosin, although prazosin has also been shown to
improve cardiac index and fractional shortening for
heart failure patients (Awan et al., 1977; Miller et al.,
1977), which suggests that ACE inhibitor have other
beneficial effects beyond reducing afterload and im-
proving left ventricular remodeling.
In the setting of advanced heart failure, marked
activation of the renin-angiotensin system and worsen-
ing functional status have been associated with a pro-
gressive elevation of the proinflammatory marker
TNF-a (Levine et al., 1990; Torre-Amione et al., 1996),
which has been demonstrated to contribute to endothe-
lial dysfunction and also an increase in vascular tone
that is produced by a RhoA/Rho kinase-mediated
inhibition of MLC phosphatase (Parris et al., 1999;
Mann, 2002). Additionally, the inflammatory marker
IL-1b, which is also elevated in heart failure, increases
Ser850 MYPT1 phosphorylation to inhibit MLC phos-
phatase (Kandabashi et al., 2000; Mann, 2002). It has
been demonstrated that impaired endothelial and
vascular smoothmuscle dysfunction are associatedwith
a poor prognosis in heart failure (Mann, 2002). Poten-
tially IL-1b and TNF-a could be involved in the regu-
lation of MYPT1 isoform expression, and defining the
role of inflammatory cytokines for the regulation of
MYPT1 isoform expression could reveal a novel therapy
to reverse the vascular dysfunction and improve prog-
nosis in heart failure.
In addition to inhibiting the RhoA/Rho kinase path-
way (Arner and Pfitzer, 1999; Somlyo and Somlyo,
2003), ACE inhibitors and ARBs also preserve the LZ+
MYPT1 isoform expression (Chen et al., 2006; Ararat
and Brozovich, 2009). The variability in LZ+ MYTP1
expression among different vascular smooth muscle
cells and the changes that occur during heart failure
could provide an explanation as to why racial differ-
ences play an important role in predicting responses to
ACE inhibitor therapy compared with the combination
of vasodilators and nitrates (Carson et al., 1999). There
are racial variations in plasma norepinephrine and
renin (Carson et al., 1999), and this could influence
both MYPT1 isoform expression as well as MLC
phosphatase activity. These factors could explain the
more significant blood pressure andmortality reduction
seen in white compared with black patients (Carson
et al., 1999). MYPT1 polymorphisms may also exist,
which could contribute to the diversity of symptoms in
patients with similar reductions in LVEF. Hence, the
ability of ACE inhibitors and ARBs to alter the vascular
smooth muscle cell phenotype could contribute to the
improvement in survival in patients with heart failure
(Pfeffer et al., 1992; Yusuf et al., 1992; Granger et al.,
TABLE 1
Disease-associated vascular abnormalities
In addition to hypertension, there are a number of diseases with abnormalities of the vasculature that contribute to patient morbidity and mortality. The vascular
abnormality, possible mechanisms as well as therapies and potential new, novel targets for therapy are listed and discussed in detail in the text.
Disease Abnormality Possible Mechanisms Treatments
Heart Failure Resting Vasoconstriction, Defect in NO/cGMP mediated
vasodilatation; ?Decrease in LZ+
MYPT1
Vasodilators (ACE inhibitors, ARBs,
hydralazine, nitrates)Decrease in sensitivity to NO
Idiopathic Pulmonary
Hypertension
Pulmonary Vascular
Vasoconstriction &
Proliferation of pulmonary SMCs,
Defect in NO/cGMP mediated
vasodilatation. ?Decrease in LZ+
MYPT1 and increase in NM
myosin
Prostaglandins (Epoprostenol),
Phosphodiesterase inhibitors
(Sildenafil), Guanylate cyclase
stimulators (Riocigaut), Endothelin
antagonists (Bosentan), NO inhalation
& Rho kinase inhibitors (Fasudil)
Decrease in sensitivity to NO
Portal Hypertension Sensitivity to vasodilators
increased & to vasoconstrictors
decreased
?Changes in isoform expression of
contractile proteins which
influence both smooth muscle
activation and relaxation
Management of fluid status
Raynaud’s Phenomenon Transient vasospasm of digital
vessels
Altered reactivity of vascular
smooth muscle
Keeping digits warm, CCBs
Pre-eclampsia/Pregnancy
Induced Hypertension
Increase in vascular tone Altered reactivity to RhoA, PKC &
Ca2+, decrease NO
Antihypertensives (non-fetotoxic)
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2003), and thus enhancing LZ+ MYPT1 expression and
normalizing the vascular response to NOmay represent
another novel target for the treatment of heart failure.
2. Pulmonary hypertension. Pulmonary arterial hy-
pertension (PAH) is a rare, incurable disease with a
poor prognosis (Geraci et al., 2001a,b; Archer et al.,
2010). In patients with PAH, the pulmonary vascula-
ture is characterized by a resting vasoconstriction and
an abnormal response to NO, and in the majority of
patients, NO-mediated vasodilatation is severely
blunted (Sitbon et al., 1998; McGoon et al., 2004).
Clinically, the initial assessment of patients with PAH
includes the evaluation of the pulmonary response to
NO (Badesch et al., 2004; Barst et al., 2004; McGoon
et al., 2004) prognosis is improved if NO decreases
pulmonary arterial pressure and PVR by 20% (Sitbon
et al., 1998; Barst et al., 2004). However, less than 10%
of patients with PAH demonstrate a significant vaso-
dilatory response to NO (Barst et al., 2004), and
although there are a number of proposed mechanisms
for the progressive increase in PVR (Stenmark et al.,
2006; Archer et al., 2010; Farkas et al., 2011), the
molecular mechanism that results in the lack of vaso-
dilatation to NO in PAH is unknown.
There are two components that produce PAH: the
extent of the structural changes (smooth muscle cell
proliferation, smooth muscle cell hypertrophy, and the
deposition of matrix proteins within the media of
pulmonary arterial vessels (Stenmark et al., 2006;
Archer et al., 2010; Farkas et al., 2011) and excess
vasoconstriction (Oka et al., 2007; Archer et al., 2010).
Structural changes have been documented in animal
models of PAH, which have demonstrated that chronic
hypoxia leads to pulmonary vascular remodeling that
increases PVR and decreases the vasodilatory response
to NO (reviewed in Stenmark et al., 2006; Archer et al.,
2010; Farkas et al., 2011). However, despite the fact
that for PAH the target and aim of all current thera-
peutic agents [prostaglandins (epoprostenol), phospho-
diesterase inhibitors (sildenafil), guanylate cyclase
stimulators (riocigaut), endothelin antagonists (bosen-
tan), NO inhalation and Rho kinase inhibitors (fasudil)]
is the smooth muscle cell to reduce pulmonary vascular
resistance, the fundamental changes in the pulmonary
smooth muscle contractile phenotype that contribute to
the excess vasoconstriction, or the increase in PVR, as
well as the decrease in vasodilatory response to NO, are
poorly characterized. Evidence supports a contribution
of changes in the pulmonary smooth muscle contractile
phenotype in PAH; an increase in the expression and
activity of Rho kinase has been demonstrated to
contribute to the pathogenesis of PAH (Connolly and
Aaronson, 2011), and Rho kinase inhibition reduces
pulmonary pressure in some animal models of PAH
(Oka et al., 2007; Archer et al., 2010). The importance of
the NO/cGMP signaling pathway for the pathogenesis
of PAH is highlighted by data demonstrating that PKG
KO mice develop pulmonary hypertension (Zhao et al.,
2012), and mice with mutations in the PKG LZ domain,
which disrupts PKG interaction with MYPT1 (Surks
et al., 1999, 2003; Huang et al., 2004; Yuen et al., 2011;
Yuen et al., 2014), develop progressive increases in
pulmonary pressures and right ventricular hypertrophy
(Ramchandran et al., 2014). Furthermore, activation of
guanylate cyclase has been demonstrated to improve
exercise capacity and reduce pulmonary pressures in
patients with PAH (Zhao et al., 2012; Ghofrani et al.,
2013a,b; Ramchandran et al., 2014). All these studies
are consistent with a defect in NO/cGMP signaling
contributing to the pathogenesis of pulmonary hyper-
tension, but do not isolate the step in the NO signaling
pathway that produces PAH.
In smooth muscle, investigators have demonstrated
that NM myosin (Fig. 7) contributes to the sustained
force response (Morano et al., 2000; Lofgren et al., 2003)
and a decrease in NMmyosin expression will result in a
decrease in vascular tone (Yuen et al., 2009). Addition-
ally, changes in the sensitivity to NO-mediated vasodi-
latation are due to changes in the expression of
LZ+/LZ2 MYPT1 (Huang et al., 2004). Thus, an in-
crease in NM myosin and decrease in LZ+ MYPT1
expression will produce abnormalities of pulmonary
vascular reactivity and may participate in the molecu-
lar mechanism that produces PAH (Konik et al., 2013).
Konik et al. (2013) demonstrated that with the devel-
opment of severe PAH, there is a 3.5-fold increase inNM
myosin expression, which could contribute to the pro-
longation in the rates of both force activation and
relaxation, as well as the increase in force maintenance.
Similarly, an increase in NM myosin expression has
also been reported for hypoxia induced PAH (Packer
et al., 1998), and therefore drugs that target NMmyosin
expression or activation could represent a new class of
therapeutic agents for the treatment of PAH.
Konik’s data also demonstrated that a decrease in
LZ+ MYPT1 expression is associated with severe PAH
(Konik et al., 2013). The sensitivity of smooth muscle to
NO is regulated, in part, by relative LZ+ MYPT1
expression (Huang et al., 2004). In severe PAH, these
data would suggest that the decrease in LZ+ MYPT1
expression would result in a decrease in the sensitivity
of the pulmonary vasculature to NO. Similarly, a
decrease in LZ+ MYPT1 expression has been reported
for cultured pulmonary SMC exposed to hypoxia (Singh
et al., 2011). Additionally, the transition from a phasic
to tonic SM contractile phenotype has been suggested
to be associated with a decrease in the ratio of
LZ+ MYPT1/MYPT1 expression (Fisher, 2010). Tonic
contractile properties would produce an increase in
vascular tone, similar to that observed in patients with
PAH. These results are consistent with a decrease in
LZ+ MYPT1 expression contributing to the pathogen-
esis of PAH; a decrease in LZ+ MYPT1 expression
would reduce the sensitivity to cGMP, and riociguat
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treatment (Ghofrani et al., 2013a,b) would increase cGMP
to counteract and overcome the decrease in sensitivity to
NO to reducePVRandpulmonary pressures. If a decrease
in LZ+ MYPT1 expression contributes to the molecular
mechanism for PAH, these data could provide a unifying
mechanism to explain the variable response to drugs that
act on the NO/cGMP signaling pathway (NO, PDE5
inhibitors, and riociguat), i.e., patients with a mild
decrease in LZ+ MYPT1 expression would represent
“responders,” whereas patients in which LZ+ MYPT1
expression is severely depressed would not respond to
this class of therapeutics. Developing therapeutics that
increase LZ+ MYPT1 expression should normalize the
pulmonary vascular response to NO and decrease PVR,
whichwould represent a novel target for treating patients
with PAH.
3. Portal hypertension. Vascular reactivity is known
to be altered in portal hypertension, with increased
sensitivity to dilatation and decrease sensitivity to
constriction (Benoit et al., 1984; Sikuler et al., 1985;
Bomzon and Blendis, 1994;Wu and Benoit, 1994; Payne
et al., 2004). The mechanism that contributes to this
altered reactivity is unclear, but evidence suggests that
splice variant expression of the contractile proteins is
modulated by flow and/or pressure (Zhang and Fisher,
2007). Payne et al. (2004) examined the expression of
SM MHC, ELC17, and MYPT1 in the portal vein
stenosis model of portal hypertension (Benoit et al.,
1984). The ligature of the portal vein produces dynamic
changes in flow and pressure; there is an initial increase
in both splanchnic pressure and flow (Benoit et al.,
1984), which fall with the development of porto-
systemic shunting. Similar to these dynamic changes
in flow, these investigators (Payne et al., 2004) demon-
strated that in both the portal veins and mesenteric
arteries within 1 day of the increase in portal pressure,
although total MYPT1 expression decreased, the ex-
pression of the LZ+ MYPT1 isoform increased. These
changes in MYPT1 expression were maintained for ;7
days before returning to preportal hypertension levels
by 14 days after the ligature of the portal vein. Similar
to MYPT1 isoform expression, ELC17 and SM MHC
expression were modulated with an increase in the
expression of the slow isoforms (ELC17b and SMA) 3
days after ligature, but SMA expression returned to
baseline at day 14.
Others have altered flow in themesenteric circulation
by ligating alternative pairs of second order mesenteric
arteries to produce either low or high flow in the
upstream first order mesenteric arteries (Zhang and
Fisher, 2007). These investigators demonstrated that
there was an initial increase in LZ+ MYPT1 expression
in both low and high flow vessels, but by 1 month
LZ+MYPT1 expression returned toward baseline in the
low flow vessels, whereas in the high flow vessels,
LZ+MYPT1 expression continued to increase. As would
be predicted, the sensitivity to NO/cGMP-mediated
relaxation paralleled LZ+ MYPT1 expression. Further-
more, total MYPT1 expression rapidly fell in both the
low and high flowmesenteric vessels, and pretreatment
with an inhibitor of the proteosome attenuated the
decrease in MYPT1. These data suggest that the rapid
decrease in total MYPT1 is due to degradation by the
proteosome (Zhang and Fisher, 2007), which is similar
to the results in the mesenteric arterioles in heart
failure (Han and Brozovich, 2013). These data demon-
strate that flow and/or pressure is also important in
regulating the smooth muscle contractile phenotype,
and thus vascular reactivity.
4. Raynaud’s phenomenon. Raynaud’s phenomenon
is described as a transient cessation of blood flow in the
fingers and toes and can be triggered by either cold or
emotional stress. The phenomenon is the result of a
transient vasospasm of the digital arteries in the hands
and/or feet that leads to a cessation of blood flow, which
produces pallor, followed by cyanosis and pain due
ischemia of the sensory nerves. As the vasospastic
attack subsides, blood flow to the digits is restored,
and the resulting hyperemia produces a red phase. The
estimates of the prevalence of this disease vary, but it is
more common in women, and the onset and severity of
the disease peaks between menarche and menopause.
Treatment of Raynaud’s involves keeping the digits
warm and pharmacologic therapy with CCBs can be
helpful; however the usefulness of CCBs is often limited
by hypotension (Cooke and Marshall, 2005).
There are a number of mechanisms proposed for the
transient vasoconstriction of the digital vessels; these
have been reviewed (Cooke and Marshall, 2005) and
there is evidence supporting roles for hyperactivity of
adrenergic nervous system, a2 adrenoceptors, central
stress responses, 5-HT, endothelin, oxidative stress,
cyclo-oxygenase, andNO.However, it is interesting that
the vasodilation of the digital vessels produced by both
sodium nitroprusside and ACh are reduced in patients
with Raynaud’s (Morris and Shore, 1996; Cooke and
Marshall, 2005), which suggest that the defect lies
within the cGMP/PKG signaling cascade. Consistent
with this hypothesis are the results that show L-arginine
does not restore the normal vasodilatory response to ACh
(Khan et al., 1997), which indicates that the vasodilatory
response to NO is depressed in Raynaud’s disease, and
the mechanism lies beyond the bioavailability of NO
within the cGMP/PKG signaling cascade. These data
could suggest that a decrease in LZ+ MYPT1 expression
in the digital vessels could contribute to the abnormal
vascular reactivity.
5. Pre-eclampsia/pregnancy-induced hypertension.
During a normal pregnancy, vascular resistance falls,
which is thought to be the results of increased synthesis
and activity of NO and prostacyclin (Bird et al., 2003;
James and Nelson-Piercy, 2004). However, approxi-
mately 5–15% of pregnancies are complicated by hyper-
tension, which increases perinatal morbidity and
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mortality of both the mother and fetus (Lindheimer,
1993; James and Nelson-Piercy, 2004). Antihyperten-
sive therapy is limited due to the effects on the fetus,
i.e., ACE inhibitors and ARBs are fetotoxic (James and
Nelson-Piercy, 2004). A number of mechanisms have
been proposed for the increase in PVR and blood
pressure, including both a decrease in NO produced by
endothelial dysfunction and an increase in circulating
vasoconstrictors including Ang II, thromboxane, and
endothelin (Khalil and Granger, 2002; Bird et al., 2003;
Granger et al., 2003). NOS inhibition is commonly used
to produce a model of pregnancy-induced hypertension,
and studies have suggested that the increase in blood
pressure is due to altered vascular reactivity produced
by RhoA, PKC, and Ca2+ signaling (Khalil and Granger,
2002; Carter and Kanagy, 2003).
Lu et al. (2008) recently examined MYPT1 isoform
expression in pregnancy-induced hypertension. These
investigators demonstrated that during a normal preg-
nancy total MYPT1 expression increased, but there was
no change in MYPT1 isoform expression. However,
during pregnancy-induced hypertension, although there
were no changes in MYPT1 expression in mesenteric
arteries or the aorta, in uterine arteries, pregnancy-
induced hypertension was associated with an increase
in LZ+MYPT1 expression but an;50% decrease in total
MYPT1 expression. As would be predicted, the increase
in LZ+ MYPT1 expression was associated with an in-
crease in the sensitivity of uterine artery relaxation to
both sodium nitroprusside and cGMP. The increase in
LZ+ MYPT1 expression did not occur when the blood
pressure of the pregnant hypertensive rats was nor-
malized with hydralazine. It is interesting to speculate
that during pregnancy-induced hypertension the
changes in MYPT1 expression are compensatory, and
the resulting reduction in uterine vascular resistance
maintains blood flow despite the inward remodeling of
the arteries (Lu et al., 2008).
C. Personalized Medicine
A number of studies demonstrate that blood pressure
is a genetically determined trait with heritability
estimates of 31–68% (Padmanabhan et al., 2012). There
are several, rare monogenic syndromes, which are due
to abnormalities in renal fluid balance that result in
hypertension (Lifton et al., 2001; Ji et al., 2008).
However, because the regulation of blood pressure is
due to complex interactions of fluid balance, cardiac
contractility, and vascular tone, the genetic basis of
essential hypertension has yet to be elucidated (Oparil
et al., 2003; Padmanabhan et al., 2012). Recently, a
number of genomewide-association studies (GWAS) have
identified SNPs in a number of genes that could contrib-
ute to the development of essential hypertension
(Adeyemo et al., 2009; Johnson et al., 2011; Kato et al.,
2011; Wain et al., 2011; Havulinna et al., 2013; Tragante
et al., 2014). These studies have focused on populations of
European decent, but GWAS have examined East Asia
(Kato et al., 2011) as well as African American cohorts
(Adeyemo et al., 2009). A complete discussion of GWAS
methods as well as the results of these studies are beyond
the scope of the present review, and we would refer
readers to recent reviews on this subject (Ehret, 2010;
Padmanabhan et al., 2012). In addition to SNPs, gene
expression is also regulated by miR and DNA methyl-
ation. The importance of miRs in the regulation of blood
pressure is highlighted by a recent study demonstrating
that mice lacking miR-142 and miR-145 have reduced
vascular tone and blood pressure (Xin et al., 2009).
Additionally, hcmv-miR-UL122 is highly expressed in
hypertensive patients (Cheng et al., 2009), a number of
miRs are increased in hypertensive nephrosclerosis
(Wang et al., 2010), and furthermore, renin expression
appears to be regulated by mi-RNA-181a and miR-663
renin (Marques et al., 2011). These factors illustrate that
SNPs, miRs, and posttranslational modifications all play
a role in the development of hypertension.
In addition to revealing candidate genes important in
the pathogenesis of essential hypertension, pharmaco-
genomic GWAS have the potential to reveal the likeli-
hood of a patient to respond to therapy or even to
develop a rare adverse drug reaction (Crowley et al.,
2009; Johnson et al., 2008). There are several reports of
an association between polymorphisms in the b1-adrenergic
receptor gene and the lowering of blood pressure
(reviewed in Shin and Johnson, 2007). An association
of Ser49Gly and Arg389Gly polymorphisms has been
demonstrated to be associated with a significant re-
duction in bloodpressurewithb-blocker therapy (Johnson
et al., 2003), and furthermore, one or both of these SNPs
were carried by 54% of Chinese and 44% of whites
(Johnson et al., 2003), perhaps suggesting an etiology of
the ethnic differences in response to b-blocker therapy.
The PEAR study (Gong et al., 2012) evaluated the
association of 39 SNPs known to be associated with
hypertension from GWAS studies with a response to
monotherapy with atenolol or HCTZ in 768 hyperten-
sive patients (60% white and 40% black). The response
to atenolol therapy was greater in the white patients;
six SNPs were associated with a response to atenolol
therapy, with greater responses with in those with all
six BP lowering alleles. HCTZ lowered blood pressure
less in white compared with black patients. In the white
patients, three alleles were associated with BP lowering
for HCTZ monotherapy, and similarly, the association
was strongest for those with all three alleles, but none of
these were associated with BP lowering in blacks.
Interestingly for HCTZ therapy, one SNP was associ-
ated with a BP reduction in white hypertensive pa-
tients, whereas it was associated with an increase in BP
in the black patients. A G825C polymorphism in the
gene encoding the G-protein b3-subunit has been asso-
ciated with a response to HCTZ therapy, and this
genotype was a stronger predictor of response to
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diuretics than ethnicity (Turner et al., 2001). There
have been two large trials examining polymorphisms in
the genes encoding ACE (Arnett et al., 2005) and the
AT1 receptor (Brunner et al., 2007) and the response to
ACE inhibition. No association was found for the
insertion/deletion polymorphism in the ACE gene and
the response to lisinopril therapy (Arnett et al., 2005),
and similarly for all ethnic groups examined, no genetic
association was present for the 1166A-C genotype of the
AT1 receptor and response to trandolapril. These data
suggest that pharmacogenomic GWAS have the poten-
tial to identify genotypes that not only contribute to the
development of hypertension but will also predict a
positive response to antihypertensive therapy. An
individual’s genotype could be then used for a person-
alized approach for selecting an effective antihyperten-
sive with minimal chance of the patient developing an
adverse reaction.
D. Summary of Novel Targets and Potential for
Improved Therapies
There is no question that essential hypertension is
due, in part, to changes at the level of vascular smooth
muscle that lead to excess vasoconstriction and a
concomitant increase in SVR and blood pressure. In
this review, we suggested have several novel targets for
the treatment of essential hypertension. Details and the
strategy for the each target can be found in the individ-
ual sections. These targets include those that affect
Ca2+, including 1) downregulation of AKAP150, 2)
increasing the expression of the b1 subunit of the BK
channel, 3) novel BK channel openers, 4) inhibiting or
decreasing the expression of STIM/Orai (Ca2+ release-
activated Ca2+ channels), and 5) increasing cleavage of
the C terminal of LTCC or increasing CCt expression.
One could also consider inhibition of MLCK as a novel
target; the soybean isoform of calmodulin (SCaM-4) has
been demonstrated to bind Ca2+ but not activate MLCK
and thus inhibit the activation of smooth muscle (Lee
et al., 2000a; Van Lierop et al., 2002). Thus, targeted
expression of SCaM-4 or a CaM fragment in vascular
smooth muscle should reduce SVR and blood pressure.
There are also a number of scaffolds including those for
ERK (calponin, SmAV, and paxillin) and MLC phos-
phatase (M-RIP and Par-4) that could be examined as
potential therapeutic targets, which could result in a
reduction of vascular tone. Inhibition of the signaling
pathways for Ca2+ sensitization including Rho kinase
and GEF signaling could represent another area for
rational drug design, and similarly, activation of path-
ways leading to Ca2+ desensitization including gua-
nylate cyclase and increasing the expression of
LZ+ MYPT1 would enhance NO/flow mediated vasodi-
latation, which should decrease blood pressure. Other
attractive targets would be pathways leading to remod-
eling of the actin cytoskeleton including integrins, focal
adhesion proteins, as well as the activation of tyrosine
kinases. Targeted delivery of miRs to the vasculature
also may prove to be an effective strategy for the
treatment of hypertension; miRs could be used as a
strategy to change vascular smooth muscle gene pro-
gram from high force (tonic) and NO unresponsive to a
lower force (phasic) and NO responsive and hence
produce a reduction in vascular tone and blood
pressure.
These novel targets could form the basis for rationale
drug design, and could be exploited for development of
therapeutic agents that are effective for the treatment
of hypertension. For some targets, small molecule
inhibitors/activators would appear to be a reasonable
choice, whereas for other targets, i.e., to reverse the
decreases in MYPT1 expression, adenoviral delivery of
MYPT1 to the vasculature could also be used as a
strategy to increase the sensitivity to NO or flow-
mediated vasodilation, which would decrease in vascu-
lar tone and blood pressure.
The contribution of alteration in the vascular pheno-
type from Ca2+ signaling, regulation of the cytoskeleton
and contractility, and biomechanics to the pathogenesis
of essential hypertension may vary among ethnic
groups and/or individuals. Currently, antihypertensive
therapy is generally approached by a method that could
be best summarized as trial and error: an agent is
selected, usually without consideration of the patient’s
ethnic background, and if control is not adequate, either
the dose is increased or another agent is added.
In this review, we discussed the importance of the
vascular phenotype in the mechanism that leads to
essential hypertension. Therefore, mechanisms to iden-
tify the etiology of the increase in blood pressure in each
patient are important for ultimately selecting an in-
dividualized and effective therapeutic agent. These
future studies will hopefully lead to amore personalized
approach to antihypertensive therapy.
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